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CD C, our planners, and our content experts wish to disclose that 
they have no financial interests or other relationships w ith the 
manufacturers o f commercial products, suppliers of commercial 
services, or commercial supporters. This report will not include 
any discussion of the unlabeled use of a product or a product under 
investigational use with the exception o f the following situations:
1. For varicella postexposure prophylaxis for persons without 
evidence o f  im m un ity  w ho have co n tra in d ica tio n s for 
vaccination  and w ho are at risk  for severe disease and 
complications, the product currently used in the United States, 
V ariZ IG  (C angene C orporation , W innipeg, C anada), is 
available under an Investigational New D rug Application 
Expanded Access Protocol.
2. The interval between administration of T d  and Tdap might be 
<5 years as indicated in package insert.
3. O ne Tdap product, Adacel (sanofi pasteur, Toronto, Canada), 
is labeled for use in persons aged 11—64 years. The other Tdap 
product, Boostrix (GlaxoSmithKline Biologicals, Rixensart, 
Belgium), is labeled for use in persons aged >10 years. Until 
ACIP reviews the current recommendations on use o f Tdap in 
persons aged >65 years, either Tdap product may be used in 
persons aged >65 years.
4. Meningococcal conjugate vaccines are licensed only as a single 
dose. The 2-dose series of meningococcal conjugate vaccine is 
recommended for persons with certain medical risk factors, and 
the booster dose o f m eningococcal conjugate vaccine is 
recommended for persons who remain at increased risk for a 
prolonged period.
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Summary
This report updates the previously published summary o f  recommendations fo r  vaccinating health-care personnel (HCP) in 
the United States (CDC. Immunization o f  health-care workers: recommendations o f  the Advisory Committee on Immunization 
Practices [ACIP] and the Hospital Infection Control Practices Advisory Committee [HICPAC]. M M W R  1997;46[No. RR-18J). 
This report was reviewed by and includes input from  the Healthcare (formerly Hospital) Infection Control Practices Advisory 
Committee. These updated recommendations can assist hospital administrators, infection-controlpractitioners, employee health 
clinicians, and H C P in optimizing infection prevention and control programs. The recommendations fo r  vaccinating H C P are 
presented by disease in two categories: 1) those diseases fo r  which vaccination or documentation o f  immunity is recommended because 
o f  risks to H C P in their work settings fo r  acquiring disease or transmitting to patients and 2) those fo r  which vaccination might 
be indicated in certain circumstances. Background information fo r each vaccine-preventable disease and specific recommendations 
fo r  use ofeach vaccine are presented. Certain infection-control measures that relate to vaccination also are included in this report. 
In addition, AC IP  recommendations fo r  the remaining vaccines that are recommended fo r  certain or all adults are summarized, 
as are considerations fo r  catch-up and travel vaccinations and fo r  work restrictions. This report summarizes all current ACIP  
recommendations fo r  vaccination o f  H C P  and does not contain any new recommendations or policies.
T he m aterial in this report orig inated  in the N ational C en te r for 
Im m u n iz a tio n  an d  R esp ira to ry  D iseases, A nn e S ch u ch a t, M D , 
Director.
C orresponding preparer: Abigail Shefer, M D , N ational C en ter for 
Im m unization  and  R espiratory Diseases, 1600 C lifton  Rd., M S A-19, 
A tlanta, GA 30333. Telephone: 404-639-8233; Fax: 404-417-0791; 
E-mail: ams7@cdc.gov.
The recommendations provided in this report apply, 
but are not limited, to H C P  in acute-care hospitals; long- 
term—care facilities (e.g., nursing homes and skilled nursing 
facilities);physician’s offices; rehabilitation centers; urgent 
care centers, and outpatient clinics as well as to persons who 
provide home health care and emergency medical services.
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This report updates the previously published sum m ary 
o f  reco m m en d a tio n s  o f  th e  A d v isory  C o m m itte e  on 
Im m unization Practices (ACIP) and the Healthcare (formerly 
H ospital) Infection Control Practices Advisory Com m ittee 
(HICPAC) for vaccinating health-care personnel (HCP) in 
the United States (1). The report, which was reviewed by 
and includes input from HICPAC, summarizes all current 
ACIP recommendations for vaccination o f H C P  and does 
not contain any new recommendations or policies that have 
not been published previously. These recommendations can 
assist hospital administrators, infection-control practitioners, 
employee health clinicians, and H C P  in optimizing infection 
prevention and control programs.
H C P  are defined as all paid and unpaid persons working 
in health-care settings who have the potential for exposure 
to patients and /or to infectious materials, including body 
substances, contam inated medical supplies and equipment, 
contam inated environmental surfaces, or contam inated air. 
H C P  m ight include (but are no t lim ited to) physicians, 
nurses, nursing assistants, therapists, technicians, emergency 
medical service personnel, dental personnel, pharmacists, 
laboratory personnel, autopsy personnel, students and trainees, 
contractual staff not employed by the health-care facility, and 
persons (e.g., clerical, dietary, housekeeping, laundry, security, 
m aintenance, adm inistrative, billing, and volunteers) not 
directly involved in patient care but potentially exposed to 
infectious agents that can be transm itted to and from H C P 
and patients (2).
Because o f their contact with patients or infective material 
from patients, many H C P are at risk for exposure to (and possible 
transmission of) vaccine-preventable diseases. Employers and 
H C P have a shared responsibility to prevent occupationally 
acquired infections and avoid causing harm to patients by taking 
reasonable precautions to prevent transmission o f vaccine- 
preventable diseases. Vaccination programs are therefore an 
essential part o f infection prevention and control for H C P 
Optimal use o f recommended vaccines helps maintain immunity 
and safeguard H C P from infection, thereby helping protect 
patients from becoming infected; pertinent ACIP statements 
on various individual vaccines and diseases have been published 
(Table 1). Nationwide, ongoing implementation o f these vaccine 
recommendations through well-managed vaccination programs 
could substantially reduce both the number o f susceptible H C P 
in any setting in which they interact with patients and their risks 
for transmitting vaccine-preventable diseases to patients, other 
HCP, and other contacts (3).
H IC P A C  and C D C  have recom m ended  th a t secure, 
preferably computerized, systems should be used to manage
Introduction vaccination records for H C P  so records can be retrieved easily as needed (3). Each record should reflect im m unity status 
for indicated vaccine-preventable diseases (i.e., documented 
disease, vaccination history, or serology results) as well as 
vaccinations adm inistered  du ring  em ploym ent and any 
docum ented episodes o f adverse events after vaccination (4). 
For each vaccine, the record should include date o f  vaccine 
adm inistration (including for those vaccines that might have 
been received prior to employment), vaccine manufacturer 
and lot number, edition and distribution date o f  the language- 
appropriate Vaccine Inform ation Statement (VIS) provided 
to the vaccinee at the time o f vaccination, and the name, 
address, and title o f  the person adm inistering the vaccine 
(4). Accurate vaccination records can help to rapidly identify 
susceptible H C P  (i.e., those w ith no history o f vaccination 
or lack o f docum entation o f immunity) during an outbreak 
situation and can help reduce costs and disruptions to health­
care operations (5—7). H C P  should be provided a copy of 
their vaccination records and encouraged to keep it w ith their 
personal health records so they can readily be made available 
to future employers.
HICPAC has encouraged any facility or organization that 
provides direct patient care to formulate a comprehensive 
vaccination policy for all H C P (3). T he American Hospital 
Association has endorsed the concept o f vaccination programs 
for both hospital personnel and patients (8). To ensure that all 
H C P  are up to date with respect to recommended vaccines, 
facilities should review H C P  vaccination and im m unity status 
at the time ofhire and on a regular basis (i.e., at least annually) 
w ith consideration o f offering needed vaccines, if  necessary, in 
conjunction with routine annual disease-prevention measures 
(e.g., influenza vaccination or tuberculin  testing). These 
recom m endations (Tables 2 and 3) should be considered 
during policy development. Several states and health-care 
facilities have established requirements relating to assessment 
o f  vaccination status and/or adm inistration o f one or more 
vaccines for H C P  (9,10). Disease-specific outbreak control 
measures are described in this report and elsewhere (3,11,12). 
All H C P should adhere to all other recommended infection- 
contro l guidelines, w hether or no t they are individually 
determined to have im m unity to a vaccine-preventable disease.
Methods
In 2008, the ACIP Im m unization o f Health-Care Personnel 
W ork Group (the W ork Group) was formed as a subgroup of 
the ACIP Adult Im m unization W ork Group to update the 
previously published recom m endations for im m unization 
o f  HCP. T he W ork G roup com prised professionals from
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academic m edicine (pediatrics, family m edicine, internal 
medicine, occupational and environm ental medicine, and 
infectious disease); federal and state public health professionals; 
and liaisons from the Society for Healthcare Epidemiology 
o f America and HICPAC. The W ork Group met monthly, 
developed an outline for the report, worked closely with subject 
m atter experts at C D C  (who developed, revised, and updated 
sections o f the report), and provided subsequent critical review 
o f the draft documents. The approach o f the W ork Group was 
to summarize previously published ACIP recommendations 
and n o t to m ake new  recom m endations or policies; a 
comprehensive list o f  publications containing the various 
vaccine-specific recommendations is provided (Table 1). In 
February 2011, the updated report was presented to ACIP, 
which voted to approve it.
T he recommendations for vaccination o f H C P are presented 
below by disease in two categories: 1) those diseases for 
which routine vaccination or docum entation o f im m unity is 
recommended for H C P  because o f risks to H C P  in their work 
settings and, should H C P become infected, to the patients they 
serve and 2) those diseases for which vaccination o f H C P might 
be indicated in certain circumstances. Vaccines recommended 
in the first category are hepatitis B, seasonal influenza, measles, 
mumps, and rubella, pertussis, and varicella vaccines. Vaccines 
in the second category are meningococcal, typhoid, and polio 
vaccines. Except for influenza, all o f  the diseases prevented by 
these vaccines are notifiable at the national level (13). Main 
changes from the 1997 ACIP recommendations have been 
summarized (Box).
Diseases for Which Vaccination Is 
Recomm ended
O n  the basis o f  docum ented nosocom ial transm ission, 
H C P  are considered to be at substantial risk for acquiring 
or transm itting  hepatitis B, influenza, measles, m um ps, 
rubella, pertussis, and varicella. Current recommendations for 
vaccination are provided below.
Hepatitis B
Background
Epidemiology and Risk Factors
Hepatitis B is an infection caused by the hepatitis B virus 
(HBV), w hich is transm itted th rough percutaneous (i.e., 
breaks in the skin) or mucosal (i.e., direct contact w ith  
mucous membranes) exposure to infectious blood or body 
fluids. T he virus is highly infectious; for nonim m une persons,
disease transm ission from a needlestick exposure is up to 
100 times more likely for exposure to hepatitis B e antigen 
(HBeAg)-positive blood than to HIV-positive blood (14). 
HBV infection is a well recognized occupational risk for U.S. 
H C P and globally. T he risk for HBV is associated w ith degree 
of contact with blood in the work place and with the hepatitis B 
e-antigen status o f the source persons (15). The virus is also 
environmentally stable, remaining infectious on environmental 
surfaces for at least 7 days (16).
In 2009 in the United States, 3,371 cases o f acute HBV 
infection were reported nationally, and an estimated 38,000 
new cases o f  HBV infection occurred after accounting for 
underreporting and underdiagnosis (17). O f  4,519 persons 
reported w ith acute HBV infection in 2007, approximately 
40% were hospitalized and 1.5% died (18). HBV can lead 
to chronic infection, which can result in cirrhosis o f the liver, 
liver failure, liver cancer, and death. An estimated 800,000—1.4 
million persons in the United States are living with chronic 
HBV infection; these persons serve as the main reservoir for 
continued HBV transmission (19).
Vaccines to prevent hepatitis B became available in the 
United States in 1981; a decade later, a national strategy to 
eliminate HBV infection was implemented, and the routine 
vaccination of children was recommended (20). During 1990­
2009, the rate o f  new HBV infections declined approximately 
84%, from 8.5 to 1.1 cases per 100,000 population (17); the 
decline was greatest (98%) among persons aged <19 years, for 
whom  recommendations for routine infant and adolescent 
vaccination have been applied. Although hepatitis B vaccine 
coverage is high in infants, children, and adolescents (91.8% 
in infants aged 19-35 m onths and 91.6%  in adolescents aged 
13-17 years) (21,22), coverage remains lower (41.8% in 2009) 
for certain adult populations, including those w ith behavioral 
risks for HBV infection (e.g., men who have sex with men and 
persons who use injection drugs) (23).
Hepatitis B in Health-Care Settings
During 1982, when hepatitis B vaccine was first recommended 
for HCP, an estimated 10,000 infections occurred among 
persons employed in a medical or dental field. By 2004, 
the num ber o f HBV infections among H C P had decreased 
to an estimated 304 infections, largely resulting from the 
im p lem entation  o f  routine preexposure vaccination and 
improved infection-control precautions (24—26).
T he risk for acquiring HBV infection from occupational 
exposures is dependent on the frequency o f percutaneous and 
mucosal exposures to blood or body fluids (e.g., semen, saliva, 
and w ound exudates) containing HBV, particularly fluids 
containing HBeAg (a marker for high HBV replication and 
viral load) (27—31). T he risk is higher during the professional
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BOX. Summary of main changes* from 1997 Advisory Committee on Immunization Practices/Hospital (now Healthcare) Infection Control 
Practices Advisory Committee recommendations for immunization of health-care personnel (HCP)
Hepatitis B
• H C P  and trainees in certain populations at high risk for chronic hepatitis B (e.g., those born in countries with high and 
intermediate endemicity) should be tested for HBsAg and anti-HBc/anti-H Bs to determine infection status.
Influenza
• Emphasis that all HCP, not just those w ith direct patient care duties, should receive an annual influenza vaccination
• Comprehensive programs to increase vaccine coverage among H C P  are needed; influenza vaccination rates among H C P 
w ithin facilities should be measured and reported regularly.
Measles, mumps, and rubella (MMR)
• History o f disease is no longer considered adequate presumptive evidence o f measles or mumps im m unity for HCP; 
laboratory confirmation o f disease was added as acceptable presumptive evidence o f immunity. History o f disease has 
never been considered adequate evidence o f im m unity for rubella.
• The footnotes have been changed regarding the recommendations for personnel born before 1957 in routine and 
outbreak contexts. Specifically, guidance is provided for 2 doses o f  M M R  for measles and m um ps protection and 1 dose 
o f M M R  for rubella protection.
Pertussis
• HCP, regardless o f age, should receive a single dose o f Tdap as soon as feasible if  they have not previously received Tdap.
• The minimal interval was removed, and Tdap can now be administered regardless o f interval since the last tetanus or 
diphtheria-containing vaccine.
• Hospitals and ambulatory-care facilities should provide Tdap for H C P and use approaches that maximize vaccination rates.
Varicella
Criteria for evidence o f im m unity to varicella were established. For H C P  they include
• written docum entation with 2 doses o f  vaccine,
• laboratory evidence o f im m unity or laboratory confirm ation o f disease,
• diagnosis o f  history o f  varicella disease by health-care provider, or diagnosis o f  history o f herpes zoster by health-care 
provider.
M eningococcal
• H C P  with anatomic or functional asplenia or persistent com plem ent com ponent deficiencies should now receive a
2-dose series o f meningococcal conjugate vaccine. H C P  with H IV  infection who are vaccinated should also receive a 2 
dose series.
• Those H C P who remain in groups at high risk are recommended to be revaccinated every 5 years.
Abbreviations: HBsAg = Hepatitis B surface antigen; anti-HBc = hepatitis B core antibody; anti-HBs = hepatitis B surface antibody; Tdap = tetanus toxoid,
reduced diptheria toxoid and acellular pertussis vaccine; H IV  = hum an immunodeficiency virus.
•  U pdated recommendations m ade since publication o f the 1997 summary o f recommendations (C D C  Im munization o f health-care workers: recommendations 
o f the Advisory Com m ittee on Im munization Practices [ACIP] and the Hospital Infection C ontrol Practices Advisory C om m ittee [H ICPA C]. M M W R  
1997;46[No. RR-18]).
training period and can vary throughout a person’s career (1). 
D epending on the tasks perform ed, health-care or public 
safety personnel m ight be at risk for H B V  exposure; in 
addition, personnel providing care and assistance to persons 
in outpatient settings and those residing in long-term -care 
facilities (e.g., assisted living) might be at risk for acquiring or 
facilitating transmission o f HBV infection when they perform 
procedures that expose them to blood (e.g., assisted blood- 
glucose m onitoring and wound care) (32—34).
A Federal S tandard  issued in  D ecem ber 1991 under 
the O ccupational Safety and H ealth  Act m andates that 
hepatitis B vaccine be made available at the employer’s expense 
to all health-care personnel who are exposed occupationally 
to blood or other potentially infectious materials (35). The 
Federal Standard defines occupational exposure as reasonably 
an ticipated  skin, eye, m ucous m em brane, or parenteral 
contact with blood or other potentially infectious materials 
that m ight result from the perform ance o f an employee’s 
duties (35). Occupational Safety and Health Administration
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(OSHA) vaccination practice requirements (e.g., preexposure 
and postexposure antibody testing) are based on current ACIP 
recommendations. O SH A  regulations might have accelerated 
the use o f hepatitis B vaccine in H C P  (36).
D ata from a national, cross-sectional survey demonstrated 
that during 20 0 2 -2 0 0 3 , an estim ated 75%  o f H C P  had 
received the 3-dose hepatitis B vaccination series (37). Since 
2002, rates o f 1-dose and 3-dose vaccination coverage have 
remained stable. D ata obtained through the National Health 
Interview Survey (NHIS) in 2009 dem onstrated a >1-dose 
coverage rate o f 75% -77%  and a >3-dose rate o f 67% -68%  
among H C P  aged 18-49 years (23). Similarly, data obtained 
through the N ational Im m unization Survey-A dult (NIS- 
Adult) in 2007 dem onstrated a >3-dose coverage o f 62% 
am ong H C P  aged 18 -64  years (38). T he H ealthy People 
2020 goal (objective no. IID-15.3) o f a hepatitis B vaccination 
coverage rate o f  90% among H C P  (39 ) has not been achieved.
Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety
Vaccine Effectiveness
The 3-dose vaccine series administered intramuscularly at 
0, 1, and 6 m onths produces a protective antibody response 
in approximately 30% -55%  o f healthy adults aged <40 years 
after the first dose, 75%  after the second dose, and >90% 
after the third dose (40—42). After age 40 years, <90% of 
persons vaccinated with 3 doses have a protective antibody 
response, and by age 60 years, protective levels o f  antibody 
develop in approximately 75%  o f vaccinated persons (43). 
Smoking, obesity, genetic factors, and im m une suppression 
also are associated w ith  dim inished im m une response to 
hepatitis B vaccination (43—46).
Duration of Immunity
Protection against symptomatic and chronic HBV infection 
has been docum ented to persist for >22 years in vaccine 
responders (47). Im m unocom petent persons who achieve 
hepatitis B surface antibody (anti-HBs) concentrations o f 
>10 m IU /m L after preexposure vaccination have protection 
against both acute disease and chronic infection. Anti-HBs 
levels decline over time. Regardless, responders continue to 
be protected, and the majority o f  responders will show an 
anamnestic response to vaccine challenge (47—51). Declines 
might be somewhat faster among persons vaccinated as infants 
rather than as older children, adolescents, or adults and among 
those administered recom binant vaccine instead o f plasma 
vaccine (which has not been commercially available in the 
United States since the late 1980s). Although immunogenicity is 
lower among immunocompromised persons, those who achieve
and maintain a protective antibody response before exposure 
to HBV have a high level o f protection from infection (52).
Among persons who do not respond to a primary 3-dose 
vaccine series (i.e., those in whom anti-HBs concentrations 
of >10 m IU /m L were not achieved), 25% -50%  respond to 
an additional vaccine dose, and 44% -100%  respond to a 
3-dose revaccination series using standard or high dosage vac­
cine (43,53—58). Persons who have measurable but low (i.e., 
1-9 mIU/mL) levels o f anti-HBs after the initial series have 
better response to revaccination than persons who have no anti- 
HBs (49,53,54). Persons who do not have protective levels of 
anti-HBs 1-2 months after revaccination either are infected with 
HBV or can be considered primary nonresponders; for the latter 
group, genetic factors might be associated with nonresponse to 
hepatitis B vaccination (54,58,59). ACIP does not recommend 
more than two vaccine series in nonresponders (52).
Vaccine Safety
Hepatitis B vaccines have been dem onstrated to be safe 
when administered to infants, children, adolescents, and adults 
(52,60,61). Although rare cases o f arthritis or alopecia have 
been associated temporally with hepatitis B vaccination, recent 
data do not support a causal relationship between hepatitis B 
vaccine and either arthritis or alopecia (61—63). During 1982­
2004, an estimated 70 million adolescents and adults and 50 
million infants and children in the United States received >1 
dose o f hepatitis B vaccine (52). T he most frequently reported 
side effects in persons receiving hepatitis B vaccine are pain 
at the injection site (3% -29% ) and temperature o f >99.9 F 
(>37.7 C) (1% -6% ) (64—67). However, in placebo-controlled 
studies, these side effects were reported no more frequently 
am ong persons receiving hepatitis B vaccine than am ong 
persons receiving placebo (40,41,64—67). Revaccination is not 
associated with an increase in adverse events.
Hepatitis B vaccination is contraindicated for persons with a 
history o f hypersensitivity to yeast or any vaccine com ponent 
(4,64—66). Persons with a history o f serious adverse events (e.g., 
anaphylaxis) after receipt o f hepatitis B vaccine should not 
receive additional doses. As with other vaccines, vaccination of 
persons with moderate or severe acute illness, with or w ithout 
fever, should be deferred until illness resolves (4). Vaccination 
is not contraindicated in persons with a history o f m ultiple 
sclerosis, G uillain-Barre Syndrom e, auto im m une disease 
(e.g., systemic lupus erythematosis and rheum atoid arthritis), 
or other chronic diseases. Pregnancy is not a contraindication 
to vaccination; limited data suggest that developing fetuses 
are not at risk for adverse events when hepatitis B vaccine is 
administered to pregnant wom en (4,68). Available vaccines 
contain noninfectious hepatitis B surface antigen (HBsAg) 
and do not pose any risk for infection to the fetus.
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Two single-antigen hepatitis B vaccines, Recombivax HB 
(Merck &  Co., Inc., W hitehouse Station, New Jersey) and 
Engerix-B (GlaxoSmithKline Biologicals, Rixensart, Belgium) 
and one com bination hepatitis A and hepatitis B vaccine, 
Twinrix (GlaxoSmithKline Biologicals), are available in the 
United States. Primary vaccination consists o f >3 intramuscular 
doses o f hepatitis B vaccine or o f the combined hepatitis A and 
hepatitis B vaccine. T he hepatitis vaccine series does not need 
to be restarted if  the second or third dose is delayed. Detailed 
vaccination recom m endations are available in previously 
published guidelines (52). Vaccine schedules are available at 
http://www.cdc.gov/vaccines/recs/schedules/adult-schedule. 
h tm #H C W s. In adults, hepatitis B vaccine always should be 
administered into the deltoid muscle. Longer needles (up to
1.5 inches in length) m ight be required for obese adults (4).
Preexposure
Unvaccinated and Incompletely Vaccinated HCP 
and Trainees: Pre- and Postvaccination Serologic Testing
• Prevaccination serologic testing for previous infection is 
not indicated for the majority o f persons being vaccinated 
because o f occupational risk unless the hospital or health­
care organization considers such testing cost-effective 
(3,52,69—72). However, such testing is indicated for H C P 
and is cost-effective in certain high-risk populations (see 
H C P  and Trainees at A dditional Risk), regardless o f 
vaccination status (71,73).
• All unvaccinated persons whose work- and training-related 
activities involve reasonably anticipated risk for exposure 
to blood or other infectious body fluids (e.g., HCP, long- 
term -care facility staff, and public safety workers) should 
be vaccinated w ith the complete, >3-dose hepatitis B 
vaccine series.
• Persons w ith  an incom plete series are not considered 
protected and should complete the >3-dose series.
• Because h igh er risk has been rep o rted  d u rin g  the 
professional training period, the vaccination series should 
be completed before trainees have contact with blood; 
vaccination should be offered in schools o f medicine, 
dentistry, nursing, laboratory technology, and other allied 
health professions.
• To determine the need for revaccination and to guide 
postexposure prophylaxis, postvaccination serologic testing 
should  be perfo rm ed  for all H C P  at h igh  risk for 
occupational percutaneous or mucosal exposure to blood 
or body fluids. Postvaccination  serologic testing  is 
performed 1-2  m onths after adm inistration o f  the last 
dose o f the vaccine series using a m ethod that allows
Recommendations detection o f the protective concentration o f anti-HBs 
(>10 m IU /m L). Persons determ ined to have anti-HBs 
concentrations of >10 m IU /m L after receipt o f the primary 
vaccine series are considered im m une, and the result 
should be documented. Im m unocom petent persons have 
long-term protection and do not need further periodic 
testing to assess anti-HBs levels. Postvaccination testing 
for persons at low risk for mucosal or percutaneous 
exposure to blood or body fluids (e.g., public safety 
workers and H C P  w ithout direct patient contact) likely 
is not cost effective (52); however, persons who do not 
undergo postvaccination testing should be counseled to 
seek immediate testing if  exposed.
• Persons determined to have anti-HBs concentrations of <10 
m IU /m L soon after receipt o f the primary vaccine series 
should be revaccinated. For these persons, administration 
o f a second complete 3-dose series on an appropriate 
schedule, followed by anti-HBs testing 1-2 months after 
the third dose, usually is more practical than conducting 
serologic testing after each additional dose o f vaccine.
• Persons who do not have a protective concentration of 
anti-HBs (>10 m IU/m L) after revaccination (i.e., after 
receiving a total o f 6 doses) should be tested for HBsAg 
and an ti-H B c to determ ine in fection  status. Those 
determined not to be infected but who have anti-HBs <10 
m IU/m L (nonresponders) should be considered susceptible 
to H B V  in fec tio n  and sho u ld  be counseled  about 
precautions to prevent HBV infection and the need to 
obtain hepatitis B im m une globulin (HBIG) postexposure 
prophylaxis for any known or likely exposure to HBsAg- 
positive blood (72). Persons determined to be infected 
(anti-HBc-positive) and positive for HBsAg should be 
provided counseling regarding how to prevent HBV 
transmission to others and referred for further evaluation 
(e.g., HBV viral load testing), care, treatm ent, and other 
services, as appropriate (69-71). Persons who are HBsAg- 
positive and who perform  exposure-prone procedures 
should seek counsel from a review panel comprised o f 
experts with a balanced perspective (e.g., HCPs’ personal 
physicians and infectious disease specialists) regarding the 
procedures that they can perform safely. They should not 
be excluded from work (69). Persons who were infected 
in the past (anti-HBc-positive but negative for HBsAg) 
require no vaccination or treatment.
Postexposure
T he need for postexposure prophylaxis should be evaluated 
immediately after H C P  experience any percutaneous, ocular, 
m ucous-m em brane or non in tact skin exposure to blood 
or body fluid in the workplace. Decisions to adm inister
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postexposure prophylaxis should be based on the HBsAg status 
o f the source and the vaccination history and vaccine-response 
status o f the exposed H C P  (Table 4) (72).
Unvaccinated and Incompletely Vaccinated HCP 
and Trainees
• Unvaccinated or incompletely vaccinated persons who 
experience a workplace exposure from persons known to 
be HBsAg-positive should receive 1 dose o f hepatitis B 
im m une globulin H B IG  (i.e., passive vaccination) as soon 
as possible after exposure (preferably w ithin 24 hours). 
T he effectiveness o f  H B IG  when administered >7 days 
after percutaneous or permucosal exposures is unknown 
(Table 4).
• Hepatitis B vaccine should be administered in the deltoid 
muscle as soon as possible after exposure; H B IG  should 
be administered at the same time at another injection site. 
T he 3-dose hepatitis B vaccine series should be completed 
for previously unvaccinated and incompletely vaccinated 
persons who have needlestick or o ther percutaneous 
exposures, regardless o f the HBsAg status o f the source 
and w hether the status o f  the source is know n. To 
docum ent protective levels o f anti-HBs (>10mIU/mL), 
postvaccination testing o f persons who received HBIG for 
postexposure prophylaxis should be performed after anti- 
HBs from H BIG is no longer detectable (4-6  m onths after 
administration).
Vaccinated HCP and Trainees
• Vaccinated H C P  w ith docum ented im m unity (anti-HBs 
concentrations o f >10 m IU/m L) require no postexposure 
prophylaxis, serologic testing, or additional vaccination.
• Vaccinated H C P  w ith docum ented nonresponse to a 
3-dose vaccine series should receive 1 dose o f H B IG  and 
a second 3-dose vaccine series if the source is HBsAg- 
positive or known to be at high risk for carrying hepatitis. 
I f  the source is know n or determ ined to be HBsAg- 
negative, these previously nonresponding H C P  should 
c o m p le te  th e  re v a c c in a tio n  series an d  u n d e rg o  
postvaccination testing to ensure that their response status 
is docum ented (Table 4). Postvaccination testing of 
persons who received HBIG for PEP should be performed 
after anti-HBs from H BIG  is no longer detectable (4-6  
m onths after administration).
• Vaccinated H C P with docum ented nonresponse to two
3-dose vaccine series should receive 2 doses o f HBIG , 1 
m onth apart if  the source is HBsAg-positive or known to 
be at high risk for carrying hepatitis; no additional 
vacc ination  is necessary. I f  the source is know n or 
determ ined  to be HBsAg-negative, these previously
no nrespond ing  H C P  need no add itional testing  or 
treatm ent (Table 4).
• Vaccinated H C P with no documentation o f postvaccination 
serologic response who are exposed to an HBsAg-positive 
source should have serum obtained for anti-HBs testing 
immediately. Those determined to have protective levels 
o f antibody (anti-HBs >10 mIU/mL) require no additional 
treatment; those with concentrations <10 m IU /m L should 
receive 1 dose o f H B IG , along with a booster dose of 
hepatitis B vaccine. To docum ent protective levels o f anti- 
HBs (>10mIU/mL), postvaccination testing o f persons 
who received H B IG  for postexposure prophylaxis should 
be performed after anti-HBs from H B IG  is no longer 
detectable (4—6 m onths after administration).
• Vaccinated H C P with no documentation o f postvaccination 
serologic response who are exposed to a source w ith 
unknown infection status should be tested for anti-HBs. 
Those determined to have protective levels o f antibody 
require no additional treatment; those with concentrations 
<10 m IU /m L should receive a booster dose o f hepatitis B 
vaccine and serologic testing 1—2 m onths later.
• Vaccinated H C P with no documentation o f postvaccination 
serologic response who are exposed to a source known to 
be HBsAg-negative require no testing or treatment (Table 4).
HCP and Trainees at Additional Risk
• Regardless o f vaccination history, H C P  and trainees in 
certain high-risk populations, including those born in 
geographic regions with high HBsAg prevalence (>8%) and 
intermediate (2%—7%) prevalence (71), unvaccinated U.S- 
born H C P whose parents were born in regions o f high 
HBsAg prevalence, HIV-positive HCP, H C P who have 
disclosed having engaged or currently engaging in high-risk 
substance abuse or sexual behaviors, and H C P who require 
immunosuppressive therapy or who are on hemodialysis 
should be tested for HBsAg and anti-HBc/anti-HBs to 
determine infection status. For those who are unvaccinated, 
blood should be drawn for testing before the first dose of 
vaccine is adm inistered , and vaccination  should  be 
administered during the same health-care visit. Persons 
testing negative for hepatitis B infection or immunity should 
be managed in the same manner as other uninfected H C P 
Persons determ ined to be HBsAg-positive should be 
provided counseling regarding how to prevent HBV 
transmission to others and referred for further evaluation 
(e.g., HBV viral load testing), care, treatment, and other 
services as appropriate (69—71). Persons who are HBsAg- 
positive and who perform  exposure-prone procedures 
should seek counsel from a review panel comprised o f 
experts with a balanced perspective (e.g., personal physicians
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of H C P and infectious disease specialists) regarding the 
procedures that they can perform safely. They should not 
be excluded from  w ork (69). A dditional inform ation 
regarding prevaccination testing for H C P  w ith  other 
hepatitis B risk factors and for pregnant women has been 
published previously (52,71). H C P receiving hemodialysis 
should be provided annual anti-HBs testing and should be 
administered a booster dose ofvaccine when anti-HBs levels 
decline to <10 m IU /m L (52).
• For other immunocompromised H C P (e.g., HIV-infected 
persons, hematopoietic stem-cell transplant recipients, and 
persons receiving chem otherapy), the frequency o f 
postvaccination testing and the need for booster doses has 
not been determined (52).
Other Considerations
• Occupational health programs and others responsible for 
infection prevention and control should identify all staff 
whose work-related activities involve exposure to blood or 
other potentially infectious body fluids in a health-care, 
laboratory, public safety, or institutional setting (including 
employees, students, contractors, attending clinicians, 
emergency medical technicians, paramedics, and volunteers); 
provide education to staff to encourage vaccination; and 
im plem ent active follow-up, w ith reminders to track 
completion o f the vaccine series and postvaccination testing 
among persons receiving vaccination (72).
• In partnership w ith state and local health authorities, 
household, sex, or needle-sharing contacts o f  HBsAg- 
positive H C P and trainees should be identified, tested, 
vaccinated (if indicated), and provided with counseling and 
referral for needed services, when appropriate.
Influenza
Background
Epidemiology and Risk Factors
In flu en za  causes an e stim ated  average o f  > 2 00 ,00 0  
hospitalizations and 3 ,000 -49 ,000  deaths annually in the 
U nited States (74—76). T he m ajority o f  influenza-related 
severe illnesses and deaths occur among persons with chronic 
medical conditions, infants and young children, seniors, and 
pregnant wom en (74—78). Reducing the risk for influenza 
among persons at higher risk for complications is a major focus 
o f influenza prevention strategies (77).
Influenza Transmission in Health-Care Settings
H C P are exposed to patients with influenza in the workplace 
and are thus at risk o f occupationally acquired influenza and of
transm itting influenza to patients and other HCP. In a cross­
sectional survey o f hospital house staff (physicians in training), 
37% reported influenza-like illness during September-April, 
and 9% reported more than one respiratory illness. Length o f 
illness varied (range: 1-10 days; mean: 7 days), as did days of 
work missed (range: 0 -1 0  days; mean: 0.7 days) (79). Infected 
H C P who continue to work while ill m ight transm it influenza 
to patients, many o f whom  are at increased risk for severe 
outcomes from influenza. H C P  are therefore recommended 
for routine annual influenza vaccination (77).
Few randomized trials o f the effect that influenza vaccination 
has on illness in H C P have been conducted. In one randomized 
trial o f 427 HCP, influenza vaccination o f H C P  failed to 
decrease episodes o f respiratory infection or duration o f illness 
but was associated with a 28% decrease in absenteeism (from 
1.4 days to 1.0 day) attributable to respiratory infections (80). 
No laboratory confirm ation o f influenza was obtained in this 
study. In another randomized trial among HCP, vaccination 
was associated with a significantly lower rate o f serological 
evidence o f influenza infection, with a vaccine efficacy rate of 
88% for influenza A and 89% for influenza B (p<0.05) (81); 
however, no significant differences were noted in days o f febrile 
respiratory illness or absenteeism.
Influenza can cause outbreaks o f severe respiratory illness 
among hospitalized persons and long-term-care residents (82— 
90). Influenza outbreaks in hospitals (86—88) and long-term - 
care facilities (91) have been associated with low vaccination 
rates among HCP. O ne nonrandom ized study demonstrated 
an increase in H C W  vaccination  rates and decrease in 
nosocomially acquired, laboratory-confirmed influenza in a 
hospital after a mobile cart-based H C P  vaccination program 
was introduced (86). Several randomized controlled studies of 
the impact o f H C P  vaccination on m orbidity and m ortality 
in long-term  care facilities have been perform ed (92—95). 
These studies have demonstrated substantial decreases in all­
cause m ortality (92—95) and influenza-like illness (92,94,95). 
However, studies which examine and demonstrate efficacy in 
preventing more specific outcomes (e.g., laboratory-confirmed 
influenza illness and mortality) are lacking. Recent systematic 
reviews suggest that vaccination o f H C P in settings in which 
patients also were vaccinated provided significant reductions 
in deaths among elderly patients from all causes and deaths 
from pneum onia, but also note that additional randomized 
controlled trials are warranted (96,97), as are examination of 
more specific outcomes.
Preventing influenza among H C P who might serve as sources 
o f influenza virus transmission provides additional protection 
to patients at risk for influenza complications. Vaccination 
o f H C P  can specifically benefit patients who cannot receive 
vaccination (e.g., infants aged <6 m onths or those w ith severe
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allergic reactions to prior influenza vaccination), patients 
who respond poorly to vaccination (e.g., persons aged >85 
years and imm une-comprom ised persons), and persons for 
whom  antiviral treatm ent is not available (e.g., persons with 
medical contraindications). Although annual vaccination has 
long been recommended for H C P  and is a high priority for 
reducing m orbidity associated with influenza in health-care 
settings (98—100), national survey data have demonstrated 
that the vaccination coverage level during the 2008-09  season 
was 52.9% (101).
Considerations Regarding Influenza Vaccination 
of HCP
Barriers to H C P  aceptance o f influenza vaccination have 
included fear o f vaccine side effects (particularly influenza­
like symptoms), insufficient time or inconvenience, perceived 
ineffectiveness o f  the vaccine, perceived low likelihood o f 
contracting influenza, avoidance o f medications, and fear of 
needles (79,102—109). Factors demonstrated to increase vaccine 
acceptance include a desire for self-protection, previous receipt 
o f influenza vaccine, a desire to protect patients, and perceived 
effectiveness o f  vaccine (79,105 ,106,109—112). Strategies 
that have dem onstrated im provement in H C P  vaccination 
rates have included campaigns to emphasize the benefits of 
H C P  vaccination for staff and patients, vaccination o f senior 
medical staff or opinion leaders, removing adm inistrative 
barriers (e.g., costs), providing vaccine in locations and at 
times easily accessible by HCP, and m onitoring and reporting 
H C P  influenza vaccination rates (99,113—120). Intranasally 
administered live attenuated influenza vaccine (LAIV) is an 
option for healthy, nonpregnant adults aged <50 years who 
dislike needles.
T he practice o f obtaining signed declinations from H C P 
offered influenza vaccination has been adopted by some 
institutions but has not yet been dem onstrated to exceed 
coverage rates o f >70% -80%  (99,115,121—123). Institutions 
that require declination statements from H C P  who refuse 
influenza vaccination should educate and counsel these H C P 
about benefits o f  the vaccine.
Each health-care facility should develop a comprehensive 
influenza vaccination strategy that includes targeted education 
about the disease, including disease risk among H C P  and 
patients, and about the vaccine. In addition, the program 
should establish easily accessible vaccination sites and inform 
H C P  about their locations and schedule. Facilities that 
employ H C P  should provide influenza vaccine at no cost to 
personnel (124). The most effective combination o f approaches 
for achieving high influenza vaccination coverage among 
H C P  likely varies by institution. Hospitals and health-care
organizations in the United States traditionally have employed 
an im m unization strategy that includes one or more o f the 
following components: education about influenza, easy access 
to vaccine, incentives to encourage im m unization, organized 
campaigns, institution o f declination policies, and legislative 
and regulatory efforts (e.g., vaccination requirements) (99, 
115, 121-126).
Beginning January 1, 2007, the Join t Com m ission on 
A cc red ita tio n  o f  H ea lth -C a re  O rg an iza tio n s  requ ired  
accredited organizations to offer influenza vaccinations to staff, 
including volunteers and licensed independent practitioners 
and to report coverage levels among H C P (127). Standards 
are available for m easuring vaccination coverage am ong 
H C P as a measure o f program performance w ithin a health­
care setting (128). Beginning January 2013, the Centers for 
Medicaid Services will require acute care hospitals to report 
H C P influenza vaccine as part o f  its hospital inpatient quality 
reporting program.*
Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety
Effectiveness o f influenza vaccines varies from year to year 
and depends on the age and health status o f the person getting 
the vaccine and the similarity or “match” between the viruses 
or virus in the vaccine and those in circulation. Vaccine strains 
are selected for inclusion in the influenza vaccine every year 
based on international surveillance and scientists’ estimations 
about which types and strains o f viruses will circulate in a 
given year. Annual vaccination is recommended because the 
predom inant circulating influenza viruses typically change 
from season to season and, because im m unity declines over 
time postvaccination (77).
In placebo-controlled studies am ong adults, the m ost 
frequent side effect o f  vacc ination  was soreness at the 
vaccination site (affecting 10% -64%  o f patients) that lasted 
<2 days (129,130). These injection-site reactions typically were 
mild and rarely interfered with the recipient’s ability to conduct 
usual daily activities. T he m ain contraindication to influenza 
vaccination is a history o f anaphylactic hypersensitivity to egg 
or other components o f the vaccine. A history o f Guillain- 
Barre Syndrome w ithin 6 weeks following a previous dose o f 
influenza vaccine is considered to be a precaution for use o f 
influenza vaccines (77).
* US D epartm ent o f Health and H um an Services. Medicare program; hospital 
inpatient prospective payment systems for acute care hospitals and the long­
term care hospital prospective payment system and FY2012 rates; hospitals’ 
FTE resident caps for graduate medical education payment; final rules. Federal 
Register 2011;76:51631-3.
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Vaccination
Annual influenza vaccination is recommended for all persons 
aged >6 m onths who have no m edical contraindication; 
therefore, vaccination o f all H C P who have no contraindications 
is recommended. T he influenza vaccine is evaluated annually 
with one or more vaccine strains updated almost every year. 
In addition , antibody titers decline during the year after 
vaccination . T h u s, annual vaccination  w ith  the current 
season’s formulation is recommended. Annual vaccination is 
appropriate and safe to begin as early in the season as vaccine 
is available. H C P should be among the groups considered for 
prioritized receipt o f influenza vaccines when vaccine supply 
is limited.
Two types o f  influenza vaccines are available. LAIV is 
administered intranasally and is licensed for use in healthy 
nonpregnant persons aged 2 -49  years. The trivalent inactivated 
vaccine (TIV) is administered as an intramuscular injection 
and can be given to any person aged >6 m onths. Both vaccine 
types contain vaccine virus strains that are selected to stimulate 
a protective im m une response against the wild-type viruses 
that are thought to be most likely in circulation during the 
upcoming season. Use o f LAIV for H C P  who care for patients 
housed in protective inpatien t environm ents has been a 
theoretic concern, but transmission o f LAIV in health-care 
settings has not been reported. LAIV can be used for H C P 
who work in any setting, except those who care for severely 
im m unocompromised hospitalized persons who require care 
in a protective environment. H C P  who themselves have a 
condition that confers high risk for influenza complications, 
who are pregnant, or who are aged >50 years should not receive 
LAIV and should be administered T IV  instead. An inactivated 
trivalent vaccine containing 60 mcg o f hemagglutinin antigen 
per influenza vaccine virus strain (Fluzone High-Dose [sanofi 
pasteur]) is an alternative inactivated vaccine for persons aged 
>65 years. Persons aged >65 years may be administered any 
o f the standard-dose T IV  preparations or Fluzone High-Dose 
(77). T he m ajority o f  T IV  preparations are adm inistered 
intramuscularly. An intraderm ally adm inistered T IV  was 
licensed in M ay 2011 and is an alternative to other T IV  
preparations for persons aged 18-64 years (131).
Use of Antiviral Drugs for Treating Exposed Persons 
and Controlling Outbreaks
Use o f antiviral drugs for chemoprophylaxis or treatm ent of 
influenza is an adjunct to (but not a substitute for) vaccination. 
Oseltam ivir or zanamivir are recom m ended currently for 
chemoprophylaxis or treatm ent o f influenza (132,133). T IV
Recommendations can be administered to exposed, unvaccinated H C P  at the 
same time as chemoprophylaxis, but LAIV should be avoided 
because the antiviral medication will prevent viral replication 
needed to stimulate a vaccine response (77). Antivirals are 
used often among patients during outbreaks in closed settings 
such as long-term -care facilities but also can be administered 
to unvaccinated H C P  during outbreaks, when an exposure 
to a person w ith influenza occurs, or after exposure when 
vaccination is not thought to be protective against the strain 
to which a vaccinated H C P  was exposed. Chemoprophylaxis 
consists o f 1 dose (of either antiviral drug) daily for 10 days, 
and treatm ent consists o f  1 dose twice daily for 5 days. In 
many instances o f  H C P  exposure, watchful waiting and early 
initiation o f treatm ent if  symptoms appear is preferred rather 
than use o f antiviral chemoprophylaxis im m ediately after 
exposure. The intensity and duration o f the exposure and the 
underlying health status o f the exposed worker are im portant 
factors in clinical judgm ents about w hether to provide 
chemoprophylaxis. If  chemoprophylaxis is used, the provider 
should base choice o f the agent on whether the circulating 
strain or strains o f  influenza have dem onstrated resistance to 
particular antivirals.
Program Evaluation
• H ealth-care adm inistrators should include influenza 
vaccination coverage among H C P  as a measure o f quality 
o f  care (124).
• Influenza vaccination rates among H C P within facilities 
should be regularly measured and reported, and ward-, 
un it-, and specialty-specific coverage rates should be 
p rov id ed  to s ta ff  and  ad m in is tra tio n  (124). Such 




Epidemiology and Risk Factors
Measles is a highly contagious rash illness that is transmitted by 
respiratory droplets and airborne spread. Severe complications, 
w h ich  m ig h t resu lt in  death , include p n eu m o n ia  and 
encephalitis. Before the national measles vaccination program 
was im plem ented in 1963, almost every person acquired 
measles before adulthood; an estimated 3 -4  million persons 
in  the U nited  States acquired measles each year (134). 
Approximately 500,000 persons were reported to have had 
measles annually, o f w hom  500 persons died, 48,000 were
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hospitalized, and another 1,000 had perm anent brain damage 
from measles encephalitis (134).
T hrough a successful 2-dose measles vaccination program 
(i.e., a first dose at age 12-15 m onths and a second dose 
between ages 4 -6  years) (135) and better measles control 
th ro u g h o u t the region o f  the Am ericas (136), endem ic 
transmission o f measles was interrupted in the United States, 
and measles was declared eliminated from the country in 2000 
(137). However, measles remains widespread in the majority of 
countries outside the W estern Hemisphere, with an estimated 
20 m illion measles cases occurring worldwide (138) and 
approximately 164,000 related deaths (139). Thus, the United 
States continues to experience international im portations that 
might lead to transmission among U.S. residents and limited 
outbreaks, especially in unvaccinated populations (140-143).
During 2001-2008, a total o f 557 confirmed measles cases 
were reported in the United States from 37 states and the District 
o f Columbia (annual median: 56; range: 37 in 2004 to 140 in 
2008), representing an annual incidence ofless than one case per 
million population (144). O fthe  557 reported case-patients, 126 
(23%) were hospitalized (annual median: 16; range: 5-29); of 
these, at least five case-patients were admitted to intensive care. 
Two deaths were reported, both in 2003 (144).
O f  the 557 reported case-patients during 2001-2008 , a 
total o f  223 (40%) were adults, including 156 (28%) aged 
20 -39  years and 67 (12%) aged >40 years. O f  the 438 measles 
cases among U.S. residents, 285 (65%) cases were considered 
preventable (i.e., occurred among persons who were eligible 
for vaccination but were unvaccinated) (144). T he remaining 
153 (35%) cases were considered nonpreventable. Cases were 
defined as nonpreventable if  they occurred among U.S. resident 
case-patients who had received >1 dose o f measles-containing 
vaccine, if patients were vaccinated as recommended if traveling 
internationally, or if  they were not vaccinated but had other 
evidence o f  im m un ity  (i.e., were born  before 1957 and 
therefore presumed im m une from natural disease in childhood, 
had laboratory evidence o f immunity, or had docum entation 
o f physician-diagnosed disease) or for whom  vaccination is not 
recommended. D uring 2001-2008, a total o f 12.5% (one of 
eight) o f measles cases reported to C D C  among H C P occurred 
in persons born before 1957; the other seven cases occurred 
among H C P  born after 1957.
Measles-mumps-rubella (MMR) vaccination policies have 
been enforced with variable success in United States health­
care facilities over the past decade. Even though medical 
settings were a prim ary site o f measles transmission during 
the 1989-1991 measles resurgence (145,146), as o f September
2011, only three states (New York, Oklahom a, and Rhode 
Island) had laws m andating that all hospital personnel have 
proof o f measles im m unity and did not allow for religious or 
philosophic exemptions (147).
Vaccine coverage in the United States is high; in 2010, a total 
o f 91.5%  o f children aged 19-35 m onths had received 1 dose 
o f M M R  vaccine (21); during 2009-2010, a total o f  94.8% 
o f kindergartners had evidence o f 2 doses (148); and in 2010, 
a total o f 90.5%  o f adolescents had evidence o f 2 doses (22). 
Nationally representative data on M M R  vaccine coverage of 
U.S. H C P  are not available.
Measles Transmission and the Costs of Mitigating 
Measles Exposures in Health-Care Settings
Health-care-associated cases o f measles are o f  public health 
concern. Because o f the severity o f measles, infected persons 
are likely to seek medical care in prim ary health-care facilities, 
emergency departments, or hospitals (141,149,150). Medical 
settings played a prom inent role in perpetuating outbreaks o f 
measles transmission during the 1989-1991 measles resurgence 
(145,146) and were a prim ary site o f  measles transmission in a 
health-care-associated outbreak in 2008 (149). During 2001­
2008, a total o f 27 reported measles cases were transm itted in 
U.S. health-care facilities, accounting for 5% o f all reported 
U.S. measles cases.
Because o f the greater opportunity for exposure, H C P are at 
higher risk than the general population for becoming infected 
with measles. A study conducted in 1996 in medical facilities 
in a county in W ashington state indicated that H C P were 19 
times more likely to develop measles than other adults (151). 
During 2001-2008 , in the 23 health-care settings in which 
measles transmission was reported, eight cases occurred among 
HCP, six (75%) o f whom  were unvaccinated or had unknown 
vaccination status. O ne health-care provider was hospitalized 
in an intensive care un it for 6 days from  severe measles 
complications (142). D uring a health-care-associated measles 
outbreak in Arizona in 2008 with 14 cases, six cases were 
acquired in hospitals, and one was acquired in an outpatient 
setting. O ne unvaccinated health-care worker developed 
measles and infected a hospital em ergency room  patien t 
who required intensive care following hospital admission for 
measles (149).
High costs also are involved in evaluating and containing 
exposures and outbreaks in health-care facilities, as well as 
a substantial disruption o f regular hospital routines when 
control measures are instituted, especially if  hospitals do not 
have readily available data on the measles im m unity status
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of their staff and others included in the facility vaccination 
program. In 2005 in Indiana, one hospital spent more than 
$113,000 responding to a measles outbreak (142), and in 2008 
in Arizona, two hospitals spent $799,136 responding to and 
containing cases in their facilities (149). The Arizona outbreak 
response required rapid review o f measles docum entation of 
14,844 H C P  at seven hospitals and emergency vaccination 
o f approximately 4,500 H C P  who lacked docum entation of 
measles immunity. Serologic testing at two hospitals among 
1,583 H C P  w ithout docum ented history o f vaccination or 
w ithout documented laboratory evidence o f measles im m unity 
revealed that 138 (9%) o f these persons lacked measles IgG 
antibodies (149).
Vaccine Effectiveness, Duration of Immunity and 
Seroprevalence Studies, and Vaccine Safety
Vaccine Effectiveness
M M R  vaccine is highly effective in preventing measles with 
a 1-dose vaccine effectiveness o f 95% when administered on 
or after age 12 m onths and a 2-dose vaccine effectiveness of
99% (135).
Duration of Immunity and Seroprevalence Studies
Two doses o f live measles vaccine are considered to provide 
long-lasting im m unity (135). Although antibody levels decline 
following vaccination, a study examining neutralizing antibody 
levels up to 10 years following the second dose o f M M R  vaccine 
in children indicates that antibodies remain above the level 
considered protective (152).
Studies among H C P  in the United States during the measles 
resurgence in the late 1980s through early 1990s demonstrated 
that 4 % -1 0 %  o f all H C P  lacked measles IgG antibodies 
(153—156). D uring the 2008 Arizona outbreak, o f  the 1,077 
health-care providers born during or after 1957 w ithout 
docum ented measles immunity, 121 (11%) were seronegative 
(149). In a study o f measles seroprevalence among 469 newly 
hired H C P  at a hospital in N orth  Carolina who were born 
before 1957, and thus considered im m une by age, who could 
not provide written evidence o f im m unity to measles, serologic 
testing indicated that six (1.3%) lacked measles IgG antibodies 
(157). O ther serologic studies o f hospital-based H C P  indicate 
that 2%—9% o f those born before 1957 lacked antibodies to 
measles (156,158—160).
A su rv ey  c o n d u c te d  d u rin g  1 9 9 9 — 2 0 0 4  fo u n d  a 
seroprevalence o f measles antibodies o f 95.9%  among persons 
in the U.S. population aged 6—49 years (161). The survey
indicated that the lowest prevalence, 92 .4% , was am ong 
adults born during 1967-1976 (161). A 1999 study o f U.S. 
residents aged >20 years determined that 93% had antibodies 
to measles virus (162).
Vaccine Safety
Measles vaccine is administered in com bination with the 
mumps and rubella components as the M M R  vaccine in the 
United States. M onovalent measles vaccine rarely has been 
used in the United States in the past 2 decades and is no longer 
available. After decades o f  use, evidence demonstrates that 
M M R  vaccine has an excellent safety profile (134).
T h e  m ajority  o f  docum ented  adverse events occur in 
children. In rare circumstances, M M R  vaccination o f adults 
has been associated w ith  the follow ing adverse events: 
anaphylaxis (approximately 1.0—3.5 occurrences per million 
doses administered) (134), thrombocytopenia from the measles 
com ponent or rubella com ponent (a rate o f  three to four cases 
for every 100,000 doses) (134), and acute arthritis from the 
rubella com ponent (arthralgia develops among approximately 
25% o f rubella-susceptible postpubertal females after M M R 
vaccination, and approximately 10% have acute arthritis-like 
signs and symptoms) (135). W hen joint symptoms occur, they 
generally persist for 1 day-3 weeks and rarely recur (135). 
Chronic joint symptoms attributable to the rubella component 
o f the M M R  vaccine are reported very rarely, if  they occur at 
all. Evidence does not support an association between M M R 
vaccination and any o f the following: hearing loss, retinopathy, 
optic neuritis, Guillain-Barre Syndrome, type 1 diabetes, 
Crohn’s disease, or autism (135,163-169).
A woman can excrete the rubella vaccine virus in breast milk 
and transm it the virus to her infant, but the infection remains 
asymptomatic (135). Otherwise, persons who receive M M R 
or its com ponent vaccines do not transm it measles, rubella, 
or mumps vaccine viruses (135). No transmission o f M M R 
vaccine virus in a health-care setting has been documented.
Recommendations
Vaccination
All persons w ho w ork in health-care facilities should 
have presum ptive evidence o f im m unity to measles. This 
inform ation should be docum ented and readily available at 
the work location. Recently vaccinated H C P  do not require 
any restriction in their work activities.
Presumptive evidence o f im m unity to measles for persons 
who work in health-care facilities includes any o f the following:
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• written docum entation o f vaccination with 2 doses o f  live 
measles or M M R  vaccine administered at least 28 days 
apart,'!'
• laboratory evidence o f immunity, §
• laboratory confirmation o f disease, or
• birth before 1957.J
Prevaccination Testing
Prevaccination antibody screening before M M R  vaccination 
for an employee who does not have adequate presumptive 
evidence o f im m unity is not necessary unless the medical 
facility considers it cost effective (134,170-172) although 
no recent studies have been conducted. For H C P  who have 
2 docum ented doses o f M M R  vaccine or other acceptable 
evidence o f im m unity to measles, serologic testing for immunity 
is not recommended. In the event that a H C P  who has 2 
docum ented doses o f M M R  vaccine is tested serologically and 
determined to have negative or equivocal measles titer results, it 
is not recommended that the person receive an additional dose 
o f M M R  vaccine. Such persons should be considered to have 
presumptive evidence o f measles immunity. Docum ented age- 
appropriate vaccination supersedes the results o f subsequent 
serologic testing. Because rapid vaccination is necessary to halt 
disease transmission, during outbreaks o f measles, serologic 
screening before vaccination is not recommended.
Use of Vaccine and Immune Globulin for Treating 
Exposed Persons and Controlling Outbreaks
Follow ing airborne in fec tio n -co n tro l precautions and 
implementing other infection-control measures are im portant 
to control the spread o f measles but m ight fail to prevent 
all nosocomial transmission, because transmission to other 
susceptible persons might occur before illness is recognized. 
Persons infected w ith measles are infectious 4 days before rash 
onset through 4 days after rash onset.
W hen a person who is suspected o f having measles visits 
a health-care facility, airborne infection-control precautions 
should be followed stringently. The patient should be asked 
immediately to wear a medical mask and should be placed
! T he first dose o f measles-containing vaccine should be administered on or after 
the first birthday; the second dose should be administered no earlier than 28 
days after the first dose.
§ Measles im m unoglobulin (IgG) in  the serum; equivocal results should be 
considered negative.
J T he majority o f persons born before 1957 are likely to have been infected 
naturally and may be presumed immune, depending on current state or local 
requirements. For unvaccinated personnel born before 1957 who lack laboratory 
evidence o f measles imm unity or laboratory confirmation o f disease, health-care 
facilities should consider vaccinating personnel with 2 doses o f M M R  vaccine 
at the appropriate interval. For unvaccinated personnel born before 1957 who 
lack laboratory evidence o f measles im m unity or laboratory confirmation of 
disease, health-care facilities should recommend 2 doses o f M M R vaccine during 
an outbreak o f measles.
in an airborne-infection isolation room (i.e., a negative air- 
pressure room) as soon as possible. I f  an airborne-infection 
isolation room  is not available, the patient should be placed 
in a private room with the door closed and be asked to wear 
a mask. If  possible, only staff with presumptive evidence o f 
im m unity should enter the room o f a person with suspect or 
confirmed measles. Regardless o f presumptive immunity status, 
all staff entering the room should use respiratory protection 
consistent with airborne infection-control precautions (i.e., use 
o f an N 95 respirator or a respirator with similar effectiveness 
in preventing airborne transmission) (3,150).
Because o f the possibility, albeit low (~1%), o f measles 
vaccine failure in H C P  exposed to infected patients (173), 
all H C P  should observe airborne precautions in caring for 
patients with measles. H C P  in whom  measles occurs should 
be excluded from work until >4 days following rash onset. 
C ontacts w ith  m easles-com patible sym ptom s should be 
isolated, and appropriate infection-control measures (e.g., rapid 
vaccination o f susceptible contacts) should be implemented to 
prevent further spread (174).
If  measles exposures occur in a health-care facility, all contacts 
should be evaluated immediately for presumptive evidence o f 
measles immunity. H C P without evidence o f im m unity should 
be offered the first dose o f M M R  vaccine and excluded from 
work from day 5-21 following exposure (135). H C P w ithout 
evidence o f im m unity who are not vaccinated after exposure 
should be removed from all patient contact and excluded from 
the facility from day 5 after their first exposure through day 21 
after the last exposure, even if  they have received postexposure 
intramuscular im m une globulin o f 0.25 mL/kg (40 mg IgG/ 
kg) (135). Those with docum entation o f 1 vaccine dose may 
remain at work and should receive the second dose.
C ase-patien t con tacts w ho do n o t have presum ptive 
evidence o f measles im m unity should be vaccinated, offered 
intramuscular im m une globulin o f 0.25 mL/kg (40 mg IgG/ 
kg), which is the standard dosage for nonimmunocompromised 
persons (135), or quaran tined  un til 21 days after their 
exposure to the case-patient. Contacts with measles-compatible 
sym ptom s should be isolated, and appropriate infection- 
control measures should be implemented to prevent further 
spread. I f  im m une globulin is administered to an exposed 
person, observations should continue for signs and symptoms 
o f measles for 28 days after exposure because im m une globulin 
might prolong the incubation period.
Available data suggest that live virus measles vaccine, if  
administered within 72 hours of measles exposure, will prevent, 
or modify disease (134). Even if it is too late to provide effective 
postexposure prophylaxis by administering M M R, the vaccine can 
provide protection against future exposure to all three infections. 
Identifying persons who lack evidence ofmeasles immunity during
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contact investigations provides a good opportunity to offer M M R 
vaccine to protect against measles as well as mumps and rubella, 
not only for H C P who are part o f an organization’s vaccination 
program, but also for patients and visitors. If an exposed person is 
already incubating measles, M M R vaccination will not exacerbate 
symptoms. In these circumstances, persons should be advised that 
a measles-like illness occurring shortly after vaccination could be 
attributable either to natural infection or to the vaccine strain. 




Epidemiology and Risk Factors
M umps is an acute viral infection characterized by fever and 
inflamm ation o f the salivary glands (usually parotitis) (175). 
The spectrum o f illness ranges from subclinical infection (20% - 
40%) to nonspecific respiratory illness, sialadenitis including 
classic parotitis, deafness, orchitis, and meningoencephalitis; 
severity increases with age (175). In the prevaccine era, mumps 
was a com m on childhood illness, with approximately 186,000 
mumps cases reported in the United States per year (176). After 
the introduction o f the Jeryl Lynn strain m umps vaccine in 
1967 and the im plem entation o f the 1-dose m um ps vaccine 
policy for children in 1977 (177), reports o f m um ps cases in 
the United States declined 99% (178). During 1986-1987, an 
increase in reported mumps cases occurred, primarily affecting 
unvaccinated adolescents and young adults. In the late 1980s, 
sporadic outbreaks continued to occur that affected both 
unvaccinated and 1-dose vaccinated adolescents and young 
adults (178). In 1989, a second dose o f M M R  vaccine was 
recommended nationwide for better measles control among 
school-aged children (179). Historically low rates o f  mumps 
followed with only several hundred reported cases per year in 
the United States during 2000-2005.
In 1998, a national goal to eliminate mumps was set for 2010 
(180). However, in 2006, a total o f 6,584 m um ps cases were 
reported in the United States, the largest U.S. mumps outbreak 
in nearly 20 years (181-183). Whereas overall national mumps 
incidence was 2.2 per 100,000 population, eight states in 
the Midwest were the most affected, with 2.5-66.1 cases per
100.000 population (183). T he highest incidence (31.1 cases 
per 100,000 population) was am ong persons aged 18-24 
years (e.g., college-aged students), the majority o f  whom  had 
received 2 doses o f m um ps-containing vaccine. O f  the 4,017 
case-patients for whom age and vaccination status were known, 
1,786 (44%) were aged >25 years (incidence: 7.2 cases per
100.000 persons); o f these 1,786 patients, 351 (20%) received
at least 2 doses, 444 (25%) received 1 dose, 336 (19%) were 
unvaccinated, and 655 (37%) had unknown vaccination status.
Since the 2006 resurgence, two additional large U.S. mumps 
outbreaks have occurred, both during 2009-2010, one among 
m em bers o f  a religious com m unity  w ith  cases occurring 
throughout the northeastern United States (184) and the other 
in Guam  (185); both outbreaks primarily affected children 
and adolescents in crowded environments who had received 
2 doses o f vaccine.
Vaccine coverage in the U nited States is high; in 2010, 
approximately 91.5%  o f children aged 19-35 m onths had 
received 1 dose o f M M R  vaccine (21); during 2009-2010, a 
total o f 94.8% ofkindergartners had evidence o f 2 doses (148). 
In 2010, a total o f  90.5%  o f adolescents had evidence o f 2 
doses (22). Nationally representative data on M M R  vaccine 
coverage o f U.S. H C P  are not available.
Mumps Transmission and the Costs of Mitigating 
Mumps Exposures in Health-care Settings
Although health-care-associated transmission o f m um ps 
is infrequent, it m ight be underreported because o f the high 
percentage (~20% -40% ) o f infected persons who might be 
asym ptom atic (186-189). In a survey o f 9,299 adults in 
different professions conducted in 1968, before vaccine was 
used routinely, the rate o f  m umps acquisition was highest 
among dentists and HCP, with rates o f 18% among dentists 
and 15% among physicians (37% for pediatricians), compared 
w ith 9% among prim ary and secondary school teachers and 
2% among university staff members (190).
In the postvaccine era, m um ps transm ission also has 
been docum ented in medical settings (191-193 ). D uring a 
Tennessee m um ps outbreak during 1986-1987, a total o f 17 
(12%) o f 146 hospitals and three (50%) o f six long-term -care 
facilities reported one or more practices that could contribute 
to the spread o f m umps, including not isolating patients with 
mumps, assigning susceptible staff to care for patients with 
mumps, and not im munizing susceptible employees. H ealth­
care-associated transmission resulted in six cases o f mumps 
infections am ong health-care providers and nine cases o f 
mum ps infections among patients (191). In Utah in 1994, 
two health-care providers in a hospital developed mumps after 
they had contact with an infected patient (192). D uring the 
2006 outbreak, one health-care facility in Chicago experienced 
ongoing m um ps transmission lasting 4 weeks (193).
D uring the 2006 m ultistate U.S. outbreak, 144 (8.5%) 
o f 1,705 adult case-patients in Iowa for whom  occupation 
was know n were health-care providers (Iowa D epartm ent 
o f  P ub lic  H ea lth , u n p u b lish ed  data , 20 06 ). W h e th e r  
transmission occurred from patients, coworkers, or persons in
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the com m unity is unknown. D uring the 2009-2010 outbreak 
in the northeastern region o f the United States, seven (0.2%) 
o f the 3,400 case-patients were health-care providers, six of 
whom  likely were infected by patients because they had no 
other known exposure.
Exposures to m um ps in health-care settings also can result 
in added economic costs because o f furlough or reassignment 
o f staff members from patient-care duties or closure o f wards 
(194). In 2006, a Kansas hospital spent $98,682 containing a 
mumps outbreak (195). During a mumps outbreak in Chicago 
in 2006, one health-care facility spent $262,788 controlling 
the outbreak (193).
Vaccine Effectiveness, Duration of Immunity and 
Seroprevalence Studies, and Vaccine Safety
Vaccine Effectiveness
M M R  vaccine has a 1-dose vaccine effectiveness in preventing 
mumps o f 80% -85%  (range: 75% -91% ) (175,196-199) and 
a 2-dose vaccine effectiveness o f 79% -95%  (199-202). In a 
study conducted on two Iowa college campuses during the 
2006 mumps outbreak among a population that was primarily 
vaccinated with 2 doses, 2-dose vaccine effectiveness ranged 
from 79%  to 88% (202).
Duration of Immunity and Seroprevalence Studies
M umps antibody levels wane over time following the first 
or second dose o f vaccination (203,204), but the correlates 
o f  im m un ity  to m um ps are poorly  understood  and the 
significance o f these w aning antibody levels is unclear. A 
study on a university campus in Nebraska in 2006 indicated 
lower levels o f m um ps neutralizing antibodies among students 
who had been vaccinated w ith a second M M R  dose >15 
years previously than among those who had been vaccinated 
1-5 years previously, but the difference was not statistically 
significant (p>0.05) (205). In a 2006 study on a university 
campus in Kansas, students w ith m um ps were more likely 
to have received a second dose o f M M R  vaccine >10 years 
previously than were their roommates w ithout mumps (206). 
However, another 2006 study from an Iowa college campus 
identified no such association (202).
D uring 1999-2004, national seroprevalence for m um ps 
antibodies for persons aged 6 -4 9  years was 90%  (95% 
confidence interval [CI]: 88.8-91.1) (207). In the Nebraska 
study, 414 (94%) o f the 440 participants were seropositive for 
m umps antibodies (205). A  study in Kansas in 2006 indicated 
that 13% of hospital employees lacked antibodies to the mumps 
virus (195). In a recent study on mumps seroprevalence among 
381 newly hired health-care personnel at a hospital in N orth 
Carolina who were born before 1957 and thus considered
im m une by age and who could not provide w ritten evidence 
o f im m unity to m umps, serologic testing indicated that 14 
(3.7%) lacked IgG antibodies to m umps (157).
Vaccine Safety
M umps vaccine is administered in com bination with the 
measles and rubella components as the M M R  vaccine in the 
United States. M onovalent mumps vaccine has rarely been 
used in the United States in the past 2 decades and is no longer 
available. After decades o f  use, evidence demonstrates that 
M M R  vaccine has an excellent safety profile. The most common 
adverse reactions to the mumps component of the M M R  vaccine 
are parotitis 10-14 days after vaccination and low-grade fever 
(175). O n  the basis o f biologic plausibility, orchitis, arthritis, 
or sensorineural deafness might rarely follow vaccination (175).
T he  m ajority  o f  docum ented  adverse events occur in 
ch ild ren . In  rare circum stances, M M R  vacc ina tion  o f  
adults has been associated with anaphylaxis (approximately 
1.0—3.5 occurrences per million doses administered) (134), 
throm bocytopenia from the measles com ponent or rubella 
com ponent (rate: three to four cases for every 100,000 
doses) (134), and acute arthritis from the rubella com ponent 
(arthralgia develops among approximately 25% o f rubella- 
susceptible postpubertal females after M M R  vaccination, 
and approximately 10% have acute arthritis-like signs and 
symptoms) (135). W hen joint symptoms occur, they generally 
persist for 1 day-3 weeks and rarely recur (135). Chronic joint 
symptoms attributable to the rubella com ponent o f the M M R  
vaccine are reported rarely, if  they occur at all. Evidence does 
not support a link between M M R  vaccination and hearing loss, 
retinopathy, optic neuritis, Guillain-Barre Syndrome, type 1 
diabetes, Crohn’s disease, or autism (135,163-169).
A woman can excrete the rubella vaccine virus in breast milk 
and transm it the virus to her infant, but the infection remains 
asymptomatic (135). Otherwise, persons who receive M M R 
or its com ponent vaccines do not transm it measles, rubella, 
or mumps vaccine viruses (135). No transmission o f M M R 
vaccine virus in a health-care setting has been documented.
Recommendations
Vaccination
All persons w ho w ork in health-care facilities should 
have presum ptive evidence o f im m unity to m um ps. This 
inform ation should be docum ented and readily available at 
the work location. Recently vaccinated H C P  do not require 
any restriction in their work activities.
Presumptive evidence o f im m unity to mumps for persons 
who work in health-care facilities includes any o f the following:
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• written docum entation o f vaccination with 2 doses o f  live 
m umps or M M R  vaccine administered at least 28 days 
apart,**
• laboratory evidence o f im m unity ,^
• laboratory confirmation o f disease, or
• birth before 1957.§§
Prevaccination Testing
For H C P who do not have adequate presumptive evidence 
o f m um ps im m unity , prevaccination an tibody screening 
before M M R  vaccination is not necessary (135,175 ). For 
H C P  who have 2 docum ented doses o f M M R  vaccine or 
other acceptable evidence o f im m unity to m umps, serologic 
testing for im m unity  is no t recom m ended. In the event 
that a health-care provider who has 2 docum ented doses 
o f M M R  vaccine is tested serologically and determ ined to 
have negative or equivocal m um ps titer results, it is not 
recommended that the person receive an additional dose of 
M M R  vaccine. Such persons should be considered im m une to 
mumps. Docum ented age-appropriate vaccination supersedes 
the results o f subsequent serologic testing. Likewise, during 
outbreaks o f m umps, serologic screening before vaccination 
is not recommended because rapid vaccination is necessary to 
halt disease transmission.
Controlling Mumps Outbreaks in Health-Care Settings
Placing patients in droplet precautions and implementing 
other infection-control measures is im portant to control the 
spread o f m um ps but might fail to prevent all nosocomial 
transmission, because transmission to other susceptible persons 
might occur before illness is recognized (208). W hen a person 
suspected o f having m um ps visits a health-care facility, only 
H C P  w ith  adequate presum ptive evidence o f  im m unity  
should be exposed to the person, and in addition to standard 
precautions, droplet precautions should be followed. The index 
case-patient should be isolated, and respiratory precautions
** The first dose o f mumps-containing vaccine should be administered on or
after the first birthday; the second dose should be administered no earlier than 
28 days after the first dose.
^  Mumps immunoglobulin (IgG) in the serum; equivocal results should be 
considered negative.
§§ T he majority o f persons born before 1957 are likely to have been infected 
naturally between birth and 1977, the year that m um ps vaccination was 
recommended for routine use, and may be presumed immune, even if they 
have no t had clinically recognizable m um ps disease. (This m ight vary 
depending on current state or local requirements.) For unvaccinated personnel 
born before 1957 who lack laboratory evidence o f m um ps im m unity or 
laboratory confirm ation o f disease, health-care facilities should consider 
vaccinating personnel with 2 doses o f M M R vaccine at the appropriate interval; 
for unvaccinated personnel born before 1957 who lack laboratory evidence 
of mumps immunity or laboratory confirmation of disease, health-care facilities 
should recommend 2 doses of M M R  vaccine during an outbreak o f mumps.
(gown and gloves) should be used for patient contact. Negative 
pressure rooms are not required. The patient should be isolated 
for 5 days after the onset o f parotitis, during which time 
shedding o f virus is likely to occur (209).
If  mumps exposures occur in a health-care facility, all contacts 
should be evaluated for evidence o f m um ps immunity. H C P 
with no evidence o f m umps im m unity who are exposed to 
patients w ith m um ps should be offered the first dose o f  M M R  
vaccine as soon as possible, but vaccine can be administered 
at any interval following exposure; they should be excluded 
from duty from day 12 after the first unprotected exposure 
through day 25 after the most recent exposure. H C P  with 
docum entation o f 1 vaccine dose may remain at work and 
should receive the second dose. H C P with m um ps should be 
excluded from work for 5 days from the onset o f parotitis (209).
Antibody response to the m um ps com ponent o f M M R  
vaccine generally is believed not to develop soon enough 
to provide effective prophylaxis after exposure to suspected 
m um ps (191 ,210), bu t data are insufficient to rule out 
a p ro p h y lac tic  effect. N o netheless , the  vaccine is no t 
recom m ended for prophylactic purposes after exposure. 
However, identifying persons who lack presumptive evidence 
o f m um ps im m unity during contact investigations provides 
a good opportunity to offer M M R  vaccine to protect against 
mumps as well as measles and rubella, not only for H C P who 
are part o f an organization’s vaccination program, but also for 
patients and visitors. If  an exposed person already is incubating 
mumps, M M R  vaccination will not exacerbate the symptoms. 
In these circum stances persons should be advised that a 
mumps-like illness occurring shortly after vaccination is likely 
to be attributable to natural infection. In such circumstances, 
specimens should be subm itted for viral strain identification 
to differentiate between vaccine and wild type virus. Im m une 
globulin is not routinely used for postexposure protection from 
mumps because no evidence exists that it is effective (135).
Rubella
Background
Epidemiology and Risk Factors
Rubella (German measles) is a viral disease characterized 
by rash, low-grade fever, lym phadenopathy, and malaise 
(211). A lthough rubella is considered a benign disease, 
transient arthralgia and arthritis are observed commonly in 
infected adults, particularly am ong postpubertal females. 
Chronic arthritis has been reported after rubella infection, 
but such reports are rare, and evidence o f an association is 
weak (212). O ther com plications that occur infrequently
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are throm bocytopenia and encephalitis (211). Infection is 
asymptomatic in 25% —50% of cases (213). Clinical diagnosis 
o f  rubella is unreliable and should no t be considered in 
assessing im m une status. M any rash illnesses might mimic 
rubella infection and m any rubella infections are unrecognized. 
T he only reliable evidence o f previous rubella infection is the 
presence o f serum rubella IgG antibody (211).
O f  prim ary concern are the effects that rubella can have 
when a pregnant woman becomes infected, especially during 
the first trimester, which can result in miscarriages, stillbirths, 
therapeutic  abortions, and congenital rubella syndrom e 
(CRS), a constellation o f birth defects that often includes 
blindness, deafness, mental retardation, and congenital heart 
defects (211,213). Postnatal rubella is transm itted through 
direct or droplet contact from nasopharyngeal secretions. The 
incubation period ranges from 12 to 23 days (214,215). An 
ill person is most contagious when the rash first appears, but 
the period o f maximal communicability extends from a few 
days before to 7 days after rash onset (213). Rubella is less 
contagious than measles.
In the prevaccine era, rubella was an endemic disease globally 
w ith larger epidemics that occurred; in the U nited States, 
rubella epidemics occurred approximately every 7 years (211). 
D uring the 1964—1965 global rubella epidemic, an estimated
12.5 million cases o f rubella occurred in the United States, 
resulting in approximately 2,000 cases o f encephalitis, 11,250 
fetal deaths attributable to spontaneous or surgical abortions, 
2,100 infants who were stillborn or died soon after birth, and
20,000 infants born w ith CRS. The economic impact o f this 
epidemic in the United States alone was estimated at $1.5 
billion in 1965 dollars ($10 billion in 2010 dollars) (216).
After the rubella vaccine was licensed in the United States in 
1969, reported rubella cases decreased from 57,686 in 1969 
to 12,491 in 1976 (216), and CRS cases reported nationwide 
decreased from 68 in 1970 to 23 in 1976 (217). Declines 
in rubella age-specific incidence occurred in all age groups, 
including adolescents and adults, but the greatest declines were 
among children aged <15 years (216). D uring 1977—1978, 
a resurgence o f  rubella occurred, prim arily am ong older 
adolescents and young adults, because the initial vaccination 
strategy targeted children (218). D uring this resurgence, 62% 
o f reported rubella cases occurred among persons aged >15 
years compared with 23% o f cases during 1966—1968 (135). 
As a result o f the change in the epidemiologic profile o f rubella, 
in 1977, ACIP modified its recommendations to include the 
vaccination o f susceptible postpubertal girls and women. In 
1989, a second M M R  vaccination dose was recommended in 
response to large measles outbreaks nationwide (179). During
2001—2004, the annual numbers o f rubella and CRS cases 
were extremely low, with 23 reported rubella cases in 2001, 
a total o f 18 in 2002, a total o f 7 in 2003, and a total o f 9 in
2004 (219).
Rubella was declared eliminated from the United States in 
2004 (219,220). D uring 2005—2009, a total o f 54 cases of 
rubella were reported; the majority o f the cases occurred among 
persons aged >20 years. O f  the reported cases, 23 (43%) were 
import-associated; only two outbreaks o f rubella were reported 
during this time, and both involved only three cases (CD C, 
unpublished data, 2009). Since 2005, only four cases o f CRS 
have been reported, with two cases reported in 2009; three 
(75%) cases were acquired internationally, and the other had 
an unknow n source (CD C, unpublished data, 2009). Rubella 
importations are expected to continue in the immediate future.
As o f September 2011, only three states (i.e., New York, 
Oklahoma, and Rhode Island) had laws m andating that all 
hospital personnel have proof o f rubella im m unity and did 
not allow for religious or philosophical exemptions (147). 
Additional states had requirements for specific types o f facilities 
or for certain employees within those facilities, but they did 
not have universal laws m andating p roof o f rubella im m unity 
for all hospital personnel (147).
M M R  vaccine coverage in the United States is high; in 
2010, an estimated 91.5%  o f children aged 19—35 months 
had received 1 dose o f M M R  vaccine (21); during 2009—2010, 
a total o f  94.8%  o f kindergarteners had evidence o f 2 doses 
(148); and in 2010, a total o f  90.5%  o f adolescents had 
evidence o f 2 doses (22). Nationally representative data on 
M M R  vaccine coverage o f U.S. H C P are not available.
Rubella Transmission and the Costs of Mitigating 
Rubella Exposures in Health-Care Settings
No documented transmission o f rubella to H C P or other 
hospital staff or patients in U.S. health-care facilities has occurred 
since elimination was declared. However, in the decades before 
elimination, rubella transmission was documented in at least 
10 U.S. medical settings (221—231) and led to outbreaks 
with serious consequences, including pregnancy terminations, 
disruption of hospital routine, absenteeism from work, expensive 
containm ent measures, negative publicity, and the threat o f 
litigation (232). In these outbreaks, transmission occurred 
from H C P to susceptible coworkers and patients, as well as 
from patients to H C P and other patients. No data are available 
on whether H C P are at increased risk for acquiring rubella 
compared with other professions.
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Vaccine Effectiveness, Duration of Immunity and 
Seroprevalence Studies, and Vaccine Safety 
Vaccine Effectiveness
Vaccine effectiveness o f  the RA 27/3 rubella vaccine against 
clinical rubella is 95% (85%—99%  CI) and >99% for clinical 
laboratory confirmed rubella (211,233). Antibody responses 
to rubella as part o f M M R  vaccine are equal (i.e., >99%) to 
those seen after the single-antigen RA 27/3 rubella vaccine 
(211,234).
Duration of Immunity and Seroprevalence Studies
In clinical trials, 97% —99%  o f susceptible persons who 
received a single dose o f the RA 27/3 rubella vaccine when 
they were aged >12 months developed antibody (211,235,236). 
Two studies have dem onstrated that vaccine-induced rubella 
antibodies m ight wane after 12—15 years (237,238); however, 
rubella surveillance data do not indicate that rubella and CRS 
are increasing among vaccinated persons.
N ational seroprevalence for rubella antibodies am ong 
persons aged 6—49 years during 1999—2004 was 91% (239). 
During 1986—1990, serologic surveys in one hospital indicated 
that 5% o f H C P  (including persons born in 1957 or earlier) 
did not have detectable rubella antibody (240). Earlier studies 
indicated that up to 14%—19% of U.S. hospital personnel, 
including young women o f childbearing age, lacked detectable 
rubella antibody (225,241,242). In a recent study on rubella 
seroprevalence among 477 newly hired H C P at a hospital 
in N orth  Carolina who were born before 1957, and thus 
considered im m une by age, who could not provide written 
evidence o f im m unity to rubella, serologic testing revealed that 
14 (3.1%) lacked detectable levels o f antibody to rubella (157).
Because o f the potential for contact with pregnant women in 
any type of health-care facility, all H C P should have documented 
presumptive evidence o f im m unity to rubella. History of disease 
is not considered adequate evidence of immunity.
Vaccine Safety
Rubella vaccine is administered in com bination with the 
measles and m um ps com ponents as the M M R  vaccine in 
the United States. M onovalent rubella vaccine has been used 
rarely in the United States in the past 2 decades and is no 
longer available. After decades o f use, evidence demonstrates 
that M M R  vaccine has an excellent safety profile. T he most 
com m on adverse reactions to the rubella com ponent o f the 
M M R  vaccine are transient rashes, which usually appear 7—10 
days after vaccination in approximately 5% o f vaccinated 
persons, or transient lymphadenopathy, fever, sore throat, and 
headache (135,211).
T he  m ajority  o f  docum ented  adverse events occur in 
children. In rare circumstances, M M R  vaccination o f adults 
has been associated w ith  the follow ing adverse events: 
anaphylaxis (approximately 1.0—3.5 occurrences per million 
doses administered) (134), thrombocytopenia from the measles 
com ponent or rubella com ponent (rate: three to four cases 
for every 100,000 doses) (134), and acute arthritis from the 
rubella com ponent (arthralgia develops among approximately 
25% o f rubella-susceptible postpubertal females after M M R  
vaccination, and approximately 10% have acute arthritis­
like signs and symptoms from the rubella com ponent o f the 
vaccine) (135). W hen joint symptoms occur, they generally 
persist for 1 day—3 weeks and rarely recur (135). Chronic joint 
symptoms attributable to the rubella com ponent o f the M M R  
vaccine are very rarely reported, if  they occur at all.
As a result o f the theoretic risk to the fetus, women should 
be counseled to avoid becoming pregnant for 28 days after 
receipt o f a rubella-containing vaccine (243). However, receipt 
o f rubella-containing vaccine during pregnancy should not 
be a reason to consider term ination o f pregnancy; data from 
18 years o f following to term 321 known rubella-susceptible 
women who were vaccinated w ithin 3 m onths before or 3 
m onths after conception indicated that none o f the 324 
infants born to these mothers had malformations compatible 
with congenital rubella syndrome, but five had evidence o f 
subclinical rubella infection (244). T he estimated risk for 
serious malformations to fetuses attributable to the m other 
receiving RA 27/3 vaccine is considered to range from zero 
to 1.6% (135,244).
Evidence does not support a link between M M R  vaccination 
and any o f the following: hearing loss, retinopathy, optic 
neuritis, Guillain-Barre Syndrome, type 1 diabetes, Crohn’s 
disease, or autism (135,163—169).
A woman can excrete the rubella vaccine virus in breast milk 
and transm it the virus to her infant, but the infection remains 
asymptomatic (135). Otherwise, persons who receive M M R  
or its com ponent vaccines do not transm it measles, rubella, 
or m umps vaccine viruses (135). No transmission o f M M R 
vaccine virus in a health-care setting has been documented.
Recommendations
Vaccination
All persons who work in health-care facilities should have 
presumptive evidence o f im m unity to rubella. Adequate rubella 
vaccination for H C P consists o f 1 dose o f M M R  vaccine. 
However, because o f the 2-dose vaccination requirements for 
measles and mumps, the use o f the combined M M R  vaccine 
will result in the majority of H C P receiving 2 doses of rubella- 
containing vaccine, which should provide an additional safeguard
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against primary rubella vaccine failure. Recently vaccinated H CP 
do not require any restriction in their work activities.
Presumptive evidence o f im m unity to rubella for persons 
who work in health-care facilities includes any of the following:
• written docum entation o f vaccination w ith 1 dose o f live 
rubella or M M R  vaccine,
• laboratory evidence o f im m unity ,^
• laboratory confirm ation o f rubella infection or disease, or
• b irth  before 1957*** (except w om en o f childbearing 
potential who could become pregnant, although pregnancy 
in this age group would be exceedingly r a r e ^ ) .
Prevaccination Testing
For H C P who do not have adequate presumptive evidence 
o f  rubella im m unity, prevaccination an tibody  screening 
before M M R  vaccination is not necessary unless the medical 
facility considers it cost effective (135). For H C P who have 
1 docum ented dose o f M M R  vaccine or other acceptable 
evidence o f immunity to rubella, serologic testing for immunity 
is not recommended. In the event that a health-care provider 
who has at least 1 docum ented dose o f rubella-containing 
vaccine is tested serologically and determined to have negative 
or equivocal rubella titer results, receipt o f an additional dose o f 
M M R  vaccine for prevention o f rubella is not recommended. 
Such persons should be considered im m une to rubella. 
However, if  the provider requires a second dose o f measles 
or m um ps vaccine, then a second dose o f M M R  should be 
adm inistered . D ocum en ted  age-appropriate  vaccination 
supersedes the results o f subsequent serologic testing. Likewise, 
du ring  outbreaks o f  rubella, serologic screening before 
vaccination is not recommended because rapid vaccination is 
necessary to halt disease transmission.
Controlling Rubella Outbreaks
To prevent transmission o f rubella in health-care settings, 
patients suspected to have rubella should be placed in private 
rooms. In addition to standard precautions, droplet precautions
JJ Rubella immunoglobulin (IgG) in the serum; equivocal results should be 
considered negative.
*** Depending on current state or local requirements, for unvaccinated personnel 
born before 1957 who lack laboratory evidence o f rubella im m unity or 
laboratory confirmation o f infection or disease, health-care facilities should 
consider vaccinating personnel w ith one dose o f M M R  vaccine; for 
unvaccinated personnel born before 1957 who lack laboratory evidence of 
rubella im m unity or laboratory confirmation o f infection or disease, health­
care facilities should recommend 1 dose of M M R vaccine during an outbreak 
o f rubella.
^  Because rubella can occur in some persons born before 1957 and because 
congenital rubella and congenital rubella syndrome can occur in the offspring 
o f women infected with rubella virus during pregnancy, birth before 1957 
is not acceptable evidence o f rubella im munity for women who could become 
pregnant.
should be followed until 7 days after onset o f symptoms. Room 
doors can remain open, and special ventilation is not required.
Any exposed H C P who do not have adequate presumptive 
evidence o f rubella im m unity should be excluded from duty 
beginning 7 days after exposure to rubella and continuing 
through either 1) 23 days after the most recent exposure or
2) 7 days after rash appears if the provider develops rubella 
(213—215). Exposed H C P  w ho do n o t have adequate 
presum ptive evidence o f im m u n ity  w ho are vaccinated 
postexposure should be excluded from duty for 23 days after 
the most recent exposure to rubella because no evidence exists 
that postexposure vaccination is effective in preventing rubella 
infection (244).
N either rubella-contain ing vaccine (244) nor im m une 
g lob u lin  (IG ) (211 ,24 4)  is effective for postexposure  
prophylaxis o f rubella. Although intramuscular administration 
o f 20 mL o f im m une globulin w ithin 72 hours o f rubella 
exposure might reduce the risk for rubella, it will not eliminate 
the risk (135,245); infants with congenital rubella have been 
born to wom en who received IG shortly after exposure (213). 
In addition, adm inistration o f IG after exposure to rubella 
might modify or suppress symptoms and create an unwarranted 
sense o f security with respect to transmission.
If  exposure to rubella does not cause infection, postexposure 
vaccination w ith M M R  vaccine should induce protection 
against subsequent infection o f rubella, as well as measles 
and mumps. If  the exposure results in infection, no evidence 
indicates that adm inistration o f M M R  vaccine during the 
presymptomatic or prodromal stage o f illness increases the risk 
for vaccine-associated adverse events (213).
Pertussis
Background
Epidemiology and Risk Factors
Pertussis is a highly contagious bacterial infection. Secondary 
attack rates am ong susceptible household contacts exceed 
80% (246,247). Transmission occurs by direct contact with 
respiratory secretions or large aerosolized droplets from the 
respiratory tract o f infected persons. The incubation period is 
generally 7—10 days but can be as long as 21 days. The period 
o f communicability starts w ith the onset o f the catarrhal stage 
and extends into the paroxysmal stage. Symptoms o f early 
pertussis (catarrhal phase) are indistinguishable from other 
upper respiratory infections.
Vaccinated adolescents and adults, whose im m unity from 
childhood vaccinations wanes 5—10 years after the most recent 
dose o f vaccine (usually administered at age 4—6 years), are an
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im portant source o f pertussis infection for susceptible infants. 
Infants too young to be vaccinated are at greatest risk for severe 
pertussis, including hospitalization and death. T he disease 
can be transm itted from adults to close contacts, especially 
unvaccinated children.
V accination coverage am ong infants and child ren  for 
diphtheria and tetanus toxoids and acellular pertussis (DTaP) 
vaccine remains high. In 2010, coverage for children aged 
19—35 months who have received >4 doses o f DTaP/diphtheria 
and tetanus toxoids and pertussis vaccine (D TP)/diphtheria 
and tetanus toxoids vaccine (D T) was 84% (21). Among 
children entering kindergarten for the 20 09-2010  school 
year, DTaP coverage was 93% (148). Vaccination coverage 
for tetanus toxoid, reduced diphtheria toxoid and acellular 
pertussis (Tdap) vaccine was 68.7% among adolescents in 2010 
and <7% among adults in 2009 (22,248). Tdap vaccination 
coverage among H C P  was 17.0% in 2009 (248).
Disease in Health-Care Settings and Impact on Health­
Care Personnel and Patients
In hospital settings, transmission o f pertussis has occurred 
from hospital visitors to patients, from H C P to patients, and 
from patients to H C P  (249—252). Although o f limited size 
(range: 2 -1 7  patients and 5-13 staff), docum ented outbreaks 
were costly and disruptive. In each outbreak, H C P  were 
evaluated for cough illness and required diagnostic testing, 
prophylactic antibiotics, and exclusion from work.
D uring  outbreaks that occur in hospitals, the risk for 
contracting pertussis among patients or staff is often difficult 
to quantify because exposure is not well defined. Serologic 
studies conducted among hospital staff indicate that exposure 
to pertussis is m uch more frequent than suggested by attack 
rates o f  clinical disease (246,249—254). In one outbreak, 
seroprevalence o f pertussis agglutinating antibodies among 
H C P  correlated w ith  the degree o f pa tien t con tact and 
was highest am ong pediatric house staff (82%) and ward 
nurses (71%) and lowest among nurses with administrative 
responsibilities (35%) (251).
A model to estimate the cost o f vaccinating H C P and the net 
return from preventing nosocomial pertussis was constructed 
using probabilistic m ethods and a hypothetical cohort of
1,000 H C P  with direct patient contact followed for 10 years 
(255). Baseline assumptions, determ ined from data in the 
literature, included incidence o f pertussis in HCP, ratio of 
identified exposures per H C P case, symptomatic percentage of 
seroconfirmed pertussis infections in HCP, cost o f infection- 
control measures per exposed person, vaccine efficacy, vaccine 
coverage, employment turnover rate, adverse events, and cost 
o f vaccine (255). In a 10-year period, the cost o f infection
control would be $388,000 w ithout T dap vaccination of 
H C P compared with $69,000 with such a program (255). 
Introduction o f a vaccination program would result in a net 
savings as high as $535,000 and a benefit-cost ratio o f 2.38 
(i.e., for every dollar spent on the vaccination program, the 
hospital would save $2.38 on control measures) (255).
Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety
A pre licensure  im m u n o g en ic ity  and  safety s tu d y  in 
adolescents and adults o f  a vaccine contain ing acellular 
pertussis estimated vaccine efficacy to be 92% (256). Recent 
postlicensure studies ofTdap demonstrate vaccine effectiveness 
at 78%  and 66% (257,258). D uration o f im m unity from 
vaccination has yet to be evaluated. D ata from  pre- and 
postlicensure studies support the safety ofTdap in adolescents 
and adults (259—263).
Since the 2005 Tdap recommendations for HCP, one study 
tried to determine if postexposure prophylaxis following pertussis 
exposure was necessary for Tdap-vaccinated H C P  (264). 
During the study period, 116 exposures occurred among 94 
HCP. Pertussis infection occurred in 2% o f those who received 
postexposure prophylaxis compared with 10% o f those who did 
not, suggesting a possible benefit o f postexposure prophylaxis 
among Tdap-vaccinated H C P (264). Because Tdap coverage is 
suboptimal among HCP, and the duration o f protection afforded 
by Tdap is unknown, vaccination status does not change the 
approach to evaluate the need for postexposure prophylaxis in 
exposed H C P Postexposure prophylaxis is necessary for H C P in 
contact with persons at risk for severe disease. O ther H C P either 
should receive postexposure prophylaxis or be monitored for 21 
days after pertussis exposure and treated at the onset o f signs and 
symptoms o f pertussis. Recommended postexposure prophylaxis 
antibiotics for H C P exposed to pertussis include azithromycin, 
clarithroymycin, or erythromycin. H C P are not at greater risk 
for diphtheria or tetanus than the general population.
Recommendations
Vaccination
Regardless o f age, H C P  should receive a single dose ofTdap 
as soon as feasible if they have not previously received Tdap and 
regardless o f the time since their most recent T d  vaccination. 
Vaccinating H C P with Tdap will protect them  against pertussis 
and is expected to reduce transmission to patients, other HCP, 
household members, and persons in the community. Tdap 
is not licensed for multiple administrations; therefore, after 
receipt o f Tdap, H C P  should receive T d  for future booster 
vaccination against tetanus and diphtheria. Hospitals and 
ambulatory-care facilities should provide T dap for H C P  and
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use approaches that maximize vaccination rates (e.g., education 
about the benefits o f vaccination, convenient access, and the 
provision o f Tdap at no charge).
Prevaccination Testing
Prevaccination serologic testing is not recommended.
Demonstrating Immunity
Im m u n ity  cannot be dem onstra ted  th ro ug h  serologic 
testing because serologic correlates o f  protection are not well 
established.
Controlling Pertussis Outbreaks in Health-Care 
Settings
Prevention o f pertussis transmission in health-care settings 
involves diagnosis and early treatment of clinical cases, droplet 
isolation o f infectious patients who are hospitalized, exclusion 
from work o f H C P  who are infectious, and postexposure 
prophylaxis. Early diagnosis o f pertussis, before secondary 
transmission occurs, is difficult because the disease is highly 
communicable during the catarrhal stage, when symptoms are 
still nonspecific. Pertussis should be considered in the differential 
diagnoses for any patient with an acute cough illness with severe 
or prolonged paroxysmal cough, particularly if characterized 
by posttussive vomiting, whoop, or apnea. Nasopharyngeal 
specimens should be taken, if  possible, from the posterior 
nasopharynx with a calcium alginate or Dacron swab for cultures 
and/or polymerase chain reaction (PCR) assay.
Health-care facilities should maximize efforts to prevent 
transmission o f Bordetella pertussis. Precautions to prevent 
respiratory droplet transmission or spread by close or direct 
contact should be employed in the care o f patients adm itted 
to hospital w ith suspected or confirm ed pertussis (265). 
These precautions should remain in effect until patients are 
improved clinically and have completed at least 5 days o f 
appropriate antimicrobial therapy. H C P in whom  symptoms 
(i.e., unexplained rhinitis or acute cough) develop after known 
pertussis exposure m ight be at risk for transm itting pertussis 
and should be excluded from work until 5 days after the start 
o f appropriate therapy (3).
D ata on the need for postexposure prophylaxis in Tdap- 
vaccinated H C P  are inconclusive (264). Certain vaccinated 
H C P  are still at risk for B. pertussis. Tdap might not preclude 
th e  need  for p o stex posu re  p rop hy lax is . P ostexposure 
antimicrobial prophylaxis is recommended for all H C P who 
have unprotected exposure to pertussis and are likely to expose 
a patient at risk for severe pertussis (e.g., hospitalized neonates 
and pregnant wom en). O ther H C P  should either receive 
postexposure antimicrobial prophylaxis or be m onitored daily
for 21 days after pertussis exposure and treated at the onset of 
signs and symptoms o f pertussis.
Varicella
Background
Epidemiology and Risk Factors
Varicella is a highly infectious disease caused by prim ary 
infection with varicella-zoster virus (VZV). VZV  is transmitted 
from person to person by direct contact, inhalation o f aerosols 
from vesicular fluid o f skin lesions o f  varicella or herpes zoster 
(HZ), a localized, generally painful vesicular rash commonly 
called shingles, or infected respiratory tract secretions that also 
m ight be aerosolized (266). The average incubation period is 
14-16 days after exposure to rash (range: 10-21 days). Infected 
persons are contagious an estimated 1 -2  days before rash 
onset until all lesions are crusted, typically 4 -7  days after rash 
onset (266). Varicella secondary attack rates can reach 90% 
among susceptible contacts. Typically, prim ary infection with 
VZV results in lifetime immunity. VZV remains dorm ant in 
sensory-nerve ganglia and can reactivate at a later time, causing 
H Z . Before the U.S. childhood varicella vaccination program 
began in 1995, approximately 90% ofvaricella disease occurred 
among children aged <15 years (266). D uring 1997-2009, 
national varicella vaccine coverage among children aged 19-35 
m onths increased from 27%  to 90% , leading to dramatic 
declines o f >85% in varicella incidence, hospitalizations, and 
deaths (267—269). The decline in disease incidence was greatest 
among children for whom  vaccination was recommended; 
however, declines occurred in every age group including infants 
too young to be vaccinated and adults, indicating reduced 
communitywide transmission o f VZV.
C u rre n t in c id ence  o f  varicella  am ong adu lts is low  
(<0.1/1,000 population), and adult cases represent <10% of 
all reported varicella cases (270). National seroprevalence data 
from 1999-2004 demonstrated that, in the early vaccine era, 
adults continued to have high im m unity to varicella (271). In 
this study, 98% o f persons aged 20 -49  years had VZV-specific 
IgG antibodies. However, with declining likelihood o f exposure 
to VZV, children and adolescents who did not receive 2 doses 
o f  varicella vaccine could remain susceptible to V Z V  infection 
as they age into adulthood, when varicella can be more severe.
T he clinical presentation o f varicella has changed since the 
im plem entation o f the varicella vaccination program, with 
more than half o f  varicella cases reported in 2008 occurring 
among persons who were vaccinated previously, the majority 
o f them  children. Varicella disease in vaccinated children 
(breakthrough varicella) usually has a modified or atypical 
presentation; the rash is typically mild, with <50 lesions that are
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more likely to be predom inantly maculopapular than vesicular 
(266). Fever is less com m on, and the duration o f  illness is 
shorter. Nevertheless, breakthrough varicella is infectious. One 
study indicated that vaccinated children with varicella with 
<50 lesions were only one third as infectious as unvaccinated 
children whereas those with >50 lesions were as infectious as 
unvaccinated children (272). Because the majority o f adults 
are im m une and few need vaccination, fewer breakthrough 
cases have been reported among adults than among children, 
and breakthrough varicella in adults has tended to be milder 
than varicella in unvaccinated adults (273,274).
The epidemiology o f varicella in tropical and subtropical 
regions differs from that in the U nited States. In these regions, 
a higher proportion ofV ZV  infections are acquired later in life. 
Persons emigrating from these regions m ight be more likely 
to be susceptible to varicella compared to U .S.-born persons 
and, therefore, are at a higher risk for developing varicella if 
unvaccinated and exposed (275,276).
Disease in Health-Care Settings and Impact on Health­
Care Personnel and Patients
A lth o u g h  re la tive ly  rare in  th e  U n ited  States since 
in troduction o f varicella vaccine, nosocomial transmission 
o f VZV is well recognized and can be life-threatening to 
certain patients (277—289). In addition to hospital settings, 
nosocomial V Z V  transmission has been reported in long- 
term -care facilities and a hospital-associated residential facility 
(290,291). Sources o f  nosocomial exposure that have resulted 
in transmission include patients, HCP, and visitors with either 
varicella or H Z . Both localized and dissem inated H Z  in 
im m unocom petent as well as im m unocompromised patients 
have been identified as sources o f nosocomial transmission of 
VZV. Localized H Z  has been dem onstrated to be m uch less 
infectious than varicella; disseminated H Z  is considered to be as 
infectious as varicella (266). Nosocomial transmission has been 
attributed to delays in the diagnosis or reporting o f varicella or 
H Z  and in failures to implement control measures promptly. In 
hospitals and other health-care settings, airborne transmission 
o f VZV from patients with either varicella or H Z  has resulted in 
varicella in H C P and patients who had no direct contact w ith 
the index case-patient (284—288,291). A lthough all susceptible 
patients in health-care settings are at risk for severe varicella 
disease with complications, certain patients w ithout evidence 
o f im m unity are at increased risk: pregnant women, premature 
infants born to susceptible mothers, infants born at <28 weeks’ 
gestation or who weigh <1,000 grams regardless o f maternal 
im m une status, and im m unocompromised persons o f all ages 
(including persons who are undergoing immunosuppressive 
therapy, have malignant disease, or are immunodeficient).
VZV exposures among patients and H C P can be disruptive 
to patient care, time-consuming, and costly even when they do 
not result in V ZV  transmission (281,282,292). Studies ofV ZV  
exposure in health-care settings have docum ented that a single 
provider with unrecognized varicella can result in the exposure 
o f  >30 patients and >30 employees (292). Identification 
o f susceptible patients and staff, medical m anagem ent o f 
susceptible exposed patients at risk for com plications o f 
varicella, and furloughing o f  susceptible exposed H C P are 
time-consuming and costly (281,282).
W ith the overall reduction in varicella disease attributable to 
the success o f  the vaccination program, the risk for exposure 
to VZV from varicella cases in health-care settings is likely 
declining. In addition, an increasing proportion o f  varicella 
cases occur in vaccinated persons who are less contagious. 
Diagnosis o f varicella has become increasingly challenging 
as a growing proportion o f cases occur in vaccinated persons 
in whom  disease is mild, and H C P encounter patients with 
varicella less frequently. A lthough not currently routinely 
recommended for the diagnosis and management o f varicella, 
laboratory testing o f suspected varicella cases is likely to become 
increasingly useful in health-care settings, especially as the 
positive predictive value o f clinical diagnosis declines.
Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety 
Vaccine Effectiveness
Formal studies to evaluate vaccine efficacy or effectiveness 
have not been performed among adults. Studies o f varicella 
vaccine effectiveness performed among children indicated good 
performance o f 1 dose for prevention o f all varicella (80% - 
85%) and >95% effectiveness for prevention o f  m oderate 
and severe disease (266,293). Studies have indicated that a 
second dose among children produces an improved hum oral 
and cellular im m une response that correlates with improved 
protection against disease (266,294).
Varicella vaccine effectiveness is expected to be lower in 
adults than in children. Adolescents and adults require 2 
doses to achieve seroconversion rates similar to those seen in 
children after 1 dose (266). A study o f adults who received 2 
doses o f varicella vaccine 4 or 8 weeks apart and were exposed 
subsequently to varicella in the household estimated an 80% 
reduction in the expected num ber o f cases (295).
Duration of Immunity
Serologic correlates o f  protection against varicella using 
commercially available assays have not been established for 
adults (266). In clinical studies, detectable antibody levels 
have persisted for at least 5 years in 97% o f adolescents and 
adults who were adm inistered 2 doses o f  varicella vaccine
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4 -8  weeks apart, but boosts in antibody levels were observed 
following exposures to varicella, which could account for 
the long-term  persistence o f antibodies after vaccination in 
these studies (295). Studies have dem onstrated that whereas 
25% —31% of adult vaccine recipients who seroconverted lost 
detectable antibodies 1-11 years after vaccination (273,296), 
vaccine-induced VZV-specific T-cell proliferation (marker for 
cell-mediated im m unity [CMI]) was maintained in 94% of 
adults 1 and 5 years postvaccination (297). Disease was mild 
in vaccinated persons who developed varicella after exposure 
to VZV, even among vaccinees who did not seroconvert or 
who lost detectable antibody (273,274). Severity o f illness 
and attack rates among vaccinated adults did not increase 
over time. These studies suggest that VZV-specific CM I 
affords protection to vaccinated adults, even in the absence of 
detectable antibody response.
Vaccine Safety
The varicella vaccine has an excellent safety profile. In clinical 
trials, the most com m on adverse events among adolescents and 
adults were injection-site complaints (24.4% after the first dose 
and 32.5%  after the second dose) (266,295). Varicella-like rash 
at the injection site occurred in 3% o f vaccine recipients after 
the first dose and in 1% after the second. A nonlocalized rash 
occurred in 5.5% o f vaccine recipients after the first dose and 
in 0.9% after the second, w ith a median num ber o f lesions 
o f five, at a peak o f 7 -21 and 0 -23  days postvaccination, 
respectively (295). Data on serious adverse events among adults 
after varicella vaccination are limited, but the proportion of 
serious adverse events among all adverse events reported to the 
Vaccine Adverse Events Reporting System during 1995-2005 
was low (5%) among both children and adults (298). Serious 
adverse events reported among children included pneum onia, 
hepatitis, H Z  (some hospitalized), m eningitis w ith  H Z , 
ataxia, encephalitis, th rom bocy topenic purpura. N o t all 
adverse events reported after varicella vaccination have been 
laboratory confirmed to be attributable to the vaccine strain 
V ZV  (266,298).
Risk for transmission o f vaccine virus was assessed in placebo 
recipients who were siblings o f vaccinated children and among 
healthy siblings o f vaccinated leukemic children (266). The 
findings suggest that transmission o f varicella vaccine virus 
from healthy persons to susceptible contacts is very rare. The 
risk might be increased in vaccinees in whom  a varicella-like 
rash develops after vaccination. However, this risk is also 
low. The benefits o f vaccinating H C P w ithout evidence of 
im m unity outweigh this extremely low potential risk. Since 
implementation o f the varicella vaccine program, transmission 
o f vaccine virus has been docum ented from eight persons 
(all o f whom  had a rash after vaccination) resulting in nine
secondary infections among household and long-term -care 




Health-care institutions should ensure that all H C P have 
evidence o f im m unity to varicella. This inform ation should 
be docum ented and readily available at the work location. 
H C P w ithout evidence o f im m unity to varicella should receive 
2 doses o f varicella vaccine administered 4 -8  weeks apart. 
If  >8 weeks elapse after the first dose, the second dose may 
be adm inistered w ithout restarting the schedule. Recently 
vaccinated H C P do not require any restriction in their work 
activities; however, H C P who develop a vaccine-related rash 
after vaccination should avoid contact with persons w ithout 
evidence o f im m unity to varicella who are at risk for severe 
disease and complications until all lesions resolve (i.e., are 
crusted over) or, if  they develop lesions that do not crust 
(macules and papules only), until no new lesions appear within 
a 24-hour period.
Evidence o f im m unity for H C P includes any of the following 
(266):
• w ritten docum entation o f vaccination w ith 2 doses of 
varicella vaccine,
• lab o ra to ry  evidence o f  im m unity§§§ or lab o ra to ry  
confirm ation o f disease,
• diagnosis or verification o f a history o f varicella disease by 
a health-care provider,JJJ or
• diagnosis or verification o f a history o f H Z  by a health-care 
provider.
In health-care settings, serologic screening before vaccination 
o f personnel w ithout evidence o f im m unity is likely to be cost 
effective. Key factors determining cost-effectiveness include 
sensitivity and specificity o f serologic tests, the nosocomial 
transmission rate, seroprevalence o f VZV antibody in the 
personnel population , and policies for m anaging vaccine 
recip ients developing po stvacc ina tion  rash or w ho are
§§§ Commercial assays can be used to assess disease-induced immunity, but they 
often lack sensitivity to detect vaccine-induced im m unity (i.e., they might 
yield false-negative results).
JJJ Verification o f history or diagnosis o f typical disease can be provided by any 
health-care provider (e.g., a school or occupational clinic nurse, nurse 
practitioner, physician assistant, or physician). For persons reporting a history 
of, or reporting with, atypical or mild cases, assessment by a physician or 
their designee is recommended, and one o f the following should be sought: 
1) an epidemiologic link to a typical varicella case or to a laboratory- 
confirmed case or 2) evidence o f laboratory confirmation if it was performed 
at the time o f acute disease. W hen such documentation is lacking, persons 
should not be considered as having a valid history o f disease because other 
diseases m ight mimic mild atypical varicella.
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exposed subsequently to VZV. Institutions may elect to test 
all unvaccinated HCP, regardless o f disease history, because a 
small proportion o f persons with a positive history o f disease 
might be susceptible. For the purpose o f screening HCP, a 
less sensitive and more specific commercial ELISA should be 
considered. The latex agglutination test can produce false- 
positive results, and H C P who remained unvaccinated because 
o f false test results subsequently contracted varicella (289).
R outine testing for varicella im m unity  after 2 doses of 
vaccine is not recommended. Available commercial assays are 
not sensitive enough to detect antibody after vaccination in 
all instances. Sensitive tests that are not generally available 
have indicated that 92% -99%  o f adults develop antibodies 
after the second dose (266). Seroconversion does not always 
result in full protection against disease and, given the role of 
CM I for providing long-term protection, absence o f antibodies 
does not necessarily m ean susceptibility. Docum ented receipt 
o f 2 doses o f  varicella vaccine supersedes results o f subsequent 
serologic testing.
H ealth-care institu tions should establish protocols and 
recom m endations for screening and vaccinating H C P and 
for management o f H C P after exposures in the work place. 
Institutions also should consider precautions for H C P  in 
whom  rash occurs after vaccination, although they should 
also consider the possibility o f  wild-type disease in H C P with 
recent exposure to varicella or H Z.
A vaccine to prevent H Z  is available and recommended 
for all persons aged >60 years w ithout contraindications to 
vaccination. H Z  vaccine is not indicated for H C P for the 
prevention o f nosocomial transmission, but H C P aged >60 
years may receive the vaccine on the basis o f the general 
reco m m en d a tio n  for H Z  vacc in a tio n , to  reduce th e ir 
individual risk for H Z.
Varicella Control Strategies
Appropriate measures should be implemented to manage 
cases and control outbreaks (300).
Patient Care
O nly H C P with evidence o f im m unity to varicella should 
care for patients who have confirmed or suspected varicella or 
H Z. Airborne precautions (i.e., negative air-flow rooms) and 
contact precautions should be employed for all patients with 
varicella or disseminated H Z  and for im m unocompromised 
patients with localized H Z  until disseminated infection is ruled 
out. These precautions should be kept in place until lesions are 
dry and crusted. If  negative air-flow rooms are not available, 
patients should be isolated in closed rooms and should not 
have contact with persons w ithout evidence o f im m unity to 
varicella. For im m unocom petent persons w ith localized H Z,
standard precautions and complete covering o f the lesions are 
recommended.
Postexposure Management of HCP and Patients
Exposure to V Z V  is defined as close contact w ith  an 
infectious person, such as close indoor contact (e.g., in the 
same room) or face-to-face contact. Experts differ regarding the 
duration o f contact; some suggest 5 minutes, and others up to 1 
hour; all agree that it does not include transitory contact (301).
All exposed, susceptible patien ts and H C P  should be 
identified using the criteria for evidence o f immunity. An 
additional criterion o f evidence o f im m unity only for patients 
who are not im m unocompromised or pregnant is birth in the 
United States before 1980. Postexposure prophylaxis with 
vaccination or varicella-zoster immunoglobulin, depending on 
immune status, o f exposed H C P and patients w ithout evidence 
o f im m unity is recommended (266).
H C P who have received 2 doses o f vaccine and who are 
exposed to VZV (varicella, disseminated H Z , and uncovered 
lesions o f a localized H Z ) should be m onitored daily during 
days 8-21 after exposure for fever, skin lesions, and systemic 
symptoms suggestive o f  varicella. H C P  can be m onitored 
directly by occupational health program or infection-control 
practitioners or instructed  to report fever, headache, or 
other constitutional symptoms and any atypical skin lesions 
immediately. H C P should be excluded from a work facility 
im m ediately if  symptoms occur. H C P  who have received 
1 dose o f vaccine and who are exposed to VZV (varicella, 
disseminated H Z , and uncovered lesions o f a localized HZ) 
(in the com m unity or health-care setting/workplace) should 
receive the second dose w ithin 3 -5  days after exposure to 
rash (provided 4 weeks have elapsed after the first dose). After 
vaccination, management is similar to that o f 2-dose vaccine 
recipients. Those who did not receive a second dose or who 
received the second dose >5 days after exposure should be 
excluded from work for 8-21 days after exposure.
Unvaccinated H C P who have no other evidence o f im m unity 
who are exposed to VZV (varicella, disseminated H Z , and 
uncovered lesions o f  a localized H Z) are potentially infective 
from days 8-21 after exposure and should be furloughed during 
this period. They should receive postexposure vaccination as 
soon as possible. Vaccination within 3 -5  days o f exposure to 
rash might modify the disease if infection occurred. Vaccination 
>5 days postexposure is still indicated because it induces 
protection against subsequent exposures (if the current exposure 
did not cause infection). For H C P at risk for severe disease for 
whom varicella vaccination is contraindicated (e.g., pregnant or 
im m unocomprosed H C P), varicella-zoster im m une globulin 
after exposure is recommended. The varicella-zoster im m une
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globulin product currently used in the United States, VariZIG 
(Cangene Corporation, W innipeg, Canada), is available under 
an Investigational New D rug Application Expanded Access 
protocol; a sample release form is available at http://www.fda. 
gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ 
U C M 176031.pdf. Varicella-zoster im m une globulin might 
prolong the incubation period by a week, thus extending the 
time during which personnel should not work from 21 to 
28 days. In case o f an outbreak, H C P  w ithout evidence of 
im m unity who have contraindications to vaccination should 
be excluded from the outbreak setting through 21 days after 
rash onset o f  the last identified case-patient because o f the risk 
for severe disease in these groups. I f  the VZV exposure was 
to localized H Z  with covered lesions, no work restrictions are 
needed if  the exposed H C P had previously received at least 
1 dose o f vaccine or received the first dose within 3 -5  days 
postexposure. A second dose should be administered at the 
appropriate interval. H C P  should be m onitored daily during 
days 8-21 after exposure for fever, skin lesions, and systemic 
symptoms suggestive o f  varicella and excluded from a work 
facility if  symptoms occur. If  at least 1 dose was not received, 
restriction from patient contact is recommended.
Diseases for W hich Vaccination Might 
Be Indicated in Certain 
Circum stances
Health-care facilities and other organizations should consider 
including in their vaccination programs vaccines to prevent 
meningococcal disease, typhoid fever, and polio for H C P who 
have certain health conditions or who work in laboratories 




Epidemiology and Risk Factors
Meningococcal disease is rare among adults in the United 
States and incidence has decreased to historic lows; during 
1998-2007 the average annual incidence o f meningococcal 
disease was 0.28 (range: 0 .2 6 -0 .3 1 )  cases per 100,000 
population among persons aged 25 -6 4  years (302).
Routine vaccination with meningococcal conjugate vaccine is 
recommended by ACIP for adolescents aged 11-18 years, with 
the prim ary dose at age 11-12 years and the booster dose at 
age 16 years. In 2010, coverage with meningococcal conjugate 
vaccine among persons aged 13-17  years was 62.7%  (22).
Nosocomial transmission o f Neisseria meningitidis is rare, 
but H C P  have become infected after direct contact with 
respiratory secretions o f infected persons (e.g., managing o f an 
airway during resuscitation) and in a laboratory setting. H C P 
can decrease the risk for infection by adhering to precautions 
to prevent exposure to respiratory droplets (303,304) and by 
taking antimicrobial chemoprophylaxis if  exposed directly to 
respiratory secretions.
Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety
Two quadrivalent (A, C, W -135, Y) conjugate meningococcal 
vaccines (M CV 4) are licensed for persons aged through 
55 years (305,306). Both protect against two o f the three 
serogroups that cause the majority o f meningococcal disease 
in the United States and against 75%  o f disease among adults. 
Available data indicate that the majority o f persons do not have 
enough circulating functional antibody to be protected >5 
years after a single dose o f M CV4. Both vaccines had similar 
safety profiles in clinical trials. Quadrivalent (A, C, W -135, Y) 
meningococcal polysaccharide vaccine (MPSV4) is available 
for use in persons aged >55 years. No vaccine for serogroup B 
meningococcal disease is licensed in the United States.
Recommendations
Vaccination
M CV 4 is not recommended routinely for all H C P
HCP Recommended to Receive Vaccine to Prevent 
Meningococcal Disease
A 2-dose vaccine series is recom m ended for H C P  with 
know n asplenia or p ersis ten t com p lem en t co m p o n en t 
deficiencies, because these conditions increase the risk for 
meningococcal disease. H C P traveling to countries in which 
meningococcal disease is hyperendemic or epidemic also are at 
increased risk for infection and should receive vaccine. Those 
w ith known asplenia or persistent com plem ent com ponent 
deficiencies should receive a 2-dose vaccine series. All other 
H C P traveling to work to high-risk areas should receive a single 
dose o f M CV 4 before travel if they have never received it or if 
they received it >5 years previously. Clinical microbiologists 
and research microbiologists who might be exposed routinely 
to isolates o f N. meningitides should receive a single dose of 
M CV 4 and receive a booster dose every 5 years if  they remain 
at increased risk. Health-care personnel aged >55 years who 
have any o f the above risk factors for meningococcal disease 
should be vaccinated with MPSV4 (305).
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HCP Who May Elect to Receive Vaccine to Prevent 
Meningococcal Disease
H C P with known H IV  infection are likely at increased risk 
for meningococcal disease and may elect vaccination. If  these 
H C P are vaccinated, they should receive a 2-dose vaccine 
series (307).
Booster Doses
H C P who receive the 2-dose M CV 4 vaccine series and/or 
remain in a group at increased risk should receive a booster 
dose every 5 years (306).
Postexposure Management of Exposed HCP
Postexposure prophylaxis is advised for all persons who 
have had intensive, unprotected contact (i.e., w ithout wearing 
a mask) w ith infected patients (e.g., via m outh-to-m outh  
resuscitation, endotracheal intubation, or endotracheal tube 
management), including H C P who have been vaccinated with 
either the conjugate or polysaccharide vaccine (3).
A ntim icrobial prophylaxis can eradicate carriage o f  N. 
meningitidis and prevent infections in persons who have 
u n p ro tec ted  exposure to  p a tien ts  w ith  m eningococcal 
infections (305). Rifam pin, ciprofloxacin, and ceftriaxone 
are effective in eradicating nasopharyngeal carriage o f N. 
meningitidis. In areas o f the United States where ciprofloxacin- 
resistant strains o f N. meningitidis have been detected (as of 
August 30, 2011, only parts o f M innesota and N orth  Dakota), 
ciprofloxacin should not be used for chemoprophylaxis (308). 
Azithromycin can be used as an alternative. Ceftriaxone can 
be used during pregnancy. Postexposure prophylaxis should 
be administered within 24 hours o f exposure when feasible; 
postexposure prophylaxis administered >14 days after exposure 
is o f limited or no value (305). H C P  not otherwise indicated 
for vaccination may be recommended to be vaccinated with 
meningococcal vaccine in the setting o f a com m unity or 
institutional outbreak o f meningococcal disease caused by a 
serogroup contained in the vaccine.
Typhoid Fever
Background
Epidemiology and Risk Factors
T he incidence o f typhoid fever declined steadily in the 
U nited States during 1900-1960  and has since remained 
low. D uring 1999-2006, on average, 237 cases were reported 
annually to the N ational Typhoid and Paratyphoid Fever 
Surveillance System (309). The median age o f patients was 22 
years and 54% were male; 79%  reported foreign travel during 
the 30 days before onset o f symptoms. Among international
travelers, the risk for Salmonella Typhi infection appears to be 
highest for those who visit friends and relatives in countries in 
which typhoid fever is endemic and for those who visit (even 
for a short time) the most highly endemic areas (e.g., the Indian 
subcontinent) (310).
In c rea s in g  re sis tan ce  to  f lu o ro q u in o lo n e s  su ch  as 
ciprofloxacin, which are used to treat m ultidrug-resistant. 
S. Typhi, has been seen particularly among travelers to south 
and southeast Asia (311). Isolates with decreased susceptibility 
to ciprofloxacin (DCS) do not qualify as resistant according 
to current Clinical and Laboratory Standards Institute criteria 
but are associated with poorer clinical outcomes (311,312). 
Resistance to nalidixic acid, a quinolone, is a marker for DCS 
and increased from 19% in 1999 to 59% in 2008 (313). Nine 
isolates resistant to ciprofloxacin also were seen during this 
time period (313).
A lthough overall S. Typhi infections have declined in the 
United States, increased incidence and antimicrobial resistance 
including resistance to fluoroquinolones have been seen for 
paratyphoid fever caused by Paratyphi A (314). No vaccines 
that protect against Paratyphi A  infection are available.
Transmission and Exposure in Health-Care Settings
During 1985-1994, seven cases oflaboratory-acquired typhoid 
fever were reported among persons working in microbiology 
laboratories, only one o f w hom  had been vaccinated (315). 
Additionally, S. Typhi might be transmitted nosocomially via the 
hands of infected persons (315).
Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety
Two typhoid vaccines are distributed in the United States: oral 
live-attenuated Ty21a vaccine (one enteric-coated capsule taken 
on alternate days for a total o f four capsules) and the capsular 
polysaccharide parenteral vaccine (1 0.5 mL intramuscular dose). 
Both vaccines protect 50% -80%  o f recipients. To maintain 
immunity, booster doses o f the oral vaccine are required every 5 
years, and booster doses o f the injected vaccine are required every 
2 years. Complication rates are low for both types o f S. Typhi 
vaccines. During 1994-1999, serious adverse events requiring 
hospitalization occurred in an estimated 0.47 to 1.3 per 100,000 
doses, and no deaths occurred (310). However, live-attenuated 
Ty21a vaccine should not be used among immunocompromised 
persons, including those infected with H IV  (316). Theoretic 
concerns have been raised about the immunogenicity o f live, 
attenuated Ty21a vaccine in persons concurrently receiving 
antimicrobials (including antimalarial chemoprophylaxis), viral 
vaccines, or immune globulin (317). A  third type o f vaccine, 
a parenteral heat-inactivated vaccine associated with higher 
reactogenicity, was discontinued in 2000 (310,318).
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Vaccination
M icrobiologists and others who w ork frequently  w ith  
S. Typhi should be vaccinated with either o f the two licensed 
and available vaccines. Booster vaccinations should  be 
adm inistered on schedule according to the manufacturers’ 
recommendations.
Controlling the Spread of Typhoid Fever
Personal hygiene, particularly hand hygiene before and after 
all patient contacts, will minimize risk for transm itting enteric 
pathogens to patients. However, H C P  who contract an acute 
diarrheal illness accompanied by fever, cramps, or bloody 
stools are likely to excrete substantial numbers o f  infective 
organisms in their feces. Excluding these H C P  from care of 
patients until the illness has been evaluated and treated can 
prevent transmission (3 ).
Poliomyelitis
Background
Epidemiology and Risk Factors
In the United States, the last indigenously acquired cases 
o f poliomyelitis caused by wild poliovirus occurred in 1979, 
and the Americas were certified to be free o f indigenous wild 
poliovirus in 1994 (319,320). W ith  the complete transition 
from use o f oral poliovirus vaccine (OPV) to inactivated 
p o liov iru s vaccine (IPV ) in  2 0 0 0 , vacc ine-associa ted  
paralytic poliom yelitis (VAPP) a ttributable to O P V  also 
has been eliminated (321,322), so the risk for exposure to 
any live poliovirus in the United States is limited. However, 
global eradication o f poliom yelitis has no t yet occurred, 
so reintroductions o f poliovirus into the United States are 
possible. Two cases of paralytic polio from vaccine-derived 
poliovirus have occurred since 2000 (one im ported case in 
2005 and one case in an im m unodeficient person in 2008), 
and evidence of limited circulating vaccine-derived poliovirus 
in an undervaccinated com m unity was docum ented in 2005
(323-325).
Transmission and Exposure in Health-Care Settings
Poliovirus can be recovered from infected persons, including 
from  pharyngeal specim ens, feces, u rine , and  (rarely) 
cerebrospinal fluid. H C P  and laboratory workers might be 
exposed if they come into close contact with infected persons 
(e.g., travelers returning from areas where polio is endemic) 
or with specimens that contain poliovirus.
Recommendations Vaccine Effectiveness, Duration of Immunity, and 
Vaccine Safety
Both IPV and O PV  are highly im m unogenic and effective 
when administered according to their schedules. In studies 
conducted in the U nited States, 3 doses o f  IPV  resulted 
in 100% serocoversion for types 2 and 3 poliovirus and 
96% —100% for type 1 (326). Im m unity is prolonged and 
might be lifelong. IPV is well tolerated, and no serious adverse 
events have been associated with its use. IPV is an inactivated 
vaccine and does not cause VAPP IPV is contraindicated in 
persons with a history of hypersensitivity to any com ponent 
of the vaccine, including 2-phenoxyethanol, formaldehyde, 
neomycin, streptomycin, and polymyxin B. O PV  is no longer 
available in the United States.
Recommendations
Vaccination
Because the majority o f adults born in the United States 
are likely im m une to polio as a result of vaccination during 
childhood, poliovirus vaccine is not routinely recommended 
for persons aged >18 years. The childhood recommendation 
for poliovirus vaccine consists o f  4 doses at ages 2, 4, and 6—18 
m onths and 4—6 years.
However, vaccination is recommended for H C P  who are 
at greater risk for exposure to polioviruses than the general 
p o p u la tio n , in c lu d in g  lab o ra to ry  w orkers w ho handle 
specimens that m ight contain polioviruses and H C P  who 
have close contact with patients who might be excreting wild 
polioviruses, including H C P who travel to work in areas where 
polioviruses are circulating.
Unvaccinated H C P  should receive a 3-dose series o f IPV, 
w ith dose 2 administered 4—8 weeks after dose 1, and dose 
3 administered 6—12 m onths after dose 2. H C P  who have 
previously completed a routine series of poliovirus vaccine and 
who are at increased risk can receive a lifetime booster dose 
o f IPV if  they remain at increased risk for exposure. Available 
data do not indicate the need for more than a single lifetime 
booster dose with IPV for adults.
Controlling the Spread of Poliovirus
Standard precautions always should be practiced when 
han d ling  b iologic specim ens. Suspect cases require an 
immediate investigation including collection of appropriate 
laboratory specimens and control measures. All suspect or 
confirmed cases should be reported immediately to the local 
or state health department.
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Other Vaccines Recomm ended  
for Adults
Certain vaccines are recommended for adults based on age 
or other individual risk factors but not because o f occupational 
exposure (327). Vaccine-specific A C IP recom m endations 
should be consulted for details on schedules, indications, 
contraindications, and precautions for these vaccines.
• Pneumococcal polysaccharide vaccine (PPSV). PPSV 
is recommended for healthy persons aged >65 years. PPSV 
is also recom m ended for persons aged <65 years with 
certain underlying medical conditions, including anatomic 
or functional asplenia, im m unocompromise (including 
H IV  infection), chronic lung, heart or kidney disease, and 
diabetes.
• Tetanus and diphtheria toxoids (Td). All adults should 
have documentation o f having received an age-appropriate 
series of Td-containing vaccine and a routine booster dose 
every 10 years. Persons w ithout docum entation o f having 
received a T d  series should receive a 3-dose series. The first 
dose of the series should be administered as Tdap (see 
Pertussis).
• H u m an  p a p illo m a v ir u s  (H P V ) v a cc in e . E ith e r  
quadrivalent H PV  vaccine (Gardasil) or bivalent H PV  
vaccine (Cervarix) is recommended for females at age 11 
or 12 years w ith catch-up vaccination recom m ended 
th ro u g h  age 26 years. Q u ad riv a len t H P V  vaccine 
(Gardasil) may be administered to males aged 9—26 years.
• Zoster vaccine. Zoster vaccine contains the same live 
attenuated varicella zoster virus as varicella vaccine but at 
a higher concentration (approximately 14 times more 
vaccine virus per dose). Zoster vaccine is recommended 
for the prevention o f H Z  (shingles) in persons aged >60 
years. Transmission of vaccine virus from the recipient to 
a contact has not been reported. Consequently, limiting 
or restricting work activities for persons who recently 
received zoster vaccine is not necessary.
• Hepatitis A vaccine. H C P  have not been demonstrated 
to be at increased risk for hepatitis A virus infection 
because o f occupational exposure, including persons 
exposed to sewage. Hepatitis A vaccine is recommended 
for person w ith  chron ic liver disease, in terna tiona l 
travelers, and certain other groups at increased risk for 
exposure to hepatitis A.
Catch-Up and Travel Vaccination 
Catch-Up Programs
Managers o f health-care facilities should implement catch-up 
vaccination programs for H C P who already are employed, in 
addition to developing policies for achieving high vaccination 
coverage among newly hired H C P H C P vaccination records 
could be reviewed annually during the influenza vaccination 
season or concurrent with annual TB testing. This strategy could 
help prevent outbreaks o f vaccine-preventable diseases. Because 
education, especially when combined with other interventions 
such as reminder/recall systems and low or no out-of-pocket 
costs, enhances the success o f m any vaccination programs, 
informational materials should be available to assist in answering 
questions from H C P regarding the diseases, vaccines, and toxoids 
as well as the program or policy being implemented (120,328). 
Conducting educational workshops or seminars several weeks 
before the initiation o f a catch-up vaccination program might 
promote acceptance o f program goals.
Travel
Hospital personnel and other H C P  who perform research 
or health-care work in foreign countries might be at increased 
risk for acquiring certain diseases that can be prevented by 
vaccines recommended in the United States (e.g., hepatitis 
B, in flu en za , M M R , T d a p , po lio v iru s , varicella , and 
meningococcal vaccines) and travel-related vaccines (e.g., 
hepatitis A, Japanese encephalitis, rabies, typhoid, or yellow 
fever vaccines) (329). Elevated risks for acquiring these diseases 
might stem from exposure to patients in health-care settings 
(e.g., poliomyelitis and meningococcal disease) but also might 
arise from circumstances unrelated to patient care (e.g., high 
endemicity o f  hepatitis A or exposure to arthropod-vector 
diseases [e.g., yellow fever]). All H C P  should seek the advice 
o f a health-care provider familiar with travel medicine at least
4—6 weeks before travel to ensure that they are up to date 
on routine vaccinations and that they receive vaccinations 
recommended for their destination (329). Although bacille 
Calm ette-Guérin vaccination is not recommended routinely 
in the United States, H C P  should discuss potential beneficial 
and other consequences o f  this vaccination w ith their health­
care provider.
Work Restrictions
W ork restrictions for susceptible H C P  (i.e., no history 
o f vaccination or docum ented lack o f im m unity) exposed 
to or infected with certain vaccine-preventable diseases can 
range from restricting individual H C P from patient contact 
to com plete exclusion from duty (Table 5). A furloughed 
employee should be considered in the same category as an
28 MMWR / November 25, 2011 / Vol. 60 / No. 7
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employee excluded from the facility. Specific recommendations 
concerning work restrictions in these circumstances have been 
published previously (3,11).
Acknowledgments
The following persons contributed to this report: Rachel J. Wilson, 
GeoffA. Beckett, M PH, Division ofViral Hepatitis, National Center 
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 
LaDora O. Woods, BS, Carter Consulting, Inc., Atlanta, Georgia.
References
1. C D C . Im m unization  o f  health-care workers: recom m endations o f  the 
A dvisory  C o m m itte e  o n  Im m u n iza tio n  Practices (A C IP) an d  the 
H ospita l Infection C ontrol Practices Advisory C om m ittee (H IC PA C ). 
M M W R  1997;46(N o. RR-18).
2. U S  D epartm en t o f H ealth  and  H u m an  Services. D efin ition  o f health ­
care personnel (H C P ). Available at h ttp://w w w .hhs.gov/ash/program s/ 
in itiatives/vacctoolkit/defin ition.h tm l. Accessed O ctob er 5 , 2011.
3. Bolyard EA, Tablan O C , W illiam s W W , Pearson M L, Shapiro C N , 
D e itc h m a n  S D , H o sp ita l In fe c tio n  C o n tro l P ractices A dv iso ry  
C om m ittee (H IC PA C ). G uideline for infection contro l in  healthcare 
personnel, 1998. Infect C ontrol H osp Epidem iol 1998;19:407-63 .
4. C D C . General recom m endations o n  im m unization: recom m endations 
o f the Advisory C om m ittee on  Im m unization Practices (ACIP). M M W R  
2011;60(N o. RR-2).
5. D ayan  G H , O rtega-Sanchez IR, LeBaron CW , Q uin lisk  M P  Iowa 
Measles Response Team. T he cost o f  con taining  one case o f  measles: the 
econom ic im pact on  th e  pub lic health  infrastructure— Iowa, 2004. 
Pediatrics 2005;116 :e1 -4 .
6. C D C . Preventing tetanus, d iphtheria, and pertussis am ong adults: use 
o f  tetanus toxoid, reduced d iph theria  toxoid  an d  acellular pertussis 
vaccine. M M W R  2006;55(N o. RR-17).
7. C D C . Local health  d epartm en t costs associated w ith  response to  a 
schoo l-based  pertussis o u tb reak — O m ah a, N ebraska, S ep tem ber­
N ovem ber 2008. M M W R  2 011;60 :5 -9 .
8. Am erican Hospital Association. Im m unization: m anagem ent advisory on 
health care delivery. Chicago, IL Am erican Hospital Association; 1992.
9. C D C . State im m unization  laws fo r healthcare personnel and  patients. 
Available a t http://w w w 2a.cdc.gov/nip/S tateV accA pp/statevaccsA pp/ 
default.asp. Accessed O ctober 5, 2011.
10. M ille r  BL, A h m e d  F, L in d ley  M C , W o rtley  P M . In s t itu tio n a l 
requirem ents fo r influenza vaccination o f  healthcare personnel: results 
from  a nationally representative survey o f  acute care hospitals— U nited
States, 2011. C lin  Infect Dis 2011;53(11):1051-9 .
11. Beltram i EM , Bolyard EA. Personnel health services. In: Jarvis W, ed. 
B ennett and Brachm ans hospital infections. Philadelphia, PA: Lippincott 
W illiam s &  W ilkins; 2007 :45 -6 3 .
12. C D C . M anual fo r th e  surveillance o f  vaccine-preventable diseases. 
Available at http://www.cdc.gov/vaccines/pubs/surv-m anual/index.htm l. 
Accessed O ctober 5, 2011.
13. C D C . Sum m ary o f  notifiable diseases— U nited  States, 2009. M M W R  
2009:58(N o.53).
14. Beltram i EM , W illiam s IT, Shapiro C N , C ham berland  M E. Risk and 
m anagem ent o f  b lood-borne infections in health  care workers. Clin
M icrobiol Rev 200 0;13 :3 8 5-40 7 .
15. W erner BG, G rady GF. Accidental hepatitis-B-surface-antigen-positive 
inoculations. A nn  In tern  M ed 1 982;97 :367-9 .
16. B ond W W , Favero M S, Petersen N J, Gravelle C R , E bert JW , M aynard 
JE. Survival o f hepatitis B virus after drying and  storage fo r one week. 
Lancet 1981;1:550-1 .
17. C D C . Viral hepatitis surveillance— 2009 surveillance. Available at h ttp :// 
w w w .cdc.gov/hepatitis/Statistics/2009Surveillance/index.htm . Accessed 
O ctober 5, 2011.
18. C D C . Surveillance fo r acute viral hep atitis— U nited  States, 2007. 
M M W R  2009;58(N o. SS-3).
19. Institu te o f  M edicine. H epatitis and  liver cancer: a national strategy for 
prevention and  contro l o f hepatitis B and  C. W ashington, D C : T he 
N ational Academies Press; 2010.
20. C D C . Achievem ents in  public health: hepatitis B vaccination— U nited  
States, 1 98 2-20 0 2 . M M W R  2 002;51 :549-52 .
21. C D C . N ational and state vaccination coverage am ong children aged 
1 9-35  m onths— U nited  States, 2010. M M W R  2 011;60 :1157-63 .
22. C D C . N ational and  state vaccination coverage am ong adolescents aged 
1 3 -1 7  years— U nited  States, 2010. M M W R  2 011;60 :1117-23 .
23. Lu P-J, Byrd KK, M urphy  TV, W einbaum  C. H epatitis B vaccination 
coverage am ong  h igh-risk  adults 1 8 -4 9  years, U .S. 2009. Vaccine 
2011;29 :7049-57 .
24. C D C . Hepatitis surveillance report N o. 60. Atlanta, GA: US D epartm ent 
o f H ealth  and  H um an  Services, C D C ; 2005.
25. A lter M J, H ad ler SC, M argolis M D , et al. T he changing epidem iology 
o f hepatitis B in  the U nited  States: need fo r alternative vaccination 
strategies. JA M A  1 990;263 :1218-22 .
26. Osterholm  M T, Garayale SM. Clinical viral hepatitis B am ong M innesota 
h osp ita l p ersonnel: results o f  a ten -year s ta tew ide survey. JA M A  
1985;254:3207-12 .
27. T hom as DL, Factor SH , G abon D , et al. V iral hepatitis in  health care 
personnel at the Johns H opk ins H ospital. A rch In te rn  M ed 1993; 
153 :1705-12.
28. D ienstag JL, Ryan D M . O ccupational exposure to  hepatitis B virus in 
h osp ita l p ersonnel: in fec tion  o r im m u n iza tio n ?  A m  J E pidem io l 
1982;115:26-39 .
29. Shapiro C N , Tokars JI, C ham berland  M E , et al. Use o f  the hepatitis B 
vaccine an d  in fection  w ith  hepatitis  B an d  C  am ong  o rth o paed ic  
surgeons. J Bone Jo in t Surg 1996;78-A :1791-800.
30. Gibas A, Blewett D R , Schoenfled DA, D ienstag JL. Prevalence and  
incidence o f  viral hepatitis in  health  w orkers in  the p rehepatitis B 
vaccination era. Am  J Epidem iol 1992;136 :603-10.
31. H adler SC, D oto  IL, M aynard JE , et al. O ccupational risk o f hepatitis B 
infection in hospital workers. Infection C ontrol 1985;6:24-31 .
32. T hom pson  N D , Perz JF. E lim inating  the blood: ongoing outbreaks of 
hepatitis B virus infection and  the need for innovative glucose m onitoring 
technologies. J D iabetes Sci Technol 2009;3 :283-8 .
33. K lonoff D C , Perz JF. Assisted m onitoring  o f  blood glucose: special safety 
needs for a new  paradigm  in testing glucose. J D iabetes Sci Technol 
2 010;4 :1027-31 .
34. C D C . Transm ission o f hepatitis B virus am ong persons undergoing 
b lood  glucose m onito rin g  in long-term -care  facilities— M ississippi, 
N o rth  C arolina, an d  Los Angeles C ounty , C alifornia, 2 0 0 3 -2 0 0 4 . 
M M W R  2005;54 :220-3 .
35. US D epartm en t o f  Labor. B loodborne pathogens: the standard. Federal 
Register 1991;60:64175-82 .
36. A gerton TB , M ahoney, SJ, Polish UB, Shapiro C N . Im pact o f  the 
B loodborne Pathogens Standard on  vaccination o f healthcare workers 
w ith  hepatitis B vaccine. Infect C on tro l H ospita l E pidem iol 1995; 
1 6 :287-91 .
37. Sim ard EP, M iller JT, George PA, et al. H epatitis B vaccination coverage 
levels am ong healthcare workers in the U nited  States, 2 00 2-20 0 3 . Infect 
C ontrol H osp Epidem iol 2 007;28 :783-90 .
38. Lu PJ, Euler GL. Influenza, hepatitis B, and tetanus vaccination coverage 
am ong healthcare personnel in the U nited  States. Am  J Infect C ontrol 
2 011;39 :488-94 .
39. US D ep artm en t o f H ealth  an d  H u m an  Services. Proposed H ealthy  
People 2020 objectives. Available at h ttp ://w w w .healthypeople.gov/ 
hp2020/O bjectives/TopicA reas.aspx. Accessed O ctober 5, 2011.
MMWR / November 25, 2011 / Vol. 60 / No. 7 29
Recommendations and Reports
40. D ienstag JL, W erner BG, Polk BF, et al. H epatitis B vaccine in  health­
care personnel: safety, im m unogenicity, and  indicators o f  efficacy. A nn 
In tern  M ed 1984;101:34-40 .
41. Zajac BA, W est D J, M cAleer W J, Scolnick EM . Overview o f  clinical 
studies w ith  hepatitis B vaccine m ade by recom binant D N A . J Infect 
1986;13(Suppl A ) :3 9 ^ 5 .
42. F rancis DP, H ad le r SC , T h o m p so n  SE, e t al. T h e  p rev en tio n  o f 
hepatitis B w ith  vaccine: report o f  th e  C enters for Disease C ontrol 
m ulti-center efficacy trial am ong hom osexual m en. A nn  In tern  M ed 
1 982;97 :362-6 .
43. A verhoff F, M ahoney F, C olem an P, Schatz G, H urw itz E, M argolis H . 
Im m unogenicity  o f  hepatitis B vaccines: im plications for persons at 
occup atio na l risk  fo r hep atitis  B virus in fection . A m  J Prev M ed 
1998;15 :1 -8 .
44. Shaw FE Jr, Guess HA, Roets JM , et al. Effect o f  anatom ic injection 
site, age and  sm oking on  the im m une response to  hepatitis B vaccination. 
Vaccine 1 989;7:425-30.
45. W eber DJ, R utala WA, Samsa GP, Santim aw  JE, Lem on SM. Obesity 
as a pred icto r o f  p oo r antibody  response to  hepatitis B plasm a vaccine. 
JA M A  1 985;254 :3187-9 .
46. W ood  RC, M acD onald  KL, W h ite  KE, H edberg  CW , H anson  M , 
O sterho lm  MT. Risk factors for lack o f  detectable an tibody  following 
h ep atitis  B vaccin atio n  o f  M in n eso ta  hea lth  care w orkers. JA M A  
1 993;270 :2935-9 .
47. M cM ahon BJ, D entinger C M , B ruden D , et al. A ntibody  levels and 
protection  after hepatitis B vaccine: results o f  a 22-year follow-up study 
and  response to  a booster dose. J Infect Dis 2009;200 :1390-6 .
48. Leuridan E, Van D am m e P. H epatitis B and the need for a booster dose. 
C lin  Infect Dis 2011;53 :68-75 .
49. H ad ler SC, Francis DP, M aynard JE, et al. Long-term  im m unogenicity  
and  efficacy o f  hepatitis B vaccine in  hom osexual m en. N  Engl J M ed 
1986;315 :209-14.
50. Jack A D , Hall AJ, M aine N , M endy  M , W h ittle  H C . W h at level o f 
hepatitis B antibody  is protective? J Infect Dis 1999;179 :489-92.
51. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control o f 
hepatitis B virus infection: im plications o f  ch ildhood  vaccination and  
long-term  protection . Pediatrics 1992;90(1 Pt 2 ):1 7 0-3 .
52. C D C . A  comprehensive im m unization strategy to elim inate transmission 
o f  hepatitis B virus infection in the U nited  States: recom m endations o f 
th e  A d v iso ry  C o m m itte e  o n  Im m u n iz a tio n  P rac tice s . P a r t II: 
im m unization  o f  adults. M M W R  2006;55(N o. RR-16).
53. C lem ens R, Sanger R, K ruppenbacher J, et al. Booster im m unization  
o f  low- and non-responders after a standard three dose hepatitis B vaccine 
s c h e d u le - r e s u l t s  o f  a p o s t - m a r k e t in g  s u rv e il la n c e . V a c c in e  
1997;15 :349-52 .
54. C raven D E, Awdeh Z L, Kunches LM , et al. N onresponsiveness to 
hepatitis B vaccine in  health  care workers. Results o f  revaccination and 
genetic typings. A nn  In tern  M ed 1986;105 :356-60.
55. G oldw ater PN. R andom ized, com parative trial o f  20 m icrograms vs 40 
m icrogram s Engerix B vaccine in hepatitis B vaccine non-responders. 
Vaccine 1997;15:353-6 .
56. K im  M J, N afziger A N , H arro  C D , et al. R evaccination o f  healthy 
nonresponders w ith hepatitis B vaccine and  prediction o f  seroprotection
response. Vaccine 2 00 3;21 :1174-9 .
57. B ertino JS Jr, Tirrell P, G reenberg R N , et al. A  com parative trial o f 
standard  o r high-dose S subun it recom binant hepatitis B vaccine versus 
a vaccine co n ta in in g  S su b u n it , p re-S 1, an d  p re-S 2  partic les for 
revaccination  o f  h ea lth y  ad u lt n on responders . J In fect D is 1997; 
175 :678-81 .
58. W eissm an JY, Tsuchiyose M M , Tong M J, C o R, C hin  K, E ttenger RB. 
Lack o f  response to  recom binant hepatitis B vaccine in  nonresponders 
to  the plasm a vaccine. JA M A  1 988;260 :1734-8 .
59. A lper CA, Kruskall M S, Marcus-Bagley D , et al. G enetic p rediction  o f 
nonresponse to  hepatitis B vaccine. N  Engl J M ed 1989;321:708-12.
60. Institu te o f  M edicine. Im m unization  safety review: hepatitis B vaccine 
and dem yelinating disorders. W ashington, D C : T he N ational Academies 
Press; 2002.
61. Institu te o f  M edicine. Adverse effects o f  vaccines: evidence and  causality. 
Available at h ttp ://w w w .iom .edu /R eports/2011 /A dverse-E ffects-o f- 
Vaccines-Evidence-and-Causality.aspx Accessed O ctober 5, 2011.
62. Global Advisory C om m ittee on  Vaccine Safety. 1 2 -1 3  D ecem ber 2007. 
W kly Epidem iol Record 2 0 0 8 ;8 3 :3 7 ^ 4 .
63. S undberg  JP, Silva KA, S undberg  BA, et al. R ecom b in an t h u m an  
hepatitis B vaccine initiating alopecia areata: testing the hypothesis using 
C 3 H /H eJ m ouse model. Vet D erm atol 2 009;20 :99-104 .
64. G laxoSm ithK line Biologicals. Engerix-B [Package insert]. Rixensart, 
Belgium: G laxoSm ithK line Biologicals; 2010.
65. M erck &  Co., Inc. Recombivax HB: hepatitis B vaccine (recom binant) 
[Package insert]. W hitehouse Station, N J: M erck &  Co., Inc.; 2011.
66. G laxoS m ithK line Biologicals. T w inrix  [Package insert]. R ixensart, 
Belgium: G laxoSm ithK line Biologicals; 2011.
67. C D C . H epatitis B vaccine inform ation statem ent. Available at h ttp :// 
ww w.cdc.gov/vaccines/pubs/vis/default.htm . Accessed O ctober 5, 2011.
68. Levy M , Koren G. H epatitis B vaccine in  pregnancy: m aternal and  fetal 
safety. A m  J Perinatol 1991;8:227-32.
69. C D C . Recom m endations for preventing transm ission o f  H IV  and  HBV 
virus to  patients d uring  exposure-prone invasive procedures. M M W R  
1991;40(N o. RR-8).
70. C D C . H epatitis  B virus: a com prehensive strategy fo r e lim inating  
tran sm iss io n  in  th e  U n ite d  S tates th ro u g h  u n iversa l c h ild h o o d  
vaccination: recom m endations o f  the Im m unization  Practices Advisory 
C om m ittee (ACIP). M M W R  1991;40(N o. RR-13).
71. C D C . R e c o m m e n d a tio n s  fo r  id e n ti f ic a t io n  a n d  p u b lic  h ea lth  
m anagem ent o f  persons w ith chronic hepatitis B virus infection. M M W R  
2008;57(N o. RR-8).
72. C D C . U p d a te d  U .S . P u b lic  H e a lth  Service g u id e lin es  fo r  th e  
m anagem ent o f  occupational exposures to  HBV, HCV, and  H IV  and 
recom m endations for postexposure prophylaxis. M M W R  2 001;50  
(No. RR-11).
73. E ckm an  M H , K aiser T E , Sherm an  KE. T h e  cost-effectiveness o f  
screening for chronic H epatitis B infection in the U nited  States. C lin 
Infect D is2011;52 :1294-306 .
74. T ho m pso n  W W , W eintraub  E, D han kh ar P, et al. Estim ates o f  US 
influenza-associated deaths m ade using four different methods. Influenza 
O th er Respi Viruses 2009;3 :37-49 .
75. C D C . Estim ates o f  deaths associated w ith  seasonal influenza— U nited  
States, 1 97 6-20 0 7 . M M W R  2 01 0;59 :1057-62 .
76. T hom pson  W W , Shay D K , W eintraub E, et al. Influenza-associated 
hospitalizations in  the U nited  States. JA M A  2 0 0 4 ;2 9 2 :1 3 3 3 ^ 0 .
77. C D C . Prevention and control o f  influenza with vaccines: recommendations 
o f  the Advisory C om m ittee o n  Im m unization  Practices (ACIP), 2010. 
M M W R  2010(N o. RR-8).
78. Jain R, G oldm an R D . Novel influenza A (H 1 N 1 ): clinical presentation, 
diagnosis, and  m anagem ent. Pediatr Em erg Care 2 009;25 :791-6 .
79. Lester RT, M cG eer A, Tom linson G, et al. Use of, effectiveness of, and 
attitudes regarding influenza vaccine am ong house staff. Infect C ontrol 
H osp Epidem iol 2 003;24 :839-44 .
80. Saxen H V irtanen  M . R andom ized, placebo-contro lled  double b lind  
study on  the efficacy o f  influenza im m unization on absenteeism o f  health 
care workers. Pediatr Infect Dis J 1999;18:779.
81. W ilde JA, M cM illan JA, Serwint J, et al. Effectiveness o f  influenza vaccine 
in  h e a lth  care p ro fessio n a ls : a ra n d o m iz e d  tr ia l . JA M A  1 999; 
281 :9 08 -1 3 .
82. M alavaud S, M alavaud B, Sandres K, et al. N osocom ial outbreak  of 
in fluenza  v irus  A  (H 3 N 2 ) in fe c tio n  in  a so lid  o rg an  tra n sp la n t 
departm ent. T ransplantation 2 001;72 :535-7 .
83. M altezou H C , D rancou rt M . N osocom ial influenza in children. J Hosp 
Infect 2 00 3;55 :83 -91 .
30 MMWR / November 25, 201 1 / Vol. 60 / No. 7
Recommendations and Reports
84. Hall CB, Douglas RG Jr. N osocom ial influenza infection as a cause o f 
in tercurrent fevers in infants. Pediatrics 1 975;55 :673-7 .
85. W einstock D M , Eagan J, M alak SA, et al. C ontro l o f  influenza A  on 
a bone m arrow  tran sp lan t u n it. In fect C o n tro l H osp  E pidem iol
2 000;21 :730-2 .
86. Salgado C D , G iannetta ET, H ayden FG, et al. Preventing nosocomial 
influenza by im proving the vaccine acceptance rate o f  clinicians. Infect 
C ontrol H osp Epidem iol 2 004;25 :923-8 .
87. Adal KA, Flowers R H , A nglim  A M , et al. Prevention o f  nosocom ial 
influenza. Infect C ontrol H osp Epidem iol 1996;17 :641-8 .
88. C unney RJ, Bialachowski A, Thornley D , et al. An outbreak o f  influenza 
A  in a neonatal intensive care unit. Infect C ontrol H osp Epidem iol 
2 00 0;21 :449-54 .
89. Bridges CB, K ueh nert M J, H all CB. T ransm ission  o f  influenza: 
im p lica tio ns for co n tro l in  h ea lth  care settings. C lin  In fect Dis 
2 00 3;37 :1094-101 .
90. Sartor C, Z an do tti C, R om ain F, et al. D isruption  o f  services in  an 
internal m edicine u n it due to  a nosocom ial influenza outbreak. Infect 
C ontrol H osp Epidem iol 2 002;23 :615-9 .
91. Saito R, Suzuki H , O shitan i H , et al. T he effectiveness o f  influenza 
vaccine against influenza a (H 3N 2) virus infections in  nursing homes 
in N iigata, Japan, during  the 1 9 9 8-19 9 9  and  1 99 9 -2 0 0 0  seasons. 
Infect C ontrol H osp Epidem iol 2 002;23 :82-6 .
92. Lemaitre M , M eret T, R othan-T ondeur M , et al. Effect o f  influenza 
vaccination o f  nursing hom e staff on  m ortality  o f  residents: a cluster- 
random ized trial. J Am  G eriatr Soc 2009;57 :1 5 80 -6 .
93. C arm an  W F, E lder A G , W allace LA, et al. Effects o f  in fluenza 
vaccination o f  health-care workers on  m ortality  o f  elderly people in 
long-term  care: a random ised controlled trial. Lancet 2000;355:93-7.
94. H ayw ard AC, H arling  R, W etten  S, et al. Effectiveness o f  an influenza 
vaccine program m e for care hom e staff to  prevent death, morbidity, 
and  health service use am ong residents: cluster random ised controlled 
trial. BMJ 2006;333:1241.
95. Potter J, S to tt D J, Roberts MA, et al. Influenza vaccination o f  health 
care workers in long-term -care hospitals reduces the m ortality  o f  elderly 
patients. J Infect Dis 1997;175:1-6 .
96. T hom as RE, Jefferson T O , D em icheli V, et al. Influenza vaccination 
for health-care workers w ho w ork w ith  elderly people in  institutions: 
a systematic review. Lancet Infect Dis 2 006;6 :273-9 .
97. T ho m as RE, Jefferson T, Lasserson T J. Influenza vaccination  for 
healthcare workers w ho w ork w ith  the elderly. C ochrane Database Syst 
Rev 2010;2 :C D 005187.
98. N ational Foundation  for Infectious Diseases. Call to  action: influenza 
im m unization  am ong health-care workers, 2003. Available at h ttp :/ /  
w w w .n fid .o rg /p d f /p u b lic a tio n s /f lu h ea lth c a re c ta0 8 .p d f. Accessed 
O ctober 5, 2011.
99. Pavia AT. M andate to  p ro tec t patients from  health  care-associated 
influenza. C lin  Infect Dis 2 010;50 :465-7 .
100. Poland GA, Tosh P, Jacobson R M . R equiring influenza vaccination for 
health  care w orkers: seven tru th s  we m ust accept. V accine 2005; 
23 :22 51 -5 .
101. C D C . 2009 A dult vaccination coverage. T he N ational H ealth Interview 
Survey. Available at http://www.cdc.gov/vaccines/stats-surv/nhis/2009- 
nh is.h tm . Accessed O ctober 5, 2011.
102. LaVela SL, Sm ith B, Weaver FM , et al. A ttitudes and practices regarding 
influenza vaccination am ong healthcare workers providing services to 
individuals w ith spinal cord injuries and  disorders. Infect C ontrol Hosp 
E pidem iol 2 00 4;25 :933-40 .
103. Begue RE, G ee SQ . Im p ro v ing  in fluenza im m u n iza tio n  am ong 
healthcare workers. Infect C ontrol H osp Epidemiol 1998;19:518-20.
104. O fstead CL, Tucker SJ, Beebe TJ, et al. Influenza vaccination am ong 
registered nurses: inform ation receipt, knowledge, and decision-making 
at an  in stitu tion  w ith  a m ultifaceted  educational p rogram . Infect 
C ontrol H osp Epidem iol 2 00 8;29 :99-106 .
105. G oldstein A O , Kincade JE , G am ble G , et al. Policies and  practices for 
im proving influenza im m unization  rates am ong healthcare workers. 
Infect C ontrol H osp Epidem iol 2 004;25 :908-11 .
106. O n g  AK, Srim anunth iphol J, Frankel RI. Influenza vaccination status 
o f  healthcare workers and  the extent o f  their dom estic con tact w ith 
individuals a t high risk fo r influenza-related com plications. Infect
C ontrol H osp Epidem iol 2 000;21 :735-7 .
107. W eingarten S, R iedinger M , B olton LB, et al. Barriers to  influenza 
vaccine acceptance: a survey o f  physicians and  nurses. Am  J Infect
C ontrol 1 989;17 :202-7 .
108. H ofm an n  F, Ferracin C, M arsh  G, et al. Influenza vaccination o f 
healthcare workers: a literature review o f  attitudes and  beliefs. Infection
2006;34 :142-7 .
109. H ollm eyer H G , H ayden  F, Poland G, et al. Influenza vaccination o f 
health care workers in  hospitals-a review o f  studies on  attitudes and 
predictors. Vaccine 200 9;27 :3 9 35 -4 4 .
110. H arbarth  S, Siegrist CA, Schira JC , et al. Influenza im m unization: 
im proving com pliance o f  healthcare workers. Infect C on tro l Hosp 
Epidem iol 1998;19 :337-42 .
111. N ichol KLHauge M . Influenza vaccination o f  healthcare workers. Infect 
C ontrol H osp Epidem iol 1997;18:189-94 .
112. W atan ak u nako rn  C, Ellis G , G em m el D . A ttitu d e  o f  healthcare 
personnel regarding influenza im m unization . Infect C on tro l H osp 
Epidem iol 1993;14 :17 -20.
113. Bryant KA, Stover B, C ain  L, et al. Im proving influenza im m unization 
rates am ong healthcare workers caring for h igh-risk pediatric patients.
Infect C ontrol H osp Epidem iol 2 004;25 :912-7 .
114. B ertin  M , Scarpelli M , Proctor AW, et al. Novel use o f  the in tranet to 
docum ent health care personnel participation in a m andatory  influenza 
vaccination reporting  program . A m  J Infect C ontrol 2 007;35 :33-7 .
115. Ajenjo M C , W oeltje KF, Babcock H M , et al. Influenza vaccination 
am ong healthcare workers: ten-year experience o f  a large healthcare 
organization. Infect C ontrol H osp Epidem iol 2 010;31 :233-40 .
116. M anuel D G , H enry  B, H ockin  J, et al. H ealth  behavior associated w ith 
influenza vaccination  am ong healthcare workers in  long-term -care 
facilities. Infect C ontrol H osp Epidem iol 2 00 2;23 :609-14 .
117. Nafziger DA, H erw aldt LA. A ttitudes o f  internal m edicine residents 
regarding in fluenza vaccination . In fect C o n tro l H osp  E pidem io l 
1994;15 :32-5 .
118. O h r t C K , M cK inney  WP. A chieving  com pliance w ith  in fluenza 
im m uniza tion  o f  m edical house staff and  students. A  random ized 
contro lled  trial. JA M A  1992;267 :1377-80 .
119. M cA rthur M A, Sim or AE, Cam pbell B, et al. Influenza vaccination in 
long-term -care facilities: s tru c tu rin g  program s for success. Infect 
C ontrol H osp Epidem iol 1999;20 :499-503 .
120. C D C . Interventions to  increase influenza vaccination o f  health-care 
workers— C alifornia and  M innesota. M M W R  2005;54 :196-9 .
121. Polgreen PM , Septim us EJ, Parry MF, et al. Relationship o f  influenza 
vaccination declination statem ents and  influenza vaccination rates for 
healthcare workers in  22 US hospitals. Infect C ontrol H osp Epidem iol 
2 008;29 :675-7 .
122. Talbot T R . D o declination  statem ents increase health  care w orker 
influenza vaccination rates? C lin  Infect Dis 2009;49 :773-9 .
MMWR / November 25, 2011 / Vol. 60 / No. 7 31
Recommendations and Reports
123. Polgreen PM , C hen  Y, B eekm ann S, et al. E lem ents o f  influenza 
vaccination program s th a t predict h igher vaccination rates: results o f 
an  em erg in g  in fec tion s  n e tw o rk  survey. C lin  In fec t D is 2008;
46 :1 4 -9 .
124. C D C . Influenza vaccination o f health-care personnel: recommendations 
o f  the H ealthcare Infection  C on tro l Practices Advisory C om m ittee 
(H ICPA C ) and  the Advisory C om m ittee on  Im m unization  Practices 
(ACIP). M M W R  2006;55(N o. RR-2).
125. Poland GA, O fstead CL, Tucker SJ, et al. Receptivity to  m andatory 
influenza vaccination policies for healthcare workers am ong registered 
nurses w orking on  inpatien t units. Infect C ontrol H osp Epidem iol 
2 008;29 :170-3 .
126. Babcock H M , G em einhart N , Jones M , et al. M andatory  influenza 
vaccination o f  health care workers: translating policy to  practice. C lin  
Infect Dis 2 01 0;50 :459-64 .
127. Jo in t C om m ission on  A ccreditation o f  H ealthcare Organizations. N ew 
infection control requirem ent for offering influenza vaccination to  staff 
a n d  lic e n s e d  in d e p e n d e n t  p ra c t i t io n e r s .  J t  C o m m  P ersp ec t 
2 006;26 :10-1 .
128. N ational Q uality  Forum . N ational voluntary  consensus standards for 
influenza and  pneum ococcal im m unizations. Available at http://w w w. 
q u a li ty fo ru m .o rg /P u b l ic a t io n s /2 0 0 8 /1 2 /N a t io n a l_ V o lu n ta ry _  
C o n s e n s u s _ S ta n d a r d s _ f o r _ I n f lu e n z a _ a n d _ P n e u m o c o c c a l_  
Im m unizations.aspx. Accessed O ctober 5, 2011.
129. Govaert T M , D in an t GJ, Aretz K, et al. Adverse reactions to  influenza 
vaccine in elderly people: random ised double b lind  placebo controlled 
trial. BMJ 1993;307 :988-90.
130. M argolis KL, N icho l KL, Poland GA, et al. Frequency o f adverse 
reactions to  influenza vaccine in  the elderly: a random ized, placebo­
controlled trial. JA M A  1990;264:1139—41.
131. C D C . P re v e n t io n  a n d  c o n tro l  o f  in f lu e n z a  w ith  v ac c in es : 
recom m endations o f th e  A dvisory C o m m ittee  o n  Im m u niza tio n  
Practices (ACIP), 2011. M M W R  2 01 1;60 :1128-32 .
132. H arper SA, Bradley JS, E nglund  JA, et al. Seasonal influenza in adults 
a n d  c h ild re n — d iag n o s is , t r e a tm e n t ,  c h e m o p ro p h y la x is , an d  
institu tional outbreak m anagem ent: clinical practice guidelines o f the 
In fec tio u s  D iseases S ociety  o f  A m erica . C lin  In fec t D is 2009; 
4 8 :10 03 -3 2 .
133. C D C . Antiviral agents for the trea tm en t and  chem oprophylaxis of 
in flu e n z a : re c o m m e n d a tio n s  o f  th e  A d v iso ry  C o m m itte e  o n  
Im m unization  Practices (ACIP). M M W R  2011;60(N o. RR-1).
134. Strebel PM , Papania M J, D ayan G H , Halsey N A . Measles vaccine. In: 
Plotkin SA, O renstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, 
PA: W.B. Saunders; 200 8 :35 3 -9 8 .
135. C D C . Measles, m um ps, and  rubella— vaccine use and  strategies for 
elim ination  o f measles, rubella, and  congenital rubella syndrom e and 
contro l o f m um ps: recom m endations o f the Advisory C om m ittee on 
Im m unization  Practices (ACIP). M M W R  1998;47(N o. RR-8).
136. C D C . Progress tow ard measles elim ination— region o f the Americas, 
2 0 0 2 -2 0 0 3 . M M W R  2 004;53 :304-6 .
137. O renstein  WA, Papania M H , W h arton  M E. Measles e lim ination  in 
the U nited  States. J Infect Dis 2004;189(Suppl 1):S1—3.
138. W orld  H ealth  O rganization. Measles fact sheet N o .286 . Available at 
h ttp ://w w w .w h o .in t/m ed ia cen tre /fac tsh e e ts /fs2 8 6 /e n /in d e x .h tm l. 
Accessed O ctober 5, 2011.
139. C D C . G lo b a l m easles m o rta lity , 2 0 0 0 - 2 0 0 8 . M M W R  2 0 0 9 ; 
5 8 :1321-6 .
140. C D C . O utbreak  of measles— San Diego, California, January-February
2008. M M W R  2 008;57 :203-6 .
141. Sugerm an D E, Barskey, Delea M G , et al. Measles outbreak  in a highly 
vaccinated population , San Diego, 2008: role o f th e  in tentionally  
undervaccinated. Pediatrics 2 01 0;125 :747-55 .
142. Parker AA, Staggs W, D ayan G H , et al. Im plications o f  a 2005 measles 
outbreak in Indiana for sustained e lim ination  o f measles in the U nited
States. N  Engl J M ed 200 6;35 5 :4 47 -5 5 .
143. C D C . Measles— U nited  States, January-Ju ly  2008. M M W R  2008; 
57 :893-6 .
144. Parker Fiebelkorn A, Redd SB, Gallagher, et al. Measles in  the U nited  
States during the postelim ination era. J Infect Dis 2010;202:1520-8.
145. Farizo KM , Stehr-Green PA, Sim pson, D M , M arkowitz LE. Pediatric 
emergency room  visits— a risk factor for acquiring measles. Pediatrics 
1991;87 :74-9 .
146. Rivera M E, M ason W H , Ross LA, W right H T  Jr. N osocom ial measles 
infection in a pediatric hospital d uring  a com m unity-w ide epidem ic. 
J Pediatr 1991;119 :183-6 .
147. C D C . Im m u n iz a tio n  a d m in is tra tio n  req u irem en ts  fo r h o sp ita l 
em ployees fo r M M R . A vailab le a t h ttp :/ /w w w 2 a .c d c .g o v /n ip / 
S ta te V a c c A p p /s ta te v a c c s A p p /A d m in is t ra t io n b y V a c c in e .a s p ?  
V accinetm p=M M R . Accessed O ctober 5, 2011.
148. C D C . Coverage estimates fo r school entry  vaccinations for school year 
2 0 0 9 -2 0 1 0 . School and  childcare vaccination  survey. Available at 
h ttp :/ /w w w 2 .c d c .g o v /n ip /s c h o o ls u rv /n a tio n a la v g .a s p . A ccessed 
O ctober 5, 2011.
149. C hen  SY, A nderson S, K utty  PK, et al. H ealth  care-associated measles 
outbreak in  the U nited  States after an im porta tion: challenges and 
econom ic im pact. J Infect Dis 2 01 1;20 3 :1 51 7-25 .
150. Siegel JD , R hinehart E, Jackson M , Chiarello L, and  the H ealthcare 
In fec tion  C o n tro l Practices A dvisory C o m m ittee . G u ide line  for 
isolation precautions: preventing transm ission o f infectious agents in 
healthcare settings. 2007. A m  J Infect C ontrol 2007;35(10 Suppl 2): 
S 65-164.
151. Steingart KR, T hom as AR, Dykewicz CA, R edd SC. Transm ission of 
measles virus in healthcare settings during  a com m unityw ide outbreak. 
Infect C ontrol H osp Epidem iol 1 999;20 :115-9 .
152. LeB aron CW , Beeler J , Sullivan BJ, e t al. Persistence o f  measles 
an tibod ies afte r 2 doses o f measles vaccine in  a p o s te lim in a tio n  
env ironm ent. Arch Pediatr Adolesc M ed 2007;161 :294-301 .
153. W illy  M E , Kozoil D E , Fleisher T, e t al. M easles im m u n ity  in  a 
population  of health-care workers. Infect C ontrol H osp Epidem iol 
1994;15 :12-7 .
154. Schwarcz S, M ccaw B, Fukushim a P. Prevalence o f measles susceptibility 
in hospital staff: evidence to  support expanding the recom m endations 
o f  the Im m unization  Practices Advisory C om m ittee. Arch In tern  M ed 
1992;152 :1481-3 .
155. H o u c k  P, S co ttjo h n so n  G , K rebs L. M easles im m u n ity  am ong  
co m m u n ity  h osp ita l em ployees. In fect C o n tro l H osp  E pidem io l 
1 991;12 :663-8 .
156. W rig h t LJ, C a rlq u is t JF. M easles im m u n ity  in  em ployees o f  a 
m ultihospital health-care provider. Infect C on tro l H osp Epidem iol 
1994;15 :8 -11 .
157. W eber D J, Consoil S, Sickbert-B ennett E, M iller M B, R utala WA. 
Susceptibility to  measles, m um ps, and  rubella in  newly h ired  (2006­
2008) healthcare workers b o rn  before 1957. Infect C on tro l H osp 
Epidem iol 2 010;31 :655-7 .
158. B raunstein  H , T hom as S, Ito  R. Im m u nity  to  measles in  a large 
population  o f varying age— significance w ith  respect to  vaccination. 
Am  J Dis C hild  1990;144 :296-8 .
32 MMWR / November 25, 201 1 / Vol. 60 / No. 7
Recommendations and Reports
159. Sm ith E, W elch W, Berhow M , W ong VK. Measles susceptibility o f 
hospital employees as determ ined  by ELISA. C lin  Res 1990;38:A183.
160. Kim M , LaPointe J, Liu FJ. Epidem iology o f  measles im m unity  in  a 
population  o f  healthcare w orkers. Infect C on tro l H osp  Epidem iol
1992;13 :399-402.
161. M cQ uillan  G M , K ruszon-M oran D , H yde TB , Forghani B, Bellini W  
D ayan G H . Seroprevalence o f  measles antibody  in the US population, 
1 99 9-20 0 4 . J Infect Dis 2 00 7;19 6 :1 45 9-64 .
162. H utch ins SS, Bellini W J, C oronado  V, Jiles R, W ooten K, Deladisma 
A. Population im m unity  to  measles in the U nited  States, 1999. J Infect 
Dis 2004;189:S 91-7 .
163. Brodsky L, Stanievich J. Sensorineural hearing loss follow ing live 
measles v irus vaccination . In t J P ed ia tr O to rh in o la ry n g o l 1985; 
10:159-63 .
164. M arshall GS, W right PF, Fenichel G M , Karzon DT. Diffuse retinopathy 
fo llow in g  m easles, m u m ps, a n d  ru b ella  v acc in a tio n . P ed ia trics
1985;76 :989-991.
165. Kazarian EL, Gager W  E. O ptic  neuritis com plicating measles, m um ps, 
and  rubella vaccination. A m  J O ph thalm ol 1978;86 :544-7 .
166. daSilveira C M , Salisbury D M , deQ uadros CA. Measles vaccination 
and  G uillain-Barre syndrom e. Lancet 1997;349(9044):14-6 .
167. H viid  A, Stellfeld M , W ohlfahrt J, Melbye M . C hildhood  vaccination 
and  type 1 diabetes. N  Engl J M ed 2 004;350 :1398-404 .
168. Bernstein C N , Raw sthorne P, Blanchard JF. Population-based case- 
contro l study o f  measles, m um ps, and  rubella and  inflam m atory bowel 
disease. Inflam m  Bowel Dis 2007;13 :759-62 .
169. Taylor B, M iller E, Lingam  R, A ndrews N , S im m ons A, Stowe J. 
Measles, m um ps, an d  rubella vaccination  and  bowel problem s or 
developm ental regression in children  w ith  autism : population  study. 
BMJ 2 002;324(7334):393-6 .
170. Grabowsky M , M arkow itz L. Serologic screening, mass im m unization, 
an d  im plications fo r im m u niza tio n  program s. J Infect D is 1991; 
164 :1237-8 .
171. Subbarao EK, A m in  S, K um ar M L. Prevaccination serologic screening 
for measles in  health-care workers. J Infect Dis 1991;163:876-8 .
172. Sellick JA, Longbine D , Schifeling R, M ylotte JM . Screening hospital 
employees fo r measles im m u nity  is m ore cost-effective th an  b lind  
im m unization . A nn  In ternM ed  1992;116:982—4.
173. A m m ari LK, Bell LM, H od inka R  L. Secondary measles-vaccine failure 
in  health-care workers exposed to  infected patients. Infect C ontrol 
H osp Epidem iol 1993;14 :81-6 .
174. D ayan G H , Rota K, Bellini W, Redd S. Measles. In: C D C . M anual 
for the surveillance o f  vaccine-preventable diseases. Available at h ttp ://  
w w w .c d c .g o v /v a c c in e s /p u b s /su rv -m a n u a l/c h p t0 7 -m e a s le s .p d f . 
Accessed O ctober 5, 2011.
175. Plo tk in  SA, R ubin  SA. M um ps vaccine. In: Plo tk in  S, O renstein  W  
O ffit P, eds. Vaccines. 5 th  ed. P hiladelphia, PA: W .B. Saunders; 
200 8 :43 5 -6 5 .
176. C D C . C urren t trends m um ps— U nited  States, 1 98 0-19 8 3 . M M W R  
1983;32 :545-7 .
177. C D C . M um ps vaccine. M M W R  1977;26 :393-4 .
178. van Loon FPL, H olm es SJ, S irotkin BI, et al. M um ps surveillance—  
U nited  States, 1 98 8-19 9 3 . M M W R  1995;44(N o. SS-3).
179. C D C . Measles prevention. M M W R  1989;38(Suppl 9).
180. US D epartm en t o f  H ealth  and  H um an  Services. H ealthy  people 2010: 
u n d e r s ta n d in g  a n d  im p ro v in g  h e a lth . W a sh in g to n , D C : US 
D epartm en t o f  H ealth  and  H um an  Services; 2000.
181. C D C . M um ps epidem ic— Iowa, 2006. M M W R  2 006;55 :366-8 .
182. C D C . M ultistate outbreak  o f  m um ps— U nited  States, January  1-M ay 
2, 2006. M M W R  2006;55 :559-63 .
183. D ayan G H , Q uinlisk  MP, Parker AA. Recent resurgence o f  m um ps in 
the U nited  States. N  Engl J  M ed 2 008;358 :1580-9 .
184. C D C . M um ps outbreak— N ew  York and  N ew  Jersey, June 2 0 0 9 -  
January  2010. M M W R  2 010;59 :125-9 .
185. N elson G, Lizama-Aguon A, Q uiam bao E, et al. T h ird  dose M M R  
in te rv e n tio n  d u r in g  a m u m ps o u tb re a k  in  a h ig h ly -v a cc in a te d  
population— G uam  2 00 9-20 1 0  [Presentation]. Presented at the 45th  
N ational Im m unization Conference, W ashington, D C; M arch 29, 2011.
186. G ordon  JE , Kilham  L. Ten years in  the epidem iology o f  m um ps. Am  
J M ed Sci 1949;218 :338-59.
187. Philip  R N , Reinhard KR, Lackm an DB, O bservations on  a m um ps 
epidem ic in  a virgin population. Am  J Hyg 1959;69 :91-111 .
188. C D C . M umps. In: Atkinson, Wolfe C, Ham borsky J, eds. Epidemiology 
and  p revention  o f  vaccine-preventable diseases. W ashington , D C : 
Public H ealth  Foundation; 2 00 9:189-98 .
189. M eyer M B. A n epidem iologic study o f  m um ps: its spread in schools 
and  families. Am  J H yg 1962;75:259-81 .
190. H arris RW, Kehrer AF, Isacson P. R elationship o f  occupations to  risk 
o f  clinical m um ps in adults. A m  J Epidem iol 1969;89 :264-70 .
191. W h a rto n  M , C och i SL, H u tc h e so n  R H , S chaffn er W . M u m ps 
transm ission in hospitals. Arch In tern  M ed 1990;150:47-9 .
192. Fischer PR, Brunetti C , W elch V, C hristenson JC . N osocom ial m umps: 
re p o r t o f  an  o u tb re a k  a n d  its c o n tro l. A m  J In fe c t C o n tro l  
1996;24 :13-8 .
193. Bonebrake AL, Silkaitis C, M onga G , et al. Effects o f  m um ps outbreak 
in  h o sp ita l , C h ica g o , Il lin o is , U SA , 2 0 0 6 . E m erg  In fe c t D is 
2010;16 :426-32 .
194. C D C . U pdated  recom m endations o f  the Advisory C om m ittee  on  
Im m unization  Practices (ACIP) for the con tro l and  elim ination  o f  
m um ps. M M W R  2 006;55 :629-30 .
195. W eber SH, M erkel D , M iller P, Tilzer L, Kliethermes J, H orvat R. 
H o sp ita l an d  clin ical lab o ra to ry  response to  m u m ps exposures. 
Labm edicine 2007;38 :285-8 .
196. Galazka A M , Robertson SE, K raigher A, M um ps and  m um ps vaccine: 
a global review. Bull W orld  H ealth  O rgan 1999;77 :3-14 .
197. H ersh BS, Fine PE, K ent W K , et al. M um ps outbreak  in a highly 
vaccinated population. J Pediatr 1991;119:187-93.
198. C heek JE, Baron R, Atlas H , W ilson DL, C rider RD. M um ps outbreak 
in a highly  vaccinated school population : evidence for large-scale 
vaccination failure. Arch Pediatr Adolesc M ed 1995;149:774-8 .
199. Schaffzin JK, Pollock L, Schulte C, et al. Effectiveness o f  previous 
m um ps vaccination  d u r in g  a sum m er cam p outbreak . Pediatrics 
2007;120:e862-8 .
200. C ohen  C , W h ite  JM , Savage EJ, et al. Vaccine effectiveness estimates, 
2 0 0 4 -2 0 0 5  m um ps ou tbreak , E ngland . E m erg  Infect Dis 2007; 
13 :12-7 .
201. H arling  R, W h ite  JM , Ramsay M E, M acsween KF, van den Bosch C. 
T he effectiveness o f  the m um ps com ponen t o f  the M M R  vaccine: a 
case contro l study. Vaccine 2005;23 :4070-4 .
202. M arin  M , Q uinlisk  P, Shim abukuro T, Sawhney C , Brown C, Lebaron 
CW. M um ps vaccination coverage and vaccine effectiveness in  a large 
o u tb re a k  am o n g  college s tu d e n ts — Iow a, 2 00 6 . V accine 2 008; 
2 6 :3601-7 .
203. D avidkin  I, Valle M , Ju lkunen  I, Persistence o f  an ti-m um ps virus 
antibodies after a two-dose M M R  vaccination. A  nine-year follow-up. 
Vaccine 1995;13 :1617-22 .
MMWR / November 25, 2011 / Vol. 60 / No. 7 33
Recommendations and Reports
204. R ubin  SA, Q i L, A udet SA. et al. A ntibody  induced by im m unization  
w ith  the Jeryl Lynn m um ps vaccine strain  effectively neutralizes a 
heterologous w ild-type m um ps virus associated w ith  a large outbreak.
J Infect Dis 2 00 8;198 :508-15 .
205. D ate AA, Kyaw M H , Rue A M , et al. Long-term  persistence o f m um ps 
antibody after receipt o f 2 measles-mumps-rubella (M M R) vaccinations 
an d  an tib o d y  response afte r a th ird  M M R  vaccination  am ong  a 
university population. J Infect Dis 2 008;197 :1662-8 .
206. Cortese M M , Jordan HT, C urns AT, et al. M um ps vaccine performance 
am ong university s tudents during  a m um ps outbreak. C lin  Infect Dis 
2 008;46 :1172-80 .
207. K utty  PK, K ruszon-M oran D M , D ayan G H , et al. Seroprevalence o f 
antibody  to  m um ps virus in the US population, 1 99 9-20 0 4 . J Infect 
Dis 2 010;202 :667-74 .
208. Brunell PA, Brickm an A, O ’H are D , Steinberg S. Ineffectiveness o f  
isolation o f patients as a m ethod  o f preventing the spread o f m um ps. 
Failure o f the m um ps skin-test antigen to predict im m une status. N  
Engl J M ed 1 968;279 :1357-61 .
209. K utty  PK, Kyaw M H , D ayan  G H , et al. G uidance fo r isolation  
precautions fo r m um ps in  the U nited  States: a review o f  the scientific 
basis for policy change. C lin  Infect Dis 2010;50 :1619-28 .
210. W h arton  M , C ochi SL, H utcheson  R H , Bistowish JM , Schaffner W  
A  large o u tb reak  o f  m um ps in th e  postvaccine era. J In fect Dis 
1988;158:1253-60 .
211. Plo tk in  SA, R eef SE. Rubella vaccine. In: Plo tk in  S, O renstein  W, 
O ffit P, eds. Vacciness 5 th  ed. Philadelphia, PA: W .B. Saunders; 
200 8 :73 5 -7 1 .
212. Bosma TJ, E therington J, O ’Shea S, et al. Rubella virus and chronic joint 
disease: is there an association? J Clin M icrobiol 1998;36:3524-6.
213. Am erican Academy o f  Pediatrics. Rubella. In: Pickering LK, Baker CJ, 
K im berlin DW , Long SS, eds. 2009 red book: report o f the C om m ittee 
o n  Infectious Diseases. 28 th  ed. E lk  Grove Village, IL: A m erican 
A cadem y o f  Pediatrics; 2009:579-84 .
214. G reen R H , Balsamo M R , Giles JP, K rugm an S, M irick  GS. Studies o f 
th e  n a tu ra l h is to ry  an d  p rev en tio n  o f  rubella. A m  J Dis C h ild  
1965;110 :348-65.
215. Ingalls T H , P lo tk in  SA, M eyer H M  Jr, P arkm an  P D . Rubella: 
epidem iology , virology, an d  im m uno logy. A m  J M ed  Sci 1967; 
253 :3 49 -7 3 .
216. O renstein  WA, Bart KJ, H in m an  AR, et al. T h e  o p p o rtu n ity  and 
o b lig a tio n  to  e lim in a te  ru b ella  from  th e  U n ite d  S tates. JA M A  
1984;251 :1988-94 .
217. W illiams N M , Preblud SR. Rubella and congenital rubella surveillance, 
1983. M M W R  1984;33(N o. SS-4):1-10.
218. C ochi SL, E dm onds LE, D yer K, et al. C ongenital rubella syndrom e 
in the U nited  States, 1970-1985: on  the verge o f  elim ination. Am  J 
E pidem iol 1989;129 :349-61.
219. C D C . A chievem ents in  pub lic  health : e lim ination  o f  rubella and  
congenital rubella syndrom e— U nited  States, 1 9 6 9 - 2004. M M W R  
2 005;54 :279-82 .
220. Reef SE, C ochi SL. T he evidence for the elim ination  o f  rubella and 
congenital rubella syndrom e in the U nited  States: a pub lic health 
achievem ent. C lin  Infect Dis 2006;43(Suppl 3):S123-5 .
221. Greaves W L, O renstein  WA, Stetler H C , Preblud SR, H in m an  AR, 
Bart KJ. Prevention o f  rubella transm ission in medical facilities. JAM A 
1982;248:861-4 .
222. G ladstone JL. Rubella exposure in an  obstetric clinic. O bste t Gynecol 
1981;57 :182-6 .
223. C D C . N osocom ial rubella infection— N o rth  D akota, Alabama, O hio. 
M M W R  1981;29 :629-31 .
224. C D C . E xposure o f  p a tien ts  to  ru b ella  by  m edical p e rso n n e l—  
C alifornia. M M W R  1978;27:123.
225. Strassburg MA, Imagawa DT, Fannin SL, et al. Rubella outbreak am ong 
hospital employees. O bste t Gynecol 1981;57:283-8 .
226. Fliegel PE, W einstein  W M . Rubella outbreak  in a prenatal clinic: 
m anagem ent and prevention. Am  J Infect C ontrol 1982;10:29-33.
227. Polk BF, W h ite  JA, D eG irolam i PC , M odlin  JF. A n outbreak o f  rubella 
am ong hospital personnel. N  Engl J M ed 1980;303 :541-5 .
228. M cLaughlin  M C , G old  LH . T he N ew  York rubella incident: a case for 
changing hospital policy regarding rubella testing and  im m unization . 
Am  J Public H ealth  1 979;69 :287-9 .
229. C D C . Rubella in  hospital personnel and  patients— Colorado. M M W R  
1 979;28 :325-7 .
230. H e se ltin e  P N R , R ip p e r M , W o h lfo rd  P. N o so co m ia l ru b ella : 
consequences o f an outbreak and  efficacy o f a m andatory im m unization 
program . Infect C ontrol 1985;6:371-4 .
231. C D C . Epidemiologic notes and reports rubella in hospitals— California. 
M M W R  1983;32 :37-9 .
232. P ap an ia  M , R ee f S, Ju m a a n  A, L in ig ap p a  JR , W illia m s W W . 
N osocom ial measles, m um ps, rubella, and  o th er viral infections. In: 
M ayhall C G , ed. H ospital epidem iology and  infection control. 3 rd  ed. 
Philadelphia, PA: L ippincott W illiam s &  W ilkins; 200 4 :82 9 -4 9 .
233. de Valk H , Rebière I. [Epidem ic o f  rubella: evaluation o f  the vaccine 
efficacy on  the ground]. Saint M aurice, France: Réseau N ational de 
Santé Publique; 1 998:1-52 .
234. W eibel RE, Carlson AJ Jr, Villarejos V M , et al. C linical and  laboratory 
studies o f com bined  live measles, m um ps, and  rubella vaccines using 
the RA 27/3  rubella virus. Proc Soc Exp Biol M ed 1980;165 :323-6 .
235. Balfour H H , G ro th  KE, Edelm an CK, RA 27/3  rubella vaccine— a 
four-year follow-up. Am  J Dis C hild , 1980;134:350-3 .
236. W eibel RE, V illarejos V M , K lein EB, B uynak EB, M cLean AA, 
H illem an M R . Clinical and  laboratory studies o f live a ttenuated  RA 
2 7/3  and  H P V  7 7-D E  rubella virus vaccines. Proc Soc Exp Biol M ed 
1 980;165 :44-9 .
237. D avidkin I, Jokinen S, B rom an M , Leinikki P, Peltola H . Persistence 
o f measles, m um ps, and  rubella antibodies in  an M M R -vaccinated 
cohort: a 20-year follow-up. J Infect Dis 2 008;197 :950-6 .
238. LeB aron CW , Forghani B, M a tte r L, et al. Persistence o f  rubella 
antibodies after 2 doses o f m easles-m um ps-rubella vaccine. J Infect Dis 
2 00 9;200 :888-99 .
239. H yde TB, K ruszon-M oran D , M cQ uillan  G M , Cossen C, Forghani 
B, Reef SE. Rubella im m unity  levels in the U nited  States population: 
has the threshold  o f viral elim ination  been reached? C lin  Infect Dis 
2006;43(Suppl 3 ):S 146-50 .
240. Fraser V, Spitznagel E, M edoff G, D unagan  W C . Results o f  a rubella 
screening program  for hospital employees: a five-year review (1986­
1990). A m  J Epidem iol 1993;138 :756-64.
241. H artstein  AI, Q uan  MA, W illiams M L, O sterud H T, Foster LR. Rubella 
screening and  im m unization  o f health care personnel: critical appraisal 
o f  a volun tary  program . A m  J Infect C ontrol 1983;11:1-9 .
242. Weiss KE, Flavo C D , B uim ovici-K lein E, M agill JW, C ooper LZ. 
Evaluation of an employee health service as a setting for a rubella screening 
and  im m unization program. Am  J Public H ealth 1979;69:281-3.
243. C D C . Revised A C IP  recom m endation  for avoiding pregnancy after 
receiving a rubella-containing vaccine. M M W R  2001;50:1117.
34 MMWR / November 25, 201 1 / Vol. 60 / No. 7
Recommendations and Reports
244. C D C . C ontrol and  prevention o f  rubella: evaluation and m anagem ent 
o f  suspected outbreaks, rubella in  p regnant w om en, and surveillance 
for congenital rubella syndrom e. M M W R  2001;50(N o. RR-12).
245. Schiff G M . T itered  lots o f  im m une g lobulin  (Ig). Efficacy in  the 
prevention o f  rubella. A m  J Dis C hild  1969;118:322-7 .
246. M ortim er EA Jr. Pertussis vaccine. In: P lo tk in  SA, M ortim er EA, eds. 
Vaccines. 2 nd  ed. Philadelphia, PA: W.B. Saunders; 1994:94.
247. M ortim er EA Jr. Pertussis and  its prevention: a fam ily affair. J Infect 
Dis 1990;161 :473-9 .
248. C D C . U p d a te d  T d a p  v a c c in a tio n  coverage rates. 2 0 0 9  A d u lt 
vaccination coverage, N ational Interview  Survey. Available at h ttp ://  
w w w .c d c .g o v /v a c c in e s /s ta ts -su rv /n h is /2 0 0 9 -n h is .h tm . A ccessed 
O ctober 5, 2011.
249. C hristie C, Glover AM , W illke M J, M arx M L, Reising SF, H utchinson 
N M . C on ta inm en t o f  pertussis in the regional pediatric hospital during 
th e  g rea ter C in c in n a ti ep id em ic  o f  1993. In fect C o n tro l H osp  
Epidem iol 1995;16:556-63 .
250. K urt TL, Yeager AS, G uennette S, D un lop  S. Spread o f  pertussis by 
hospital staff. JA M A  1972;221:264-7 .
251. Linnem ann CC, R am undo N , Perlstein PH , et al. Use o f  pertussis vaccine 
in an epidem ic involving hospital staff. Lancet 1975;2:540-3.
252. Valenti W M , Pincus PH , M essner M K. N osocom ial pertussis: possible 
spread by a hospital visitor. A m  J Dis C hild  1980;134:520-1 .
253. D ev ille  J G , C h e rry  J D , C h r is te n so n  P D , e t al. F req u en cy  o f 
unrecognized Bordetella pertussis infections in adults. C lin  Infect Dis 
1995;21 :639-42 .
254. W right SW, Decker M D , Edwards KM . Incidence o f  pertussis infection 
in  h e a lth ca re  w o rk e rs . In fe c t C o n tro l H o sp  E p id e m io l 1999; 
2 0 :12 0-3 .
255. C alugar A, Ortega-Sanchez IR, Tiwari T, Oakes L, Jahre JA, M urphy 
TV. N oso co m ial pertussis: costs o f  an  o u tb reak  an d  benefits  o f  
vaccinating health care workers. C lin  Infect Dis 2006;42 :981-8 .
256. W ard JI, C herry  JD , C hang SJ, et al. Efficacy o f  an acellular pertussis 
v acc in e  am o n g  ad o le sce n ts  a n d  ad u lts . N  E ng l J M ed  2 00 5 ; 
353 :1 55 5 -6 3 .
257. R ank C, Q u in n  H E , M cIntyre PB. Pertussis vaccine effectiveness after 
mass im m unization  o f  high school students in  Australia. Pediatr Infect 
Dis J  2009;28 :152-3 .
258. W ei SC, Tatti K, C ushing K, et al. Effectiveness o f  adolescent and  adult 
tetanus, reduced diphtheria , and  acellular pertussis vaccine (Tdap) 
against pertussis. C lin  Infect Dis 2 010;51 :315-21 .
259. Klein NP, H ansen J, Lewis E, et al. Post-m arketing safety evaluation 
o f  a te tanus toxoid, reduced d ip h theria  toxoid  an d  3 -co m p on en t 
acellular pertussis vaccine adm inistered to  a cohort o f  adolescents in  a 
U nited  States health  m aintenance organization. Pediatr Infect Dis J 
2 010;29 :613-7 .
260. Blatter M , Friedland LR, W eston W M , Li P, Howe B. Im m unogenicity  
and  safety o f  a tetanus toxoid, reduced d iphtheria toxoid and  three- 
com ponen t acellular pertussis vaccine in  adults 1 9 -6 4  years o f  age. 
Vaccine 2009;27 :765-72 .
261. Pichichero M E, Rennels M B, Edwards KM , et al. C om bined  tetanus, 
d iphtheria, and  5-com ponent pertussis vaccine for use in  adolescents 
and  adults. JA M A  2005;293 :3003-11 .
262. Jackson LA, Yu O , N elson J, et al. Risk o f  m edically attended  local 
reactions following d iphtheria toxoid containing vaccines in adolescents 
a n d  y o u n g  a d u lts : a V accine  S afe ty  D a ta l in k  stud y . V accine  
2 009;27 :4912-6 .
263. Yih W K , N ord in  JD , K ulldorff M , et al. A n  assessment o f  the safety 
o f adolescent and  adult tetanus-diphtheria-acellular pertussis (Tdap) 
vaccine, using active surveillance for adverse events in  the Vaccine Safety 
D atalink. Vaccine 2009;27 :4257-62 .
264. Goins W, Edwards KM , Vnencak-Jones CL, et al. C om parison o f two 
strategies to  p reven t pertussis in  vaccinated  healthcare personnel 
fo llo w in g  p e rtu ss is  ex p o su re  [P re se n ta tio n ] . P re se n te d  a t th e  
International Conference o f Healthcare-Associated Infections, A tlanta, 
Georgia; M arch 18-22 , 2010.
265. G arner JS. Guideline fo r isolation precautions in hospitals. T he Hospital 
Infection C ontrol Practices Advisory C om m ittee. Infect C ontrol H osp 
Epidem iol 1996;17 :53-80.
266. C D C . P revention  o f  varicella: recom m endations o f  th e  A dvisory 
C om m ittee  on  Im m uniza tion  Practices (ACIP). M M W R  2007;56 
(No. RR-4).
267. Guris D , Jum aan A O , Mascola L, et al. Changing varicella epidemiology 
in  active surveillance sites— U nited  States, 1 99 5-20 0 5 . J Infect Dis 
2008;197(Suppl 2):S 71-75 .
268. Lopez AS, Z hang J, Brown C, Bialek S. Varicella-related hospitalizations 
in  the U nited  States, 2 00 0-20 0 6 : the 1-dose varicella vaccination era. 
Pediatrics 2 01 1;127 :238-45 .
269. M arin  M , Z hang  JX, Seward JF. N ear elim ination  o f  varicella deaths 
in  the US follow ing im plem entation  o f  the ch ildhood  vaccination 
program . Pediatrics 2011;128 :214-20 .
270. K attan  JA, Sosa LE, B ohnw agner H D , H adler JL. Im pact o f  2-dose 
vaccination o n  varicella epidem iology: C o n n ec tic u t-2 0 0 5 -2 0 0 8 . J 
Infect Dis 2 01 1;203 :509-12 .
271. Reynolds M , K ruszon-M oran D , Jum aan A O , Schm id DS, M cQ uillan  
G M . Varicella seroprevalence in  the U nited  States: d ata  from  the 
N atio na l H ealth  an d  N u trit io n  E xam ination  Survey (N H A N E S ), 
1 99 9-20 0 4 . Public H ealth  Rep 2 01 0;125 :860-9 .
272. S ew ard  JF, Z h a n g  JX , M a u p in  T J , M a sc o la  L, J u m a a n  A O . 
Contagiousness o f varicella in vaccinated cases: a household contact
study. JA M A  2004;29 2 :8 51 -5 .
273. Saim an L, LaRussa P, Steinberg SP, et al. Persistence o f  im m unity  to 
varicella-zoster virus vaccination am ong health  care workers. Infect
C ontrol H osp Epidem iol 2 001;22 :279-83 .
274. A m pofo K, Saiman L, LaRussa P, Steinberg S, A nnunziato  P, G ershon 
A. Persistence o f im m unity  to  live attenuated  varicella vaccine in  healthy
adults. C lin  Infect Dis 2 002;34 :774-9 .
275. Lee BW. Review o f  varicella zoster seroepidem iology in  India and  
Southeast Asia. Trop M ed In t H ealth  1 998;3:886-90.
276. Longfield JN , W in n  Re, G ibson RL, Juchau SV, H offm an PV. Varicella 
outbreak  in arm y recruits from  Puerto Rico. Varicella susceptibility in 
a population  from  the tropics. Arch In tern  M ed 1990;150:970-3 .
277. Meyers JD , M acQ uarrie M B, M erigan T C , Jennison M H . Varicella. 
Part 1: outbreak  in oncology patients at a children’s hospital. W est J 
M ed 1979;130 :196-9 .
278. G ustafson  T L, Shehab Z , B runell PA. O u tb reak  o f  varicella in  a 
new born intensive care nursery. A m  J Dis C hild  1984;138:548-50.
279. Hyam s PJ, Stuewe M C S, H eitzer V. Herpes zoster causing varicella 
(chicken pox) in  hospital employees: cost o f a casual attitude. Am  J
Infect C ontrol 1984;12 :2 -5 .
280. W eitekam p M R , Schan P, A ber RC. A n algorithm  for the control o f 
varicella-zoster virus. A m  J Infect C ontrol 1985;13 :193-8 .
281. A lter SJ, H am m o n d  JA, McVey CJ, Myers M G . Susceptibility  to 
varicella-zoster virus am ong adults at high risk fo r exposure. Infect
C ontrol 1 986;7:448-51.
MMWR / November 25, 2011 / Vol. 60 / No. 7 35
Recommendations and Reports
282. K rasinski K, H o lzm an  RS, L aC o u tu re  R, F lo rm an  A. H osp ita l 
experience w ith  varicella-zoster virus. Infect C ontrol 1986;7:312-6 .
283. W eber D J, R utala W A, Parham  C. Im pact an d  costs o f  varicella 
p rev en tio n  in a u n iversity  h osp ita l. A m  J P ub lic  H ea lth  1988; 
78 :1 9 -2 3 .
284. Asano Y, Iwayama S, M iyata T, et al. Spread o f  varicella in hospitalized 
children having no direct con tact w ith  an indicator zoster case and  its 
prevention by a live vaccine. Biken J 1980;23 :157-61 .
285. Leclair JM , Z aia JA, Levine M J, C o n g d o n  RG, G o ld m an n  DA. 
A irborne transm ission o f  chickenpox in a hospital. N  Engl J M ed 
1980;302 :450-3 .
286. G ustafson TL, Lavely GB, Brawner ER, H utcheson  R H , W right PF, 
Schaffner W. A n o u tb reak  o f  a irb orne  varicella. Pediatrics 1982; 
7 0 :5 5 0 -6 .
287. Josephson A, G om b ert M E. A irborne transm ission o f  nosocom ial 
varicella from  localized zoster. J Infect Dis 1988;158:238—41.
288. Sawyer M H , C ham berlin  CJ, W u YN, A intablian  N , W allace M R. 
D etection  o f  varicella-zoster virus D N A  in air samples from  hospital 
room . J Infect Dis 1 994;169 :91-4 .
289. B ehrm an A, Schm id DS, Crivaro A, W atson B. A  cluster o f  prim ary 
varicella cases am ong healthcare workers w ith  false-positive varicella 
zoster virus titers. Infect C ontrol H osp Epidem iol 2 003;24 :202-6 .
290. A dler AL, Casper C, Boeckh M , H eath  J, Z err D M . A n outbreak  o f  
varicella w ith  likely breakthrough disease in  a population  o f  pediatric 
cancer patients.Infect C ontrol H osp Epidem iol 2 008;29 :866-70 .
291. Lopez SA, B urne tt-H artm an  A, N am biar R, et al. Transm ission o f  a 
newly characterized strain  o f  varicella-zoster virus from  a patien t w ith 
herpes zoster in  a long-term -care facility, W est Virginia, 2004. J Infect 
Dis 2 008;197 :646-53 .
292. H aiduven-G riffiths D , Fecko H . Varicella in hospital personnel: a 
challenge for the infection control practitioner. Am  J Infect C ontrol 
1987;15 :207-11 .
293. Seward JF, M arin  M , Vazquez M . Varicella vaccine effectiveness in  the 
US vaccination program: a review. J Infect Dis 2008;197(Suppl):S82-9.
294. Shapiro E D , Vazquez M , Esposito D , et al. Effectiveness o f  2 doses o f 
varicella vaccine in children. J Infect Dis 2011;203 :312-5
295. M erck &  C o., Inc. VARIVAX [Package insert]. W hitehouse Station, 
N J: M erck &  Co., Inc.; 1995.
296. G ershon AA, Steinberg SP, LaRussa P, Ferrara A, H am m erschlag M , 
Gelb L. Im m unization  o f  healthy adults w ith  live attenuated  varicella 
vaccine. J Infect Dis 1 988;158 :132-7
297. Z erboni L, N ader S, Aoki K, A rvin A M . Analysis o f  the persistence o f 
hum oral and cellular im m unity  in  children and adults im m unized with 
varicella vaccine. J Infect Dis 1 998;177 :1701-4 .
298. Chaves SS, H aber P, W alton K, W ise RP, Izurieta H S, Schm id DS, 
Seward JF. Safety o f  varicella vaccine after licensure in  the U nited  States: 
experience from reports to  the Vaccine Adverse Event Reporting System, 
1 99 5-20 0 5 . J Infect Dis. 2008;197(S uppl):S170-7 .
299. G ershon AA, Takahashi M , Seward JF. Varicella vaccine. In: Plotkin 
SA, O renstein  WA, O ffit PA, eds. Vaccines. 6 th  ed. Philadelphia, PA: 
W.B. Saunders. In  press.
300. Lopez AS, M arin  M . Strategies for the contro l and investigation o f  
varicella outbreaks, 2008. Available at http://www.cdc.gov/vaccines/ 
vpd-vac/varicella/outbreaks/m anual.htm . Accessed O ctober 5, 2011.
301. Am erican Academy o f  Pediatrics. Varicella-zoster. In: Pickering LK, 
Baker CJ, K im berlin  DW , Long SS, eds. 2009 red book: report o f  the 
C om m ittee on  Infectious Diseases. 28th  ed. E lk Grove Village, IL: 
A m erican A cadem y o f  Pediatrics; 200 9:71 4 -2 7 .
302. C oh n  A C , M acN eil JR , H arrison  LH , et al. Changes in  Neisseria 
meningitidis disease epidem iology in the U nited  States, 1998-2007: 
im plications for prevention o f  m eningococcal disease. C lin  Infect Dis 
2 010;50 :184-91 .
303. C D C . Guideline for isolation precautions in hospitals. Recommendations 
o f  th e  H osp ita l In fection  C o n tro l Practices A dvisory C om m ittee  
(H ICPA C ) and  the N ational C en ter for Infectious Diseases. Infect 
C ontrol H osp Epidem iol 1 996;17 :53-80.
304. C D C . O ccupational transmission o f  Neisseria meningitidis— California,
2009. M M W R  2 01 0:59 ;1480-3 .
305. C D C . Prevention and control o f meningococcal disease: recommendations 
o f the Advisory Com m ittee on  Im m unization Practices (ACIP). M M W R  
2005;54(N o. RR-7).
306. C D C . Licensure o f  a m eningococcal conjugate vaccine (Menveo) and 
guidance for use— Advisory C om m ittee on  Im m unization  Practices 
(ACIP), 2010. M M W R  2010;59:273.
307. C D C . U pdated  recom m endations for use o f  m eningococcal conjugate 
vaccines— Advisory C om m ittee on  Im m unization  Practices (ACIP),
2010. M M W R  2 011;60 :72-6 .
308. W u H M , H arcourt BH, H atcher CP, et al. Emergence o f  ciprofloxacin- 
resistant Neisseria meningitidis in  N o rth  America. N ew  E ng J M ed 
2 00 9;360 :886-92 .
309. Lynch MF, B lanton E M , Bulens S, et al. Typhoid fever in  the U nited 
States, 1 99 9-20 0 6 . JAM A. 2 009;302 :859-65 .
310. Steinberg EB, Bishop RB, Dem psey AF, et al. Typhoid fever in travelers: 
w ho  sh o u ld  be ta rg e ted  fo r p rev en tion ?  C lin  In fec t D is 2004; 
39 :18 6-91 .
311. C ru m p  JA, Kretsinger K, Gay K, et al. C linical response and  outcom e 
o f  infection w ith  Salmonella enterica serotype Typhi w ith  decreased 
susceptibility to  fluoroquinolones: a U nited States FoodNet M ulticenter 
retrospective C o h o rt Study. A ntim icrob  Agents C hem other 2008; 
52 :12 78 -8 4 .
312. C ru m p  JA, Barrett TJ, N elson JT, et al. Reevaluating fluoroquinolone 
breakpoints for Salmonella enterica serotype Typhi an d  non-T yphi 
Salmonellae. A ntim icrobial Resistance 2 003;37 :75 -81 .
313. C D C . N atio n a l A ntim icrobial Resistance M o n ito rin g  System for 
E nteric Bacteria (NARM S): h um an  isolates final report, 2008. Atlanta, 
GA: US D ep artm en t o f  H ealth  and  H um an  Services, C D C ; 2010.
314. G up ta S, M edalla F, O m ond i MW , et al. Laboratory-based surveillance 
for paratyphoid  fever in  the U nited  States: travel and  antim icrobial 
resistance. C lin  Infect Dis 2 00 8;46 :1656-63 .
315. M erm in  J H , Townes JM , G erber M , et al. Typhoid fever in the U nited 
States, 1985-1994: changing risks o f  international travel and  increasing 
antim icrobial resistance. Arch In tern  M ed 1998;158:633-8 .
316. C D C . T yphoid  im m uniza tion : recom m endations o f  th e  Advisory 
C om m ittee  o n  Im m uniza tion  Practices (A CIP). M M W R  1994;43 
(No. RR-14).
317. B hattarai A, M in tz  E. T yphoid  an d  paratyphoid . In: C D C  health  
in form ation  fo r in ternational travel 2012. N ew  York, NY: O xford 
University Press; 2012.
318. Begier E M , Burw en D R , H aber P, Ball R. Vaccine Adverse Event 
R eporting System W orking G roup. Postm arketing safety surveillance 
for typhoid  fever vaccines from  the Vaccine Adverse Event Reporting 
System, July 1990 th rough  2002. C lin  Infect Dis 2 004;38 :771-9 .
319. Strebel PM , Sutter RW, C ochi SL, et al. Epidem iology o f  poliomyelitis 
in the U nited  States one decade after the last reported case o f  indigenous 
w ild virus-associated disease. C lin  Infect Dis 1992:14 :568-79 .
320. C D C . C ertification o f  poliomyelitis elim ination— the Americas, 1994. 
M M W R  1 994;43 :720-2 .
36 MMWR / November 25, 201 1 / Vol. 60 / No. 7
Recommendations and Reports
321. C D C . P oliom yelitis  p rev en tio n  in th e  U n ite d  S tates. M M W R  
2000;49(N o. RR-5).
322. A lexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes 
an d  ep id em io log y  o f  poliom yelitis  in  th e  U n ite d  States. JA M A  
2 00 4;292 :1696-701 .
323. C D C . Im ported  vaccine-associated paralytic poliom yelitis— U nited  
States, 2005. M M W R  2 006;55 :97-9 .
324. DeVries AS, H arper J, M urray A, et al. Neuroinvasive immunodeficiency- 
associated vaccine-derived poliomyelitis twelve years after infection—  
M innesota, 2008. N  Engl J M ed 2 011;364 :2316-23 .
325. A lexander JP, Jr., E hresm ann  K, Seward J, et al. Transm ission o f 
im ported vaccine-derived poliovirus in  an undervaccinated com m unity  
in  M innesota. J Infect Dis 2 00 9;199 :391-7 .
326. V idor E, M eschievitz C, Plo tk in  S. Fifteen years o f  experience w ith 
Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr 
Infect Dis J 1 99 7 ;l6 :3 1 2 —22.
327. C D C . R ecom m ended adu lt im m unization  schedule— U nited  States,
2011. M M W R  2011;60:1—4.
328. Briss PA, R odew ald  LE, H in m an  AR, et al. Reviews o f  evidence 
regarding interventions to  improve vaccination coverage in children, 
adolescents, and  adults. T he Task Force on  C om m unity  Preventive 
Services. Am  J Prev M ed 2000;18(1 Suppl):97—l4 0 .
329. Kroger A, A tkinson W. General recom m endations for vaccination and 
im m u n o p ro p h y la x is . In : C D C . C D C  h e a lth  in fo rm a tio n  fo r  
international travel 2012. N ew  York, NY: Oxford University Press; 2012.
MMWR I November 25, 2011 I Vol. 60 I No. 7 37
Recommendations and Reports
TABLE 1. Recommendations for immunization practices and use of 
immunobiologies applicable to disease prevention among health­
care personnel* —  Advisory Committee on Immunization Practices 
(ACIP), June 9, 1989-August 26, 2011
Subject Publication in MMWR
General recommendations on immunization 2011;60(No. RR-2)
Diphtheria, tetanus, and pertussis 1991;40(No. RR-10) 
1997;46(No. RR-7)





Influenza5 2010;59(No. RR-8) 
2011;60:1128-32
Measles, mumps, rubella (MMR) 1998;47(No. RR-8)
Meningococcal disease and outbreaks 2005;54(No. RR-7) 
2011;60:72-6
Mumps (see also MMR and Measles) 1989;38:388-92, 397-400 
2006;55;629-630
Pertussis, acellular (see also Diphtheria, 2006;55(No. RR-3)
tetanus, and pertussis) 2006;55(No. RR-17) 
2008;57(No. RR-4) 
2011;60:13-15
Poliomyelitis 2000;49(No. RR-5) 
2009;58:829-30
Rubella (see also MMR, Measles, and Mumps) 2001;50:1117
Typhoid 1994;43(No. RR-14)
Varicella 2007;56(No. RR-4)
* Persons who provide health care to patients or work in institutions that provide 
patient care (e.g., physicians, nurses, emergency medical personnel, dental 
professionals and students, medical and nursing students, laboratory 
technicians, hospital volunteers, and administrative and support staff in health­
care institutions). Source: U.S. Department of Health and Human Services. 
Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ 
ask/initiatives/vacctoolkit/definition.html. 
f  This report provides guidance from CDC and is not an ACIP statement.
§ Each year influenza vaccine recommendations are reviewed and amended to 
reflect updated information concerning influenza activity in the United States for 
the preceding influenza season and to provide information on the vaccine available 
for the upcoming influenza season. These recommendations are published 
periodically in MMWR. The most current published recommendations should be 
consulted (available at http://www.cdc.gov/vaccines/pubs/acip-list.htm).
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Immunizing agents recommended for all HCP
Hepatitis B (HB) 
recombinant vaccine
Hepatitis B immune 
globulin (HBIG)
2 doses 4 weeks apart; 
third dose 5 months 
after second; booster 
doses not necessary; 
all doses should be 
administered IM in the 
deltoid
0.06 mL/kg IM as 
soon as possible after 
exposure, if indicated
Influenza vaccine (TIV Annual vaccination 
and LAIV) with current seasonal
vaccine. TIV is 
available in IM and 
ID formulations.












Preexposure: HCP at risk for On the basis of limited data, 
exposure to blood or body no risk for adverse effects to
fluids; postexposure (see 
Table 4)
developing fetuses is apparent. 
Pregnancy should not be 
considered a contraindication to 
vaccination of women. Previous 
anaphylactic reaction to common 
baker's yeast is a contraindication 
to vaccination.
Postexposure prophylaxis See package insert5 
(see Table 4)
All HCP
1 dose SC; (However, 
due to the 2-dose 
requirements for 
measles and mumps 
vaccines, the use of 
MMR vaccine will result 
in most HCP receiving
2 doses of rubella-
containing vaccine.)
Vaccination should be 
recommended for all HCP 
who lack presumptive 
evidence o f immunity;1 
vaccination should be 
considered for those born 
before 1957.
Vaccination should be 
recommended for all HCP 
who lack presumptive 
evidence o f immunity.1"" 
Vaccination should be 
considered for those born 
before 1957.
Vaccination should be 
recommended for all HCP 
who lack presumptive 
evidence o f immunity.55
The vaccine produces neither therapeutic 
nor adverse effects in HBV-infected persons. 
Prevaccination serologic screening is not 
indicated for persons being vaccinated because 
o f occupational risk but m ight be indicated for 
HCP in certain high-risk populations. HCP at 
high risk for occupational1" contact with blood or 
body fluids should be tested 1-2 months after 
vaccination to determine serologic response.
History of severe (e.g., 
anaphylactic) hypersensitivity to 
eggs; prior severe allergic reaction 
to influenza vaccine
Pregnancy; immunocompromised 
persons,** including HIV-infected 
persons who have evidence of 
severe immunosuppression; 
anaphylaxis to gelatin or 
gelatin-containing products; 
anaphylaxis to neomycin; and 
recent administration of immune 
globulin.
Pregnancy; immunocompromised 
persons,** including HIV-infected 
persons who have evidence of 
severe immunosuppression; 
anaphylaxis to gelatin or gelatin- 
containing products; anaphylaxis 
to neomycin
Pregnancy; immunocompromised 
persons** including HIV-infected 
persons who have evidence of 
severe immunosuppression; 
anaphylaxis to gelatin or gelatin- 
containing products; anaphylaxis 
to neomycin
No evidence exists of risk to mother of fetus when 
the vaccine is administered to a pregnant woman 
with an underlying high-risk condition. Influenza 
vaccination is recommended for women who 
are or will be pregnant during influenza season 
because of increased risk for hospitalization 
and death. LAIV is recommended only for 
healthy, non-pregnant persons aged 2-49 years. 
Intradermal vaccine is indicated for persons 
aged 18-64 years. HCP who care for severely 
immunosuppressed persons who require a 
protective environment should receive TIV rather 
than LAIV.
HCP vaccinated during 1963-1967 with a killed 
measles vaccine alone, killed vaccine followed by 
live vaccine, or a vaccine o f unknown type should 
be revaccinated with 2 doses of live measles virus
HCP vaccinated before 1979 with either killed 
mumps vaccine or mumps vaccine of unknown 
type should consider revaccination with 2 doses 
o f MMR vaccine.
The risk for rubella vaccine-associated 
malformations in the offspring o f women 
pregnant when vaccinated or who become 
pregnant within 1 month after vaccination is 
negligible.11 Such women should be counseled 
regarding the theoretical basis o f concern for the 
fetus.
vaccine.
See table footnotes on page 41
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1 dose IM as soon as 
feasible if Tdap not 
already received and 
regardless o f interval 
from last Td. After 
receipt o f Tdap, receive 
Td for routine booster 
every 10 years.
All HCP, regardless of age.
Varicella vaccine 
(varicella zoster virus 
live-virus vaccine)
2 doses SC 4-8  weeks 
apart if aged >13 years.
All HCP who do not have 
evidence o f immunity 
defined as: written 
documentation of 
vaccination with 2 doses 
of varicella vaccine: 
laboratory evidence of 
immunity111 or laboratory 
confirmation of disease; 
diagnosis or verification 
o f a history of varicella 
disease by a health-care 
provider,§§§ or diagnosis or 
verification of a history of 
herpes zoster by a health­
care provider.
Persons without evidence 
o f immunity who have 
contraindications for 
varicella vaccination 
and who are at risk 
for severe disease and 
complications1"  known or 
likely to be susceptible who 
have direct, nontransient 
exposure to an infectious 
hospital staff worker or 
patient
Other immunobiologics that m ight be indicated in certain circumstances for HCP
History of serious allergic 
reaction (i.e., anaphylaxis) to any 
component of Tdap. Because 
o f the importance o f tetanus 
vaccination, persons with history 
o f anaphylaxis to components 
in Tdap or Td should be referred 
to an allergist to determine 
whether they have a specific 
allergy to tetanus toxoid and 
can safely receive tetanus 
toxoid (TT) vaccine. Persons 
with history o f encephalopathy 
(e.g., coma or prolonged 
seizures) not attributable to an 
identifiable cause within 7 days of 
administration of a vaccine with 
pertussis components should 
receive Td instead of Tdap.
Pregnancy; immunocompromised 
persons;** history of anaphylactic 
reaction after receipt of gelatin or 
neomycin. Varicella vaccination 
may be considered for HIV- 
infected adolescents and adults 
w ith CD4+ T-lymphocyte count 
>200 cells/uL. Avoid salicylate use 
for 6 weeks after vaccination.
Varicella-zoster 
immune globulin












vaccine for HCP age 
>55 years
1 dose; booster dose Clinical and research
in 5 years if person 
remains at increased 
risk
The safety o f the vaccine in
microbiologists who might pregnant women has not been
routinely be exposed 
to isolates o f Neisseria 
meningitidis
Tetanus prophylaxis in wound management if not 
yet received Tdap***
Because 71%-93% of adults w ithout a history of 
varicella are immune, serologic testing before 
vaccination is likely to be cost-effective.
Serologic testing may help in assessing whether 
to administer varicella-zoster immune globulin.
If use o f varicella-zoster immune globulin 
prevents varicella disease, patient should be 
vaccinated subsequently. The varicella-zoster 
immune globulin product currently used in the 
United States (VariZIG) (Cangene Corp. Winnipeg 
Canada) can be obtained 24 hours a day from the 
sole authorized U.S. distributor (FFF Enterprises, 
Temecula, California) at 1-800-843-7477 or h ttp :// 
www.fffenterprises.com.
evaluated; it should not be 
administered during pregnancy 
unless the risk for infection is high.
See table footnotes on page 41
40 MMWR / November 25, 2011 / Vol. 60 / No. 7
Recommendations and Reports






Typhoid vaccine IM, IM vaccine: 1 dose, 
and oral booster every 2 years.
Oral vaccine: 4 
doses on alternate 
days. Manufacturer 
recommends 
revaccination with the 
entire 4-dose series 
every 5 years.
Inactivated poliovirus For unvaccinated
Workers in microbiology Severe local or systemic reaction Vaccination should not be considered an
vaccine (IPV) adults, 2 doses should 
be administered 
at intervals of 4-8 
weeks; a third 
dose should be 
administered 6-12 
months after the 
second dose.
laboratories who 
frequently work with 
Salmonella typhi.
to a previous dose.
Ty21a (oral) vaccine should 
not be administered to 
immunocompromised persons* 
or to persons receiving 
antimicrobial agents.
Vaccination is Hypersensitivity or anaphylactic 
recommended for adults at reactions to IPV or antibiotics 
increased risk for exposure contained in IPV. IPV contains 
trace amounts of streptomycin, 
polymyxin B, and neomycin.
to polioviruses including 
health-care personnel 
who have close contact 
w ith patients who might 
be excreting polioviruses. 
Adults who have previously 
received a complete course 
of poliovirus vaccine may 
receive one lifetime booster 
if they remain at increased 
risk for exposure.
alternative to the use of proper procedures 
when handling specimens and cultures in the 
laboratory.
Abbreviations: IM = intramuscular; HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; SC = subcutaneous; HIV = human immunodeficiency virus; MMR =
measles, mumps, rubella vaccine; TB = tuberculosis; HAV = hepatitis A virus; IgA = immune globulin A; ID = intradermal; TIV = trivalent inactivated split-virus vaccines;
LAIV = live attenuated influenza vaccine; BCG = bacille Calmette-Guerin; OPV = oral poliovirus vaccine.
* Persons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental 
professionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care 
institutions). Source: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/
vacctoolkit/definition.html.
1 Health-care personnel and public safety workers at high risk for continued percutaneous or mucosal exposure to blood or body fluids include acupuncturists, 
dentists, dental hygienists, emergency medical technicians, first responders, laboratory technologists/technicians, nurses, nurse practitioners, phlebotomists, 
physicians, physician assistants, and students entering these professions. Source: CDC. A comprehensive immunization strategy to eliminate transmission of 
hepatitis B virus infection in the United States: recommendations o f the Advisory Committee on Immunization Practices. Part II: immunization of adults. MMWR 
2006;55(No. RR-16).
§ The package insert should be consulted to weigh the risks and benefits o f giving HBIG to persons with IgA deficiency, or to persons who have had an anaphylactic 
reaction to an IgG containing biologic product.
1 Written documentation o f vaccination with 2 doses of live measles or MMR vaccine administered >28 days apart, or laboratory evidence of measles immunity, or 
laboratory confirmation of measles disease, or birth before 1957.
** Persons immunocompromised because of immune deficiency diseases, HIV infection (who should primarily not receive BCG, OPV, and yellow fever vaccines),
leukemia, lymphoma or generalized malignancy or immunosuppressed as a result o f therapy with corticosteroids, alkylating drugs, antimetabolites, or radiation.
11 Written documentation o f vaccination with 2 doses o f live mumps or MMR vaccine administered >28 days apart, or laboratory evidence of mumps immunity, or 
laboratory confirmation of mumps disease, or birth before 1957.
§§ Written documentation of vaccination with 1 dose of live rubella or MMR vaccine, or laboratory evidence of immunity, or laboratory confirmation o f rubella 
infection or disease, or birth before 1957, except women of childbearing potential who could become pregnant; though pregnancy in this age group would be 
exceedingly rare.
11 Source: CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001;50:1117.
*** Source: CDC. Update on adult immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991:40(No. RR-12).
111 Commercial assays can be used to assess disease-induced immunity, but they often lack sensitivity to detect vaccine-induced immunity (i.e., they might yield
false-negative results).
§§§ Verification of history or diagnosis o f typical disease can be provided by any health-care provider (e.g., school or occupational clinic nurse, nurse practitioner, 
physician assistant, or physician). For persons reporting a history of, or reporting with, atypical or mild cases, assessment by a physician or their designee is 
recommended, and one of the following should be sought: 1) an epidemiologic link to a typical varicella case or to a laboratory-confirmed case or 2) evidence 
of laboratory confirmation if it was performed at the time of acute disease. When such documentation is lacking, persons should not be considered as having a 
valid history of disease because other diseases might mimic mild atypical varicella.
111 For example, immunocompromised patients or pregnant women.
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TABLE 3. Summary of recommendations for immunization of health-care personnel* (HCP) with special certain conditions —  Advisory 
Committee on Immunization Practices, United States, 2011
Vaccine Pregnancy HIV infection
Severe
immunosuppression^ Asplenia Renal failure Diabetes
Alcoholism and 
alcoholic cirrhosis
Hepatitis B R R R R R R R
Influenza R§ R R R R R R
Measles, mumps, rubella C R' C R R R R
Meningococcus UI UI UI R** UI UI UI
IPV 11 UI UI UI UI UI UI UI
Pertussis, tetanus, diphtheria R R R R R R R
Typhoid, inactivated Vi§§ UI UI UI UI UI UI UI
Typhoid, Ty21a UI C C UI UI UI UI
Varicella C U I'' C R R R R
Abbreviations: R = recommended; C = contraindicated; UI = use if indicated; IPV = inactivated poliovirus vaccine.
* Persons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental 
professionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care institutions). 
Source: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/vacctoolkit/ 
definition.htm l.
" Severe immunosuppression can be caused by congenital immunodeficiency, leukemia, lymphoma, generalized malignancy or therapy with alkylating agents, 
antimetabolites, ionizing radiation, or large amounts of corticosteroids.
§ Women who are or will be pregnant during the influenza season.
1 Contraindicated in HIV-infected persons who have evidence of severe immunosuppression.
** Recommendation is based on the person's underlying condition rather than occupation.
t t  Vaccination is recommended for unvaccinated HCP who have close contact w ith patients who may be excreting wild polioviruses. HCP who have had a primary 
series of oral poliovirus vaccine (OPV) or IPV who are directly involved with the provision of care to patients who may be excreting poliovirus may receive another 
dose o f either IPV or OPV. Any suspected case of poliomyelitis should be investigated immediately. If evidence suggests transmission of poliovirus, control measures 
to contain further transmission should be instituted immediately.
§§ Capsular polysaccharide parenteral vaccine.
11 Varicella vaccine may be considered for HIV-infected adults w ithout evidence of immunity and with CD4 T-lymphocyte count >200 cells/Ul.
TABLE 4. Recommended postexposure prophylaxis for percutaneous or permucosal 
exposure to hepatitis B virus —  Advisory Committee on Immunization Practices, United States
Vaccination and antibody Treatment
response status o f exposed 
person Source HBsAg-positive Source HBsAg-negative Source not tested or status unknown
Unvaccinated HBIG x 1; initiate HB vaccine series Initiate HB vaccine series Initiate HB vaccine series
Previously vaccinated
Known responder No treatment No treatment No treatment
Known nonresponder
After 3 doses HBIG x 1 and initiate revaccination No treatment If known high-risk source, treat as if source 
were HBsAg-positive
After 6 doses HBIG x 2 (separated by 1 month) No treatment If known high-risk source, treat as if source 
were HBsAg-positive
Antibody response unknown Test exposed person for anti-HBs 
If adequate,* no treatment 
If inadequate,* HBIG x 1 and vaccine booster
No treatment Test exposed person for anti-HBs 
If adequate,* no treatment 
If inadequate,* initiate revaccination
Abbreviations: HBsAg = Hepatitis B surface antigen; HBIG = hepatitis B immune globulin; anti-HBs = antibody to hepatitis B surface antigen; HB = hepatitis B. 
Source: Adapted from CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations 
o f the Advisory Committee on Immunization Practices (ACIP). Part II: immunization o f adults. MMWR 2006;55(No. RR-16).
* A seroprotective (adequate) level o f anti-HBs after completion of a vaccination series is defined as anti-HBs >10 mlU/mL; a response < 10 mlU/mL is inadequate and 
is not a reliable indicator of protection.
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TABLE 5. Advisory Committee on Immunization Practices work restrictions for health-care personnel* (HCP) exposed to or infected with certain 
vaccine-preventable diseases and conditions
Disease/Condition Work restriction Duration
Hepatitis B
HCP positive for HBsAg (e.g., acute or chronic
hepatitis B infection):
HCP who do not perform exposure-prone No restriction unless linked Standard precautions always should be observed
invasive procedures epidemiologically to transmission of 
hepatitis B virus infection
HCP who perform exposure-prone These HCP should not perform Per recommendation of expert panel
invasive procedures exposure-prone invasive procedures 
until they have sought counsel 
from an expert review panel, which 
should review and recommend the 
procedures the worker can perform, 
taking into account the specific 
procedure as well as the skill and 
technique of the worker
Upper respiratory infections
HCP in contact with persons at high risk for Exclude from duty Until afebrile >24 hours (without the use of fever-reducing medicines
complications of influenza1 such as acetaminophen). Those with ongoing respiratory symptoms 
should be considered for evaluation by occupational health to 
determine appropriateness of contact with patients. If returning to 
care for patients in a protective environment (e.g., hematopoietic 
stem cell transplant patients), consider for temporary reassignment 
or exclusion from work for 7 days from symptom onset or until the 
resolution of symptoms, whichever is longer.
Those who develop acute respiratory symptoms without fever should 
be considered for evaluation by occupational health to determine 
appropriateness of contact with patients and can be allowed to 
work unless caring for patients in a protective environment; these 
personnel should be considered for temporary reassignment 
or exclusion from work for 7 days from symptom onset or until 
the resolution of all noncough symptoms, whichever is longer. If 
symptoms such as cough and sneezing are still present, HCP should 
wear a facemask during patient care activities. The importance of 
performing frequent hand hygiene (especially before and after each 
patient contact) should be reinforced.
Measles
Active Exclude from duty 4 days after rash appears
Postexposure (HCP without presumptive Exclude from duty 5 days after first exposure through 21 days after last exposure and/or
evidence of measles immunity) 4 days after the rash appears
Mumps
Active Exclude from duty 5 days after onset of parotitis
Postexposure (HCP without presumptive Exclude from duty 12 days after first exposure through 25 days after last exposure or 5
evidence of mumps immunity) days after onset of parotitis
Pertussis
Active Exclude from duty Beginning of catarrhal stage through third week after onset of 
paroxysms or until 5 days after start o f effective antimicrobial therapy
Postexposure
Symptomatic personnel Exclude from duty 5 days after start of effective antimicrobial therapy
Asymptomatic personnel -  HCP likely to expose a No restriction from duty; on
patient at risk for severe pertussis§ antimicrobial prophylactic therapy
Asymptomatic personnel -  other HCP No restriction from duty; can receive 
postexposure prophylaxis or be 
monitored for 21 days after pertussis 
exposure and treated at the onset of 
signs and symptoms o f pertussis
See table footnotes on page 44
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TABLE 5. (Continued) Advisory Committee on Immunization Practices work restrictions for health-care personnel* (HCP) exposed to or infected 
with certain vaccine-preventable diseases and conditions
Disease/Condition Work restriction Duration
Rubella
Active Exclude from duty 7 days after the rash appears
Postexposure (personnel w ithout evidence of 
rubella immunity)
Exclude from duty 7 days after first exposure through 23 days after last exposure 
and/or 7 days after rash appears
Varicella
Active Exclude from duty Until all lesions dry and crust. If only lesions that do not crust 
(i.e., macules and papules), until no new lesions appear within a 
24-hour period
Postexposure (HCP without evidence o f varicella 
immunity)
Exclude from duty unless receipt of 
the second dose within 3-5 days after 
exposure
8th day after 1st exposure through 21st day (28th day if varicella­
zoster immune globulin administered) after the last exposure; if 
varicella occurs, until all lesions dry and crust or, if only lesions that 
do not crust (i.e., macules and papules), until no new lesions appear 
within a 24-hour period
Herpes zoster
Localized in immunocompetent person Cover lesions; restrict from care of 
high-risk patients1
Until all lesions dry and crust
Disseminated or localized in immunocompromised 
person until disseminated infection is ruled out
Exclude from duty Until all lesions dry and crust
Postexposure (HCP without evidence o f varicella 
immunity)
Disseminated zoster or localized zoster with 
uncontained/uncovered lesions
Exclude from duty unless receipt of 
the second dose of varicella vaccine 
within 3-5 days after exposure
8th day after 1st exposure through 21st day (28th day if varicella­
zoster immune globulin administered) after the last exposure; if 
varicella occurs, until all lesions dry and crust or, if only lesions that 
do not crust (i.e., macules and papules), until no new lesions appear 
within a 24-hour period
Localized zoster with contained/covered lesions For HCP with at least 1dose of 
varicella vaccine, no work restrictions. 
For HCP with no doses o f varicella 
vaccine, restrict from patient contact
8th day after 1st exposure through 21st day (28th day if varicella­
zoster immune globulin administered) after the last exposure; if 
varicella occurs, until all lesions dry and crust or, if only lesions that 
do not crust (i.e., macules and papules), until no new lesions appear 
within a 24-hour period
Abbreviation: HBsAg = hepatitis B surface antigen.
Sources: Adapted from CDC. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure- 
prone invasive procedures. MMWR 1991;40(No. RR-8); CDC. Guideline for isolation precautions in hospitals: recommendations o f the Hospital Infection Control Practices 
Advisory Committee (HICPAC) and the National Center for Infectious Diseases. Infect Control Hosp Epidemiol 1996;17:53-80; Williams WW. CDC guideline for infection 
control in hospital personnel. Infect Control 1983;4(Suppl):326-49; CDC. Immunization of health-care workers: recommendations of the Advisory Committee on 
Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).
* Persons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental 
professionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care institutions). 
Source: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/vacctoolkit/ 
definition.htm l.
1 Includes children aged <5 years, adults aged >65 years, pregnant women, American Indians/Alaska Natives, persons aged <19 years who are receiving long-term 
aspirin therapy, and persons with certain high-risk medical conditions (i.e., asthma, neurologic and neurodevelopmental conditions, chronic lung disease, heart 
disease, blood disorders, endocrine disorders, kidney disorders, liver disorders, metabolic disorders, weakened immune system due to disease or medication, and 
morbid obesity).
§ Includes hospitalized neonates and pregnant women.
1 Includes patients who are susceptible to varicella and at increased risk for complications of varicella (i.e., neonates, pregnant women, and immunocompromised 
persons of any age).
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